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Abstract
Dysregulation of the Wnt signalling pathway is implicated in the carcinogenic
transformation of normal cells in a number of human tissues. Mutations in Wnt
pathway signalling molecules appear to be particularly important in the
development of colorectal neoplasia. This thesis investigates the effects of
modulating levels ofWnt pathway components on downstream molecules in vivo
and in vitro.
To examine the effects of loss ofWnt pathway components on the biology of the
mouse large intestine work was undertaken to assemble a tissue-specific,
inducible Cre (CreERtm) transgene construct. This formed part of a group effort
using various lengths of upstream sequence from the mouse homeobox gene
Cdx-1 to drive CreER"11. In order to ensure that sufficient Cdx-1 promoter
sequence to achieve adequate expression levels and localization, a recently
described methodology based on the Reda-(3-y recombination system of
bacteriophage Lambda was used in an effort to insert the CreERtm coding
sequence into a Bacterial Artificial Chromosome (BAC).
The BAC used in the construction of the transgene was found to contain
previously uncharacterised upstream Cdx-1 promoter elements, which may play a
role in determining correct tissue expression pattern. In order to further
characterise the newly isolated Cdx-1 promoter elements, portions of the BAC
derived sequence were used in the construction of reporter plasmids encoding the
Enhanced Green Fluorescent Protein (EGFP). The EGFP based reporter
plasmids, which contained various fragments of the Cdx-1 promoter encoding a
number of transcriptional control elements, were microinjected and liposome
transfected into murine embryonic stem (ES) cells, colorectal cell lines and
primary murine colonocytes in order to determine the contribution of the
transcriptional elements to levels of expression.
One of the primary targets for gene excision using a large intestine specific,
inducible Cre recombinase would be the Adenomatous Polyposis Coli (APC)
gene, the APC gene product being a central mediator of the Wnt pathway.
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Mutations of the APC gene occur in a large majority of spontaneously arising
intestinal tumours in human patients and germline APC mutations are responsible
for the human condition Familial Adenomatous Polyposis (FAP). A previously
generated floxed APC transgenic mouse strain was crossed onto a mouse line
bearing a germline truncation mutation (Min) in APC. The resulting progeny
were characterised to determine if the introduced transgenic material had an
influence on disease phenotype; comparison of survival times and embryogenesis
indicate that the transgenic material has negligible effect on the Min phenotype.
Another factor contributing to the development of colorectal tumours in humans
appears to be deficiencies in DNA mismatch repair processes. The relationship
between levels of the Wnt pathway molecule (3-catenin following methylation
damage and the functionality of the DNA damage sensor p53 and DNA
mismatch sensor Msh2 were explored in vitro in Murine Embryonic Fibroblasts
(MEFs). (3-catenin levels were found to drop following application of the
methylating agent MNNG in wild type MEFs but remained unchanged in cells
containing mutant p53. Cells null for Msh2 function showed the same drop in (3-
catenin levels as wild type fibroblast, suggesting that Msh2 is not involved in
Wnt pathway reaction to methylation damage.
The work presented in this thesis contributes to the development of a transgenic
mouse line bearing a conditional, inducible intestinal epithelial specific Cre
recombinase and to the understanding of regulation of the Wnt signalling






Chapter 1 - Introduction
1.1 Human Colorectal Cancer
1.1.1 Incidence and Epidemiology
One of the most common tissues to become cancerous in the human is the large
intestinal epithelium. A high rate of cellular turn over requiring rapid cell
division coupled with the presence of potentially damaging chemical factors in
ingested substances combine to give a relatively elevated rate of neoplasia. While
cancer of the small intestine is rare in humans, in the developed nations of the
world the incidence of colorectal cancers is such that 50% of individuals can
expect to have developed a tumour by the age of 70. In the same geo-political
areas colorectal cancer is the second most common cause of cancer deaths and is
in fact the most common form of non-smoking related cancer (Parker et al.,
1996). With populations ageing and more and more societies adopting a
"western" style diet which predisposes to colorectal tumour formation, it is
reasonable to believe that the number of people afflicted with this disease will
continue to rise worldwide (Giovannucci and Willett, 1994; Burnstein, 1993).
With these consideration it is not surprising that cancers of the large intestine,
with special emphasis on cancers of the colon, have received a great deal of
attention and been the focus of much intensive research.
Early on in the investigation of colorectal cancer it was noticed that a significant
proportion of these cancers (estimates range from 5-15%) appeared to occur
within families, susceptibility to the development of colorectal tumours being
inherited in a dominant fashion (Cannon-Albright et al., 1988; Houlston et al.,
1992a). Through study of the genes, proteins and pathways involved in the
increased rates of colorectal cancers in these syndromes a greater understanding
not only of this specific cancer but also of the process of cancer formation as a
whole has been achieved.
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1.1.2 Molecular Biology and Genetics of Colorectal Cancer
As mentioned above there has been a great deal of research looking for common
genetic defects which may predispose to development of intestinal cancers. To
date two syndromes have been defined, both leading to greatly increased rates of
tumour formation; the first being Hereditary Non-Polyposis Colorectal Cancer
(HNPCC) and the second being Familial Adenomatous Polyposis (FAP).
HNPCC patients account for up to 6% of the hereditary predispositions to
colorectal cancers while FAP accounts for only 1% of these individuals
(Salovaara et al., 2000; Aaltonen and Peltomaki, 1994).
1.1.2.1 Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
The investigation of the nature of the inherited mutation (or mutations) involved
in HNPCC proved to be more difficult than expected. While it was easily
determined that the syndrome was being inherited in a Mendelian fashion, the
search for the common mutated allele proved difficult. The unravelling of the
problem began when the search for lost microsatellite marker alleles, presumably
deleted along with the apparent missing tumour suppressor gene turned up
changes in the lengths of several microsatellites rather than deleted ones, a defect
termed Microsatellite Instability (Aaltonen et al., 1993). This suggested that the
mutation was not simply deleting the functions of a traditional tumour suppressor
gene but was instead giving rise to changes within the DNA sequence, which
may have deleterious effects on actual tumour suppressors. Studies of DNA
repair in bacteria had already revealed mutant cells with an increased rate of
mutation; the mutation leading to this phenotype was in one of a group of genes
involved in the repair of mismatched bases, the result of some sort of genotoxic
insult (Strand et al., 1993). The 5 human homologues of these genes, the
Mismatch Repair (MMR) genes, proved to be the sites of the heritable mutations
which lead to HNPCC (Fishel et al., 1993; Strand et al., 1993; Boland et al.,
1998). Today it is known that the majority of the mutations leading to HNPCC
are in three MMR genes; hMSH2, hMLHl and hPMS2. As mentioned
previously the intestinal epithelium is a tissue in constant renewal, its cells
dividing and being shed constantly. It is not surprising then that germline
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mutations in MMR genes would show themselves first in this tissue; the
combination of a potentially damaging chemical environment with the need to
constantly replicate DNA would lead to a rapid accumulation of mutations
throughout the genome, some, eventually, in tumour suppressors or proto-
oncogenes.
1.1.2.2 Familial Adenomatous Polyposis (FAP)
Unlike HNPCC, where the intestine remains free of polyps prior to the formation
of disease the hereditary disorder familial adenomatous polyposis (FAP) is
characterised by the development of hundreds to thousands of adenomas of the
colorectal mucosa. Eventually one or more of these regions of abnormal cell
growth and turnover progress to a cancerous stage (Cannon-Albright et al., 1991;
Cannon-Albright et al., 1988). FAP patients may also display a congenital
hyperplasia of the retina, indeed this may be the first apparent symptom of an
FAP genotype (Houlston et al., 1992b). Again in contrast to the case of HNPCC,
the genetic defect responsible for this disorder was relatively quickly mapped
and the mutations responsible identified. In the large majority of cases of FAP
this debilitating phenotype has been traced to a germline mutation in the
adenomatous polyposis coli (APC) gene (Nishisho et al., 1991; Groden et al.,
1991; Kinzler et al., 1991a; Kinzler et al., 1991b). It was soon discovered that a
large majority of sporadic colorectal tumours (adenomas and cancers), up to
80%, were found to be missing alleles of this gene and/or to contain mutated
sequences coding for truncated versions of the APC protein (Ichii et al., 1992).
These mutations of the APC gene were soon implicated in a large number of
tumours derived from other tissues, including osteomas, desmoid tumours and
breast tumours (Burt et al., 1992; Davies et al., 1995; Miyaki et al., 1993; Szabo
and King, 1995).
The role of APC gene mutations in the formation of a number of tumour types
prompted intensive research into the nature of the APC gene and its protein
product. Consequently the role the APC gene product plays in the maintenance of
regular cell activities has been further understood yet the implications and end
effects of the pathways involving APC have yet to be fully clarified.
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1.2 The Adenomatous Polyposis Coli (APC) Gene
1.2.1 Genomic Organisation in Mouse and Human
The APC genes of the human and the mouse occur in relatively conserved
regions. In the human the APC gene is found on chromosome 5 at ql2 while in
the mouse the homologue is to be found on chromosome 18 also at ql2 (Kinzler
et al., 1991a; Kinzler et al., 1991b; Luongo et al., 1993). Originally the gene was
thought to be composed of 15 exons with the final exon comprising
approximately half of the coding sequence (Santoro and Groden, 1997). A
number of additional exons have since been discovered, several of which are
differentially expressed and represent alternative splice forms (see figure 1.1)
(Santoro and Groden, 1997; Samowitz et al., 1995; Thliveris et al., 1994). The
best studied alternative APC isoform is one containing the Brain Specific (BS)
exon, now known not to be restricted to expression in the brain, found upstream
of the originally identified exon 1; this exon is translated to the exclusion of exon
1 in differentiated tissues such as the brain (Pyles et al., 1998). At least three
exons in addition to the BS exon have been found upstream of the originally
identified exon 1, these have been termed (from 5' to 3') exons 0.3, 0.1 and 0.2;
transcripts containing these alternative upstream exons have been identified both
with and without exon 1 (Horii et al., 1993; Thliveris et al., 1994). Interestingly
exon 1 contains a translation stop codon upstream of its translation start codon
suggesting that transcripts beginning with an alternative upstream codon which
contain exon 1 produce truncated proteins and that only those transcripts
containing an alternate upstream exon which lack exon 1 can produce full length
proteins (Thliveris et al., 1994; Santoro and Groden, 1997; Pyles et al., 1998).
Additionally exons 9 and 10 have alternative splice forms (9A and 10A) bringing
the total number of exons to 21 giving rise to at least 16 different transcripts,
including some lacking exon 7 (Santoro and Groden, 1997; Oshima et al., 1993).
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Figure 1.1: A schematic representation (not to scale) of the exonic/intronic
organisation of APC. The figure shows the large number of alternatively expressed
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1.2.2 Mutations of the APC gene
As mentioned previously, many intestinal tumours arising spontaneously, in
addition to those tumours developed by FAP individuals have been found to
contain mutations of the APC gene. Screening of the APC mutations from these
tumours has produced a map of mutation frequencies for the length of the APC
gene (Krawczak and Cooper, 1997). The large majority of disease causing
mutations have been found to be those resulting in truncated reading frames,
including stop mutations introduced through transposition mutations as well as
frameshift mutations giving rise to premature stop codons (Mandl et al., 1994).
While mutations have been found throughout the length of the APC coding
sequence the majority of mutations resulting in deleterious phenotypes, in both
germline and somatic scenarios, occur in the 5 prime portion of the coding
sequence. Additionally in germline mutations there appear to be two sites of
increased mutation frequency, accounting for -35% of the described mutations;
these occur at codons 1061 and 1309 (Nagase and Nakamura, 1993; Miyaki et
al., 1994). Similarly there are two mutation hot spots in the somatic mutations of
APC, clustered at codons 1309 and 1450 (Nagase and Nakamura, 1993).
1.2.3 The APC tumour suppressor protein; Structure and Protein
Interactions
The APC gene codes for a protein of 2844 amino acids (-310 kDa) containing a
number of distinct domains and repeated elements (see figure 1.2) (Polakis,
1995; Polakis, 1997). Many of the repeat elements of the APC protein have been
recognized as motifs involved in interaction with other proteins. To date a large
number of these interactions have been confirmed and explored.
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Figure 1.2: Schematic of some of the proteins central to the Wnt/Wg signalling
pathway. Figures are not to scale.
Figure1.2:ProteinstructurefWnt/WGpathwaycomponents oligomerizationdomain15>a.repe ts
basicdomain


























hdlgbinding *=GSK-3pphosphorylationsite □=humanmutatio alcluster
PDZdomain
K> K>
Beginning with the amino terminal region of the protein the first recognized
active region of the APC protein is an oligomerization domain, believed to
contain >95% a-helical conformation. It was established using
immunoprecipitation experiments involving truncated and wild type proteins that
APC has the ability to bind to itself (Su et al., 1993). This domain appears to be
formed of heptad amino-acid repeats, the most important of which are found in
the interval amino acid 6-57 (Joslyn et al., 1993; Su et al., 1993). The ability of
the APC protein to oligomerise may be responsible for the observations of
dominant-negative effects of mutant APC proteins made by some researchers
(Dihlmann et al., 1999). Interestingly some of the alternative splice variants of
the APC gene may fail to produce proteins containing the most important
oligomerisation domain, presumably creating a protein with altered activity or
regulation (Samowitz et al., 1995). Additionally there is an attenuated form of
FAP which appears to be characterised by the mutation of one allele ofAPC very
near its 5' end, upstream of codon 157. The truncated protein produced in this
syndrome seems to lead to a less severe FAP phenotype (fewer polyps with a
reduced rate of cancer formation) while slightly longer truncated proteins seem
to impart none of this reduction of the FAP phenotype (Groden et al., 1993;
Spirio et al., 1993; Spirio et al., 1992). This attenuated FAP phenotype appears
to arise when the initial, inherited APC mutation fails to prevent the APC gene
product performing its normal cellular functions but makes the locus more easily
inactivated by further mutations (Su et al., 2000).
The next region as we move towards the carboxy terminus of the APC protein is
a series of armadillo repeats (Polakis, 1997). These repeats are homologous to 42
amino acid motifs found initially in the Drosophila armadillo protein, the
homologue of the human (3-catenin protein (Hatzfeld, 1999). Multiple armadillo
repeats appear to form a super-helical structure, containing a positively charged
groove (Huber et al., 1997). This segment of the APC protein contains 7
armadillo repeats and the function of these repeats appears to be protein-protein
interaction, possibly needed for proper binding of (3-catenin or for competitive
binding to cadherins to the exclusion of (3-catenin (Hirschl et al., 1996). More
recently, however, it has been shown that this set of repeated elements binds to
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the regulatory domain of protein phosphatase 2a (PP2A), a protein capable of
interacting with and involved in the regulation of Axin, another component of the
Wnt-1 signalling pathway (Seeling et al., 1999; Hsu et al., 1999). These
armadillo repeats are rarely lost due to mutations causing protein truncation and
subsequent polyp and tumour formation suggesting that they may be N-terminal
to those motifs which posses tumour suppressor function or that these armadillo
repeats are absolutely vital to cell survival and mutants lacking them are selected
against. In cases where mutation does cause a loss of some armadillo repeats
from the APC protein the number of repeats lost shows a positive correlation
with development of congenital hyperplasias of the retinas (Davies et al., 1995;
Wallis et al., 1994; Wallis et al., 1999). This may lend evidence to the
observations by some researchers of a potential partial dominant-negative effect
of truncated APC protein (Dihlmann et al., 1999).
Within the segment of the APC protein containing the armadillo repeats, at
Asp777, is a DNI/LD motif conserved across a number of species, which is
recognized and cleaved by caspase-3 (Browne et al., 1994; Webb et al., 1999;
Browne et al., 1998). The caspases are final stage mediators of the apoptosis
pathway, cleaving a number of target proteins, including poly-adenosylribose
polymerase (PARP), DNA-dependant protein kinase (DNA-PK) and (3-catenin
(Woo et al., 1998; Konopleva et al., 1999; Casciola-Rosen et al., 1996; Rosen
and Casciola-Rosen, 1997; Webb et al., 1999). The cleavage of APC during the
process of apoptosis results in a 90 kDa amino-terminal fragment which contains
a number of the armadillo repeat elements independent of the more carboxy
terminal effector regions of APC.
Downstream of the armadillo repeat segment of the APC protein are found three
15 amino acid repeats, responsible for the binding of (3-catenin (Su et al., 1993).
These repeats are not homologous to the motifs found on other proteins which
interact with (3-catenin (T-cell factor (TCF)/Lymphocyte enhancer factor (LEF)
transcription factors and cadherins for example) and need not be removed by
truncation mutation to eliminate the tumour suppressor functions of the APC
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protein (Kintner, 1992; Ozawa et al., 1995; Polakis, 1995; Beroud and Soussi,
1996).
Following the (3-catenin binding repeats are a series of 7 relatively dispersed 20
amino acid motifs (Groden et al., 1991). These motifs are conserved within APC
homologs in a number of different species including Drosophila (Hayashi et al.,
1997). These 20 amino acid repeats bear some resemblance to the 15 amino acid
repeats found more N-terminal and were believed to play a role in the binding
and subsequent degradation of (3-catenin. This is in part supported by the fact that
most tumourigenic truncation mutations of APC eliminate some or all of these
motifs (Polakis, 1995). This may not be the whole story, however, as interspersed
with these (3-catenin binding and degradation domains are amino acid motifs
which bind Axin (Zeng et al., 1997). Axin is the gene product of the fused locus
in the mouse, Axil/Conductin in Xenopus while the Drosophila homologue is
called D-axin (Behrens et al., 1998; Hamada et al., 1999; Fagotto et al., 1999). It
appears that Axin acts as a scaffold protein in these diverse species, bringing
together a number of proteins involved in the Wnt-1 signalling pathway (see
section 1.3) in order to function as a regulator of free cellular (3-catenin levels
and hence regulate transcription of Wnt-1 target genes (Ikeda et al., 1998;
Kishida et al., 1999; Sakanaka et al., 1998; Sakanaka and Williams, 1999;
Yamamoto et al., 1999; Yamamoto et al., 1998). It may be that the tumourigenic
potential of the truncated APC proteins is not entirely due to the loss of the 20
amino acid repeats but rather due to the loss of Axin interaction elements
preventing the formation of protein clusters necessary for (3-catenin degradation.
Within the same region of the APC protein is one of three S(T)PXX motifs, the
other two being located further C-terminal. These motifs have been recognised as
being involved in protein interactions with A/T rich DNA sequences and it has
been demonstrated that APC will co-immunoprecipitate genomic DNA with a
high A/T content (Deka et al., 1999). This may indicate a direct role for nuclear
APC in the regulation of transcription or its involvement in the binding of
proteins closely involved with transcription control. The decreasing gradient of
nuclear APC along the crypt matches nuclear proliferation, lending further
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support to a possible role in proliferation control (Midgley et al., 1997; Smith et
al., 1993).
The next region of protein interaction on the APC protein as we move towards
the C-terminal is the Basic Domain (Groden et al., 1991). This region, stretching
approximately from amino acid 2200 to 2400, contains a higher proportion of the
basic residues arginine and lysine, hence its nomenclature. This region of the
APC protein enables it to bind to microtubules and full length APC is believed to
be capable of promoting the polymerisation of tubulin in vitro, while mutant
APC proteins are unable to encourage this reaction (Smith et al., 1994;
Munemitsu et al., 1994). This ability to assemble and/or associate with
microtubules may in part explain the localisation of APC to the leading edge of
migrating cells, a region where microtubule assembly is required, as well as the
observations of disordered cell migration in models of APC overexpression and
in animal models of FAP (Nathke et al., 1996; Mahmoud et al., 1999; Mahmoud
et al., 1997; Wong et al., 1996).
In addition to interacting with A/T rich DNA sequences, the C-terminal third of
APC also interacts with at least two other proteins; EB1 and Human Discs Large
(hdlg). EB1 has been shown to bind in the final 284 amino acids of APC while
hdlg binds in the final 72 amino acids (Su et al., 1995; Matsumine et al., 1996).
EB1 was found to bear little resemblance to any protein of known function when
it was first isolated, although its coding sequence was similar to one yeast and
two human sequences. More recently EB1 has been found to be homologous to
Mal3, a yeast protein found to associate with microtubules and a number of
cellular structures involve in mitosis, including centrosomes and spindle poles
(Beinhauer et al., 1997; Morrison et al., 1998). EB1 therefore may be partially
responsible for the observation of APC localisation to these cell division
structures and for its close association with microtubules. The hdlg protein is the
human homolog of the Drosophila Discs Large (dig) tumour suppressor protein;
loss of dig in Drosophila results in neoplastic growth in the imaginal disc of the
developing embryo (Lue et al., 1994; Woodhouse et al., 1998). APC interacts
with hdlg/dlg through conserved S/TXV domains in its C-terminal portion,
which have been found to bind to the PDZ domain of the discs large homologs.
26
Recently, in addition to its innate roles in cell cycle control hdlg has been found
to play a role in APC induced control of the cell cycle in mammalian systems,
implying that loss of the terminal regions of the APC protein may result in
neoplastic transformations through modulation of hdlg activity as well as through
mediation of (3-catenin levels (Ishidate et al., 2000).
Also in the C-terminal third of the APC protein are a number of target sites for
the Cyclin Dependant Protein Kinase p34cdc2. Eleven potential phosphorylation
sites {(S/T)PX(R/K)} have been identified in the region of APC most often
deleted in truncation mutation. (Trzepacz et al., 1997) These sites appear to be
phosphorylated in a cell cycle dependant manner, with the highest levels of
phosphorylation occurring during mitosis (Bhattacharjee et al., 1996). Alteration
of the phosphorylation state of APC appears to alter its binding activities and its
ability to down-regulate levels of (3-catenin.
1.2.4 Expression pattern
The APC gene is expressed in many human and animal epithelial tissues, the
gene products including a number of protein isoforms which appear to be
restricted to a small number of tissues, the most apparent being the Brain
Specific isoform which is encoded using an alternative first exon (Midgley et al.,
1997; Bardos et al., 1997). The expression of APC in epithelial tissues seems to
be strongest in differentiated cells (Midgley et al., 1997).
Immunoelectronmicroscopy reveals that the APC gene product localises in both
the nucleus and the cytoplasm of mammalian cells (Neufeld and White, 1997;
Miyashiro et al., 1995). In the former the protein seems to cluster into distinct
regions, possibly nucleoli. In the latter, the protein appears in some cases to
cluster on the ends of microtubules, particularly at the leading edge of actively
migrating cells, hinting at its role in cellular adhesion and morphology
maintenance (Morrison et al., 1997; Nathke et al., 1996). The cytoplasmic
staining patterns vary from tissue to tissue, in some cases showing staining
predominantly apically, in others showing strong staining on the lateral borders
of cells (Midgley et al., 1997). Levels of APC expression appear to be variable
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and may depend on a number of factors, including developmental signals as in
differentiating rat neuronal cells (Bhat et al., 1994; Dobashi et al., 1996; Jaiswal
and Narayan, 1998).
1.2.5 Function
The role of APC in the prevention of tumour development, or more accurately
the failure of truncated APC to prevent neoplastic transformation, has led to an
intense study of its role in normal and dysregulated cell functioning. Like many
tumour suppressor proteins APC appears to play a role in the embryonic
development of organisms as well as in the maintenance of health in adult
animals. Homologs of APC appear to play important roles in pattern
development in a number of diverse species. In Drosophila an APC equivalent
acts as a signalling step in the wingless pathway (Hayashi et al., 1997). C.
Elegans also utilises an APC homologue in the Wnt7/wingless pathway; in
embryonic development this pathway functions to promote differentiation of
cells into endoderm (Rocheleau et al., 1997). In Xenopus an overexpression of
another APC-related gene brought on by injected RNA results in the formation of
a second dorsoanterior axis and Wnt signalling appears to be involved in the
formation of the Spemann organiser (Vleminckx et al., 1997; Laurent et al.,
1997). Studies in the rat have revealed that the APC gene is upregulated in the
developing nervous system, particularly during the differentiation of certain cell
types (Bhat et al., 1994; Dobashi et al., 1996). It would appear that APC and its
homologues are vital in a number of developmental processes, including cellular
differentiation, segment polarity and axis induction. Studies of murine Ape's role
in development also indicate a vital embryonic dependence on its proper
functioning (see section 1.4.2) (Moser et al., 1995).
It is the involvement of APC and its many cross species homologs in the
VDz/Avingless signalling pathway which appears to be primarily responsible for
its influence on cellular growth and differentiation, both in healthy and cancerous
tissues. It is easiest, perhaps to elucidate the pivotal role of APC in this pathway
by outlining the functions of the other signalling proteins involved in this
cascade.
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1.3 The Wnt/Wingless signalling pathway
1.3.1 Components of the Wnt Pathway
1.3.1.1 Wnt
The Wnt proteins are a family of secreted signalling molecules with a number of
actions in a variety of organisms. The Wnt family was first identified in the
mouse, when two family members (initially named intl and 2) were discovered
to behave as oncogenes when activated by the insertion of Mouse Mammary
Tumour Virus (MMTV) in mammary tumours (Nusse and Varmus, 1982). This
correlation with tumour development lead to a great deal of study, Wnt-1
homologs were quickly identified in a wide range of species including human, C.
elegans and Drosophila\ in the latter the conserved protein was known as
wingless (wg) (Cabrera et al., 1987). In all of these species the Wnt/wingless
family of proteins play important developmental roles; defining segment polarity
in Drosophila, controlling gut development in C. elegans and determining axis
formation in Xenopus (Nusslein-Volhard, 1991; Nusslein-Volhard and Roth,
1989; Han, 1997; McMahon and Moon, 1989a; McMahon and Moon, 1989b).
Subsequently, a large number of Wnt proteins (see
http://www.Stanford.edu~rnusee/wntwindow.html and Nusse, 1999) have been
identified in the mouse, all of which also have important developmental role and
a number of which appear to be able to play a part in the development of cancers,
particularly mammary tumours (Mester et al., 1987; Nusse et al., 1990;
Tsukamoto et al., 1988).
1.3.1.2 Frizzled
Frizzled or frizzled homologs have been found to be the receptor for the secreted
Wnt signalling family (see figure 1.3) (Vinson and Adler, 1987; Zheng et al.,
1995; Yang-Snyder et al., 1996). The frizzled loci of a wide range of species
encode a seven pass transmembrane protein; the cysteine-rich N-terminal portion
being exterior with the C-terminal portion extending into the cytoplasm (Vinson
et al., 1989; Bhanot et al., 1996). This exterior N-terminal region, containing 10
highly conserved cysteine residues is believed to interact with the circulating
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Wnt proteins and thereby transfer growth signals (Bhanot et al., 1996). It is not
completely clear how the interactions of some Wnt and Frizzled pairings can lead
to downstream modulation of the rest of the Wnt pathway. The C-terminal region
of many of the Frizzled molecules contain a S/TXV motif, a candidate for
binding with the PDZ domain (Songyang et al., 1997). Dishevelled contains one
of these domains at its C-terminus but evidence to date suggests that it does not
interact directly with Frizzled (Cadigan and Nusse, 1997; Nusse, 1997; Nusse et
al., 1997). There is some suggestion that G-protein signalling may be involved.
Some Wnt/Frizzled effects, such as regulation of Protein Kinase C in Xenopus,
can be blocked through the application of G-protein inhibitors while two of the
target proteins in the Wnt/wingless cascade, Axin and Dishevelled, contain
motifs found in other molecules known to be involved in G-Protein signalling
(Slusarski et al., 1997; Fagotto et al., 1999; Sheldahl et al., 1999).
1.3.1.3 Dishevelled
The next group of molecules involved in the transduction of the Wnt signal are
the dishevelled (dsh) protein and its cross-species homologs (see figure 1.2).
First characterised in Drosophila, dsh, a protein of approximately 650 amino
acids, has been determined to be vital to the conduction of developmental
Wingless signals (Klingensmith and Nusse, 1994a; Klingensmith et al., 1994b;
Noordermeer et al., 1994; Theisen et al., 1994). The dsh protein appears to fall
between frizzled activation and modulation of the next step in the Wg cascade;
zesty-white (the homolog of the mouse glycogen synthase kinase-3(3 or GSK-3(3)
(Siegfried et al., 1992; Noordermeer et al., 1994; Dominguez et al., 1995; Butz
and Larue, 1995; He et al., 1995). In the mouse, there are at least 2 homologs of
the dsh protein, dvl-1 and dvl-2, this multiplicity may explain why the dvl-1
knock-out mouse develops normally, showing only subtle neurological and
behavioural phenotype (Lee et al., 1999; Lijam et al., 1997). These proteins
exhibit very similar properties to Drosophila dsh, including co-
immunoprecipitation with casein kinase II (CKII), hyperphosphorylation on
overexpression of themselves or of frizzled homologs and the ability to suppress
GSK-3(3 activity (Ruel et al., 1999; Lee et al., 1999). It is not entirely clear how
the Wnt/Wg signal is conveyed through dsh proteins; in response to Wnt/Wg
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cellular dsh becomes hyperphosphorylated on serine and threonine residues and
tends to associate more closely with the plasma membrane (Yanagawa et al.,
1995; Axelrod et al., 1998; Klingensmith et al., 1996). Proteins of the
dishevelled family contain at least 4 conserved domains: there are 50 amino acids
referred to as the DIX domain in the N-terminal portion of the protein which
resemble a region of axin (another of the proteins involved in the WntAVg
pathway) as well as conserved PDZ and DEP domains in the central and C-
terminal regions (see figure 1.2) (Vasicek et al., 1997; Zeng et al., 1997;
Klingensmith et al., 1994b; Klingensmith et al., 1996; Heslip et al., 1997;
Theisen et al., 1994; Ponting et al., 1997). The dishevelled family of proteins
also appear to play a role in another signalling pathway; one of its conserved
domains, the DEP-domain, is implicated in the stimulation of the c-Jun/JNK
pathway (Li et al., 1999). Additionally, there is some evidence that, at least in
Drosophila, dsh proteins can interact with and influence the activity of the
important developmental protein notch (Rulifson et al., 1996).
1.3.1.4 Glycogen Synthase Kinase 3P (GSK-3P)
GSK-3P and its Drosophila homolog zeste-white 3 (zw3) are cytoplasmic
serine/threonine protein kinases with a number of target proteins in the Wnt/Wg
pathway (Ruel et al., 1999). Targets of GSK-3|3 and zw3 include P-catenin, axin
and APC as well as other related proteins such as the microtubule binding protein
Tau (Rubinfeld et al., 1996; Wagner et al., 1996). The primary role of GSK-3p
and its homologs in the conduction of the Wnt/Wg pathway appears to be in the
phosphorylation of P-catenin, a reaction that ultimately marks it for degradation
(see figure 1.3) (Aberle et al., 1997). The current model is that Wnt/Wg
signalling acts through frizzled and dishevelled homologs to downregulate the
activity of GSK-3P, thereby reducing the phosphorylation of the target proteins
involved in the Wnt/Wg pathway and creating an increase in the free cytoplasmic
pool of P-catenin through reduction in its rate of turnover. GSK-3P also appears
to bind other proteins which may influence its activity and may play some role in
regulation of the Wnt/Wg pathway; one of these proteins is Frequently
Rearranged in Advanced T-cell lymphomas, or FRAT1 (Thomas et al., 1999).
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This peptide appears to bind GSK-3(3 in such a way as to inhibit its interaction
with Wnt cascade proteins but does not inhibit its binding of other targets such as
glycogen synthase.
1.3.1.5 Axin
While (3-catenin was known to be a phosphorylation target of GSK-3(3, it was
discovered that, in vitro, this reaction is very inefficient (Yost et al., 1996). The
suggestion was that another cellular factor must be involved, increasing the
efficiency of the reaction. A candidate was soon identified in the mouse, Axin,
the gene product of the fused locus, so named because mutation at this locus
results in axial duplication (Zeng et al., 1997). As mentioned previously, Axin
bears a resemblance in its N-terminal region to the dvl-1 protein and also to G
protein signalling (RGS) proteins (Zeng et al., 1997). The role of the RGS region
of Axin is not clear, although its loss through mutation seems to lead to dominant
negative effects in Xenopus, resulting in axis duplication as seen in the fused
mouse (Vasicek et al., 1997). The roles of other regions of Axin are much better
understood, these regions include motifs for the binding of a number of different
proteins including the armadillo repeat region of (3-catenin, GSK-3(3, APC and
itself through a C-terminal DIX dimerisation domain (see figure 1.2) (Behrens et
al., 1998; Nakamura et al., 1998; Hamada et al., 1999; Fagotto et al., 1999;
Sakanaka et al., 1998; Sakanaka and Williams, 1999; Ikeda et al., 1998; Hart et
al., 1998; Zeng et al., 1997). There is strong evidence to suggest that axin acts as
a scaffold, bringing together a number of different proteins to induce
phosphorylation of (3-catenin by GSK-3(3 with the participation of APC (see
figure 1.3) ultimately resulting in the degradation of (3-catenin (Behrens et al.,
1998; Hamada et al., 1999; Nakamura et al., 1998).
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Figure 1.3: A simplified diagram of the Wnt pathway signalling cascade. A) In the
absence of Wnt binding to membrane bound frizzled proteins the GSK-
3f3/Axin/APC complex retains phosphorylation and promotes the phosphorylation
and subsequent ubiquitination/degradation of (3-catenin. Wnt target genes remain
repressed by Groucho/CBP binding of the TCF/LEF transcription factors. B) On
Wnt binding to the surface frizzled proteins dishevelled represses the activity of the
GSK-3(3/Axin/APC complex and (3-catenin accumulates in the cytoplasm and can
translocate to the nucleus where it displaces Groucho/CBP to activate transcription
through interaction with TCF/LEF.
































(3-catenin plays at least two important roles in the cell, firstly mediating cellular
adhesion through its interactions with E-caherin and, indirectly, the cytoskeleton,
and secondly functioning as the lynchpin in the control of expression through the
Wnt/Wingless pathway (Gumbiner and McCrea, 1993; Butz and Kemler, 1994;
Behrens, 1999).
1.3.1.6.1 Structure and function
(3-catenin shows a great degree of cross-species conservation both in its structure
and its function. Human (3-catenin consists of 781 amino acids arranged broadly
into 3 important domains (see figure 1.2) (Hulsken et al., 1994a). The first
comprises the N-terminal 130 amino acids and contains a number of
phosphorylation target residues for the GSK-3(3 (Yost et al., 1996). The central
section of (3-catenin contains twelve 42 amino acid armadillo repeats and forms
an important protein interaction domain while the carboxy terminal 100 amino
acids form a region of interaction with nuclear transcription factors (Huber et al.,
1997; van de Wetering et al., 1997; Behrens et al., 1996; Vleminckx et al.,
1999).
The most N-terminal domain, the initial 130 amino acids, contains a number of
conserved serine and threonine residues (Polakis, 1999; Rubinfeld et al., 1997;
Orford et al., 1997). These residues have been found to be phosphorylated in vivo
and at least one kinase, GSK-3(3 in co-operation with the scaffold protein Axin,
appears to be responsible (Yost et al., 1996; Zeng et al., 1997). As a clue to the
function of this phosphorylation it has been found that N-terminal truncation
mutations of (3-catenins artificially introduced into cells tend to accumulate in the
cytoplasm, escaping the normal turn-over mechanisms (Barth et al., 1997;
Munemitsu et al., 1996). Additionally, in many tissues, activation mutations of
(3-catenin, those that result in its cellular accumulation and oncogenic effects,
often involve those bases coding for the N-terminal serine and/or threonine
residues (Iwao et al., 1998; Miyoshi et al., 1998a; Miyoshi et al., 1998b; de La
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Coste et al., 1998; Fukuchi et al., 1998). The residues involved in most of the
activation mutations have been found to be serines 33, 37 and 45 as well as
threonine 41 (Morin et al., 1997; Polakis, 1999). The phosphorylation of these
residues has been hypothesised to regulate the stability of free pools of (3-catenin
in the cell by modulating the targeting of (3-catenin to the
ubiquitination/proteosome pathway (Aberle et al., 1997; Orford et al., 1997).
The importance of the maintenance of appropriate concentrations of free (3-
catenin in the cytoplasm to normal cell function is highlighted by the apparent
mutual exclusiveness of (3-catenin C-terminal mutations and APC truncation
mutations in the same neoplasias; nearly all colorectal cell lines as well as
spontaneous or induced tumours of the colon show either one or the other
mutation, but not both (Ilyas et al., 1997; Sparks et al., 1998). With the majority
of phenotypic mutations of APC leading to a lack of (3-catenin binding and
phosphorylation and the majority of (3-catenin mutations resulting in
phosphorylation incompetence, this suggests that colorectal carcinogenesis may
have a near absolute requirement for interruption of normal (3-catenin
phosphorylation through APC interaction. One mutation in this pair of proteins
may lead to a reduction in selective pressure for another mutation.
The central portion of the (3-catenin protein, as mentioned previously, consists of
12 armadillo repeats. As previously mentioned armadillo repeats together form a
complex 3-dimensional structure, encompassing a tightly packed series of short
a-helices with a positively charged central groove, usually associated with
protein-protein interactions (Huber et al., 1997). Indeed, this central region does
appear to be involved in the interaction of (3-catenin with a number of other
proteins, including T-cell Transcription Factor 1 (TCF-l)/Lymphocyte Enhancer-
binding Factor 1 (LEF-1), APC, E-cadherin, Axin and the actin associate protein
Fascin (Molenaar et al., 1996; Behrens et al., 1996; Rubinfeld et al., 1995;
Hulsken et al., 1994b; Nakamura et al., 1998; Tao et al., 1996). Many of these
interactions appear to occur in overlapping portions of the armadillo tertiary
structure groove; indeed, some of these protein interactions appear to be mutually
exclusive (Hulsken et al., 1994b). The evidence for the interaction of these
proteins with this portion of the (3-catenin molecule is supported by the fact that
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many of these proteins are acidic and as such are negatively charged at cellular
pH. Additionally, the phosphorylation of APC by GSK 3(3, which increases the
stability of (3-catenin/APC interactions, also increases the negative charge of
APC (Huber et al., 1997). It is this central section of (3-catenin which is perhaps
most responsible for its cellular effector functions. The interactions of the (3-
catenin armadillo repeat domain with E-cadherin and with a-catenin play a role
in cellular adhesion; E-cadherin is a calcium ion dependant cell adhesion
molecule, whose cytoplasmic domains bind either (3-catenin or y-catenin
(plakoglobin) (Aberle et al., 1996). Either catenin molecule (y or (3) is then
complexed with a-catenin which in turn acts as a bridge to bind to actin
molecules making up the cytoskeleton (Aberle et al., 1996). In this way P-
catenin links cell surface adhesion molecules to the cell architecture.
The carboxy terminal region of P-catenin has been determined to act as a
transactivation domain, influencing transcription of target genes when binding
TCF/LEF transcription factors (van de Wetering et al., 1997; Vleminckx et al.,
1999). P-catenin appears to displace the corepressor molecule groucho from
these High Mobility Group (HMG) transcription factors when cytoplasmic levels
of free P-catenin have reached a sufficient concentration (see figure 1.3) (Roose
et al., 1998). An additional repressor of this transcriptional activation appears to
be CREB-binding protein (CBP) which also binds TCF transcription factors
(Waltzer and Bienz, 1998).
1.3.1.6.2 Downstream targets of P-catenin
As mentioned above, p-catenin associates with the HMG transcription factors
LEF-1 and the TCF family, especially TCF-4, and contains a transactivation
domain (Aoki et al., 1999; Clevers and van de Wetering, 1997; van de Wetering
et al., 1997). In order to have an effect on levels of transcription of target genes
the p-catenin/transcription factor complex must locate to the nucleus.
Interestingly it appears that P-catenin can translocate into the nucleus
independent of importins and without containing a nuclear localisation signal
(Yokoya et al., 1999; Fagotto et al., 1998). Additionally it appears that binding
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of (3-catenin to the LEF transcription factors can increase the uptake of the
complex by the nucleus (Huber et al., 1996b). Although the mechanism for (3-
catenin/transcription factor nuclear localisation is unclear at present, it is clear
that the complex upregulates transcription levels of a number of target genes.
Genes which have been identified as targets of the (3-catenin/LEF/TCF
transcriptional activation include a number of genes thought to be involved in
adhesion or growth control and neoplasia; these include c-myc, cyclooxygense-2,
cyclin Dl, fibronectin and E-cadherin among others (He et al., 1998; Howe et
al., 1999; Shtutman et al., 1999; Gradl et al., 1999; Huber et al., 1996a). Other
genes which have been implicated in neoplastic growth have also been found to
be targets of (3-catenin/TCF activation, an example being the matrilysin
metalloproteinase, which appears to confer growth potential to cells and Cdxl, a
murine homeobox gene which is downregulated in most human colorectal cell
lines (Brabletz et al., 1999; Wilson et al., 1997; Crawford et al., 1999; Eickert et
al., 2000). The number of genes identified as targets of the (3-catenin/TCF
complex is rapidly increasing and encompass genes involved in a large number
of cellular pathways (see http://www.stanford.edu/~rnusse/wntwindow.html).
The final effects ofWnt activation would appear to be very complex on the level
of gene transcription control, although the final effects on development and
neoplasia are perhaps better understood.
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1.3.2 The Wnt pathway in development
It appears that the Wnt pathway plays a very important role in pattern
development in a number of diverse species. In Drosophila, C. Elegans,
Xenopus and the mouse the wingless pathway seems to be intimately involved in
the specification of cellular differentiation and/or in the development of body
axis (Hayashi et al., 1997; Rocheleau et al., 1997; Vleminckx et al., 1997;
Dobashi et al., 1996). In Drosophila the Wingless pathway is essential to the
induction of segment polarity, while in C. Elegans this pathway functions to
promote differentiation of cells into endoderm (Cabrera et al., 1987; Rocheleau
et al., 1997). In Xenopus Wnt/Wingless signalling appears to control the
formation of dorsoanterior axis; injections of a number of Wnt RNAs which
result in the overexpression of various members of the Wnt family has been
observed to result in the duplication of this axis (Wodarz and Nusse, 1998; Miller
and Moon, 1997; Fagotto et al., 1997; Itoh et al., 1998). Also in Xenopus the
Wnt pathway appears to interact with the SMAD/STAT pathway in the assembly
of the Spemann organiser (Laurent et al., 1997; McKendry et al., 1997).
Additionally it would appear that Wnt and its homologues are vital to the process
of cellular differentiation. Studies in the rat have revealed that the APC gene is
upregulated in the developing nervous system, particularly during the
differentiation of certain cell types (Bhat et al., 1994; Dobashi et al., 1996).
This process of differentiation takes place not only during embryogenesis, during
which structures and organs are produced, but also occurs in certain tissues of the
mammal in a life-long manner. Some examples include the haemopoietic system,
wherein mature blood cells differentiate from progenitor cells (stem cells) and
the epithelium of the intestine, where cells are continuously sloughed into the
lumen to be replaced by cells derived from stem cells found in intestinal crypt
structures. In the mouse the development of the intestine begins on the seventh
day of gestation, with connection to the oral cavity occurring on day 9 and fusion
with the hindgut to give rise to the anal opening on day 10 (Gilbert, 1994).
While the large-scale structures of the mouse gut are in place prenatally, the
maturation of the epithelial lining is not complete until some weeks after birth.
Intestinal crypts, the basic unit of cell proliferation in the mammalian large and
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small intestine are fully mature until between two and three weeks postnatally
(Calvert and Pothier, 1990). The crypts are, in a sense, a source of cells in
continuous development. At the base of the crypts are found a number of stem
cells, which divide continuously to give daughter cells which are themselves
capable of division although not indefinitely. The number of stem cells and their
location differ in the large and small intestine (Potten and Booth, 1997). In the
small intestinal crypts the 4-16 stem cells, capable of division every -24 hours,
are found arranged in a ring at the fourth position from the base of the crypt
which is occupied by differentiated paneth cells (see figure 1.4a). In the large
intestine a similar number of stem cells are found in the very base of the crypt
(see figure 1.4b) (Bach et al., 2000). The process of cell division in the crypt is
coupled with a continuous migration of these cells out from the base of the crypt
to the villi of the small intestine or the lumenal surface in the large intestine
where the cells are eventually sloughed off. During this migration the cells
become less and less capable of division and become more differentiated. This
process gives a crypt to lumen gradient of differentiation, marked by changing
expression patterns including expression ofmany of the proteins involve in the
Wnt signalling pathway including (3-catenin and APC (Nathke et al., 1996;
Nathke et al., 1994). This constant process of differentiation may be driven in
part by the Wnt pathway and may explain the central importance of this pathway
in the maintenance of growth control and prevention of carcinogenesis in the
mammalian intestine.
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Figure 1.4: A) The basic structure of the small intestinal crypt. The crypt is
composed of ~250 cells of which 4-16 are stem cells and some 150 retain
proliferative capability. The cells migrate out of the crypt and onto adjacent villi
from which they are eventually shed into the intestinal lumen. B) The large















1.3.3 Dysregulation of the Wnt /Wingless pathway
The role of the Wnt pathway in the control of embryonic development and the
differentiation of cells in particular tissues has been largely elucidated by study
of its dysregulation. Axis duplication and failure of segment polarity
development are just some of the disruptions of development possible with
altered Wnt/Wingless signalling. Additionally, disruption of normal Wnt
signalling in the adult organism can result in a disease phenotype, most notably
in the development of neoplastic disorders. Neoplastic cells are those which have
gained the ability to grow independent of physiological regulation; this
regulation may take the form of internal signals such as those which promote
apoptosis or external signals such as growth factors or contact inhibition. While
the events leading to this loss of control are not yet fully understood it has
become clear that such a dramatic change in cellular behaviour is not the result of
a single factor but more often the result of accumulated genetic alterations
(Vogelstein and Kinzler, 1993). The "multi-step" progression from normal to
neoplastic cell has been well studied in colorectal cancers, where mutations in
genes involved in the Wnt pathway have been found to be common events. The
APC gene has been found to be mutated in over 80% of both sporadic adenomas
and sporadic human colorectal carcinomas and so is strongly linked to tumour
development and (3-catenin has also been found to be mutated in a significant
proportion of these lesions (Smith et al., 1993; Jen et al., 1994; Iwao et al.,
1998). Study of these colorectal tumours has also suggested that the order in
which genetic lesions occur is integral to tumour formation: in the case of
colorectal carcinoma the loss of wild-type APC function is thought to be a very
early event (Luongo et al., 1994; Powell et al., 1992). The sequence of events in
the genesis of a colorectal tumour is thought to begin with the loss of the
"gatekeeper" function of APC, in which APC is thought to work to integrate
several cellular signals to limit cell proliferation. Loss of this function leads to
altered cell proliferation; colonic crypts become dysplastic, accumulating cells
more rapidly than they are lost or absorbed thus leading to polyp formation. One
or more of these accumulating cells may then go on to experience mutations in
cellular oncogenes, such as RAS which allows more prolific cell growth. The
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rapid growth of these cells, possibly coupled to deficiencies in DNA repair
mechanisms, may eventually lead to the loss of a number of tumour suppressor
genes (such as p53) allowing the more rapid accumulation of genetic damage.
These altered cells may finally accumulate further changes which allows them to
become invasive, achieving metastasis.
As mentioned above it is not only mutations in APC which can result in Wnt
pathway mediated growth control escape. The first identified Wnt gene was
found as a result of its virus integration activation leading to breast cancer in
mice (Nusse and Varmus, 1982; Li et al., 2000). (3-catenin mutations have been
detected in colorectal tumours, as well as in hepatocellular carcinomas and
ovarian carcinomas (de La Coste et al., 1998; Gamallo et al., 1999). Additionally
levels of a secreted frizzled homolog appear to be depressed in some breast
cancers, possibly enhancing regular Wnt signalling interactions by freeing more
Wnt ligand to bind with membrane bound frizzled molecules (Zhou et al., 1998).
The implication of many of the members of the Wnt pathway in various
neoplastic disorders, primarily deriving from epithelial tissues, suggests a
fundamental role for this pathway in the control of growth and differentiation in
this tissue type.
It has been relatively recently discovered that the Wnt pathway is modulated in
vitro in response to genotoxic insult, leading to speculation that this regulation
may also occur in vivo. Human derived colorectal cell lines as well as murine
embryonic fibroblasts appear to upregulate levels of both APC mRNA and
protein in response to treatment with N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG), a powerful methylating agent (Jaiswal and Narayan, 1998). This APC
upregulation may lead to the increased degradation of P-catenin and concomitant
downregulation of Wnt target genes. Interestingly, the methylation dependant
induction of APC appears to be dependant on functional p53 tumour suppressor
protein activity as cell lines and primary cultures lacking p53 failed to show a
response when subjected to MNNG (Narayan and Jaiswal, 1997).
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1.4 The Min Mouse; a murine model of FAP
The human syndrome FAP (section 1.1.2.2) led to the discovery and
characterisation of the human APC gene and its product. The role of APC as a
potent tumour suppressor in the intestine, and to a lesser degree in other tissues,
suggested that an understanding of the cellular functions of APC would lead to a
more global understanding of the process of tumour formation. The in depth
study of APC's interactions and the changes in cellular responses following APC
mutation would be near impossible if human tumours or tissues from FAP
patients were the only sources of experimental models. What was needed was an
animal model.
Random mutagenesis using the point mutagen Ethylnitrosourea (ENU) created a
mutant which displayed two unusual phenotypes caused by separate mutations; it
tended to run in circles and it rapidly developed anaemia (Moser et al., 1990).
The anaemia was soon found to be caused by bleeding from the intestine, itself
precipitated by the presence of a number of polyps; the mice were termed Min
(multiple intestinal neoplasia) mice and the phenotype was eventually traced to a
heterozygous truncation mutation at codon 850 in the murine homolog of the
human APC gene (Moser et al., 1990; Su et al., 1992). Because of the obvious
parallels between this mutant mouse line and the human FAP patients, the Min
mice soon became involved in the study of tumour development.
1.4.1 Phenotype of the Min Mouse
While mainly phenotypically normal the Min mouse, like the human FAP
patient, is prone to development of numerous intestinal polyps which have lost
the remaining wild type copy of murine Ape, eventually leading to tumour
development (Luongo et al., 1994). Interestingly the polyps and subsequent
tumours in the Min mouse tend to develop primarily in the small intestine, while
in the human they are largely associated with the large intestine and colon
(Moser et al., 1995; Chow et al., 1996; Neugut et al., 1998). While the Min
phenotype is eventually lethal it has nevertheless enabled the study of many
aspects of the genetics of intestinal cancers (Moser et al., 1990). Once the Min
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mouse line was phenotypically characterised it was used in the search for factors
which may modulate the penetrance of the Ape mutation initiated
adenocarcinomas. Matings with mouse strains bearing other genetic alterations,
provided clues to the mediators of Ape function and its role in neoplasia. One of
the first genes which was discovered to alter the severity of the Min phenotype
was Mom-1 (Modulator of Min), which was mapped to the distal portion of
chromosome 4 (Dietrich et al., 1993). It was discovered that the Mom-1
background on which the Min genotype was crossed could alter the number of
intestinal polyps formed by several fold and that -50% of this change could be
directly attributed to the genetic influence of Mom-1 (Dietrich et al., 1993).
Recently the Mom-1 gene product has been identified as the secretory
phospholipase-a2 (Pla2g2) which is expressed in the murine small intestine and
is involved in the cleavage of fatty acids from lipids (MacPhee et al., 1995;
Gould et al., 1996a; Gould et al., 1996b) Although it is yet to be understood how
this molecule modulates the Min phenotype it is known that all mouse strains
displaying sensitivity to the Min phenotype contain a premature stop codon in the
Pla2g2 gene and Min sensitive mouse lines which have been engineered to
express a full length Pla2g2 transgene construct which does not contain the
premature stop codon display markedly reduced polyp formation (Cormier et al.,
1997).
Mice bearing the Min mutation, when crossed onto resistant genetic
backgrounds, survive long enough to develop tumours other than those of the
intestinal epithelium, including mammary carcinomas in 10% of female mice
(Moser et al., 1993). Coupled with the observation that APC is lost from human
breast cancer tissues at a significant rate the Min mouse may also prove to be a
model for some types of breast cancer (Thompson et al., 1993).
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1.4.2 Embryonic lethality of the homozygote
Double (homozygous) knock-out animals generated using traditional genetic
engineering technologies generally prove unsuitable for the study of tumour
suppressor genes which are both vital to embryonic development and involved in
tumour development in the adult. In the mouse it was soon revealed that Ape was
one of these genes, perhaps not surprising due to the central importance of the
Wnt pathway in development (Moser et al., 1995). Mice bearing one functioning
copy of the murine equivalent of the human APC gene could develop to term and
were live born, although they developed a large number of polyps of the intestine
later in life (Su et al., 1992). Mice homozygous for the Min mutation are
embryonic lethals; these animals fail to develop past the stage of gastrulation and
are reabsorbed well prior to birth, before day 10 of gestation (Moser et al., 1995).
This fact, combined with the localisation of Ape at the leading edge of migrating
cells seems to indicate that the early lethality of these mutants may be due to
inability to initiate or to control migration, either through E-cadherin dependant
adhesion or through (3-catenin related cellular proliferation.
1.4.3 Comparison of the Min model and human disease
While the Min mouse has served as a model of FAP there are nevertheless some
significant differences between the human FAP phenotype and symptoms
displayed by the Min mouse. As mentioned previously, the Min mouse tends to
develop tumours predominantly in the small intestine, while in the human the
disease is characterised by polyp and tumour formation in the large intestine or
colon (Moser et al., 1990; Bilger et al., 1996). Additionally the mammary
tumours developed by a significant proportion of female Min mice do not afflict
human FAP patients, although APC mutations are found in some human
mammary carcinoma (Moser et al., 1993; Furuuchi et al., 2000; Jonsson et al.,
2000). On the other hand, FAP patients tend to develop extraintestinal
complications not observed in the Min mouse; these include desmoid and bone
tumours, skin cysts and enlarged retinal pigment cells (Soravia et al., 1997).
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Some of these differences in phenotype between human FAP patients and Min
mice may be caused by the location of the relevant APC truncation mutations. A
number of alternative murine Ape truncation models have been generated
through targeted insertion of mutations; these include the APC 1638N mutation,
which produces no detectable Ape protein from the altered allele (Yang et al.,
1997). This line displays a phenotype closer to that traditionally associated with
FAP; in addition to the expected intestinal lesions these mice develop the
desmoid tumours, cutaneous cysts and display retinal epithelial abnormalities
mimicking the symptoms observed in FAP patients (Smits et al., 1998; Marcus et
al., 1997). It is also possible that the difference in the predominant location of
tumour development, small intestine in the mouse and large intestine/colon in the
human may be partially influenced by diet; APC 1638N mice fed on a high fat
"western" diet displayed more invasive cancers of the colon, like those found in
the human disease, than those on control diet (Yang et al., 1998).
1.5 Transgenic and knock-out mice as cancer models
The modelling of a human disease is often facilitated by the identification of a
homologous disorder in a model organism. Because of its small size, short
generation and its relatively close evolutionary link to humans the mouse is often
the model organism of choice. However, while spontaneous or recessive
mutations in mouse lines can sometimes be identified which mimic human
disorders, the screening of huge numbers of mice would be required to find
"natural" models of human disease. Several techniques have been used to
generate models in a more efficient manner, including the application of
chemical mutagens to increase the natural rate of mutation followed by screening
and identification of affected genes. One notable success of this approach is the
Min mouse, generated by ENU treatment of male mice prior to breeding (Moser
et al., 1990). The generation of mouse mutants through chemical mutagenesis
techniques has been complemented by the planned alteration of the mouse
genome; altering gene homologues already known to be dysregulated in human
disorders.
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The ability to modify the genomes of model organisms has given much insight
into the developmental and disease roles of a large number of target genes. The
study of many human diseases has been made considerably easier through the
ability to specifically alter the expression of genes in the mammalian model
organism. Congenital genetic disorders such as cystic fibrosis and some forms of
diabetes have been successfully mimicked in the mouse through planned
genomic modifications, most often through introduced deletion or loss of
function mutations in single genes (Dorin et al., 1992; Dorin, 1995; Yamamura
et al., 1992; Janson et al., 1996). These altered lines can be crossed with other
engineered lines to explore the roles of multiple gene loss in disease progressions
or can themselves be further modified (Toft et al., 1999). One of the most
important uses for these knock-out or transgenically modified mice is in the
study of cancer development and progression.
While tumour development often requires the mutation and/or modification of
large numbers of genes it has been discovered that a relatively small number of
genes are mutated in a large proportion of cancers; these genes fall into the
categories of proto-oncogenes or tumour suppressor genes depending whether
gain of function or loss of function mutations lead to initiation of disease. These
genes make likely candidates for site specific gene knock-out (loss of function)
and/or transgenic (gain of function) manipulation of the mouse genome. Several
tumour suppressor genes have been successfully knocked-out in the mouse; these
include p53, retinoblastoma (rb-1), pl6 and pl9ARF, BRCA1/2 and Ape among
others (Donehower et al., 1992; Clarke et al., 1992; Kamijo et al., 1997; Hakem
et al., 1996; Yang et al., 1997). All of these mice display phenotypes mimicking
those observed in human patients with germline deficiencies in the human
homolog genes; increased tumour incidence either globally or in tissues relevant
to the specific gene. Additionally these mice have been used in the development
of chemotherapeutic or chemopreventative drugs and have provided a wealth of
information on the accumulation of further genetic defects which cause tumour
progression (Lipkin, 1997; Smits et al., 1997). Transgenics have been used to
allow the overexpression of genes in mouse lines, either through the use of strong
promoter or through the inclusion of multiple copies of the transgene
simultaneously in the genome. Transgenics have also been used to modulate
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knock-out phenotypes generated by site-specific alterations of the mouse
genome; by partially compensating for disease causing mutations or rescuing
potentially lethal homozygotes (Zhou et al., 1994; Shibata et al., 1997).
1.5.1 Introduction of exogenous DNA into mouse oocytes; transgenics
Transgenic mice were first engineered over 25 years ago; the injection of Simian
Virus 40 (SV40) viral DNA into the developing mouse blastocyst resulted in the
successful integration of the viral sequences into the host genome, where they
were subsequently detectable in all tissues (Jaenisch, 1975). Since this time, the
technology has progressed to the injection of more significantly altered DNA
sequences into the pronuclei of the fertilised mouse egg; the injected DNA will
undergo illegitimate recombination, inserting at one or more essentially random
points in the genome, often as concatamers of transgene DNA (Palmiter and
Brinster, 1986). Mice produced by this method are screened to determine the
number of integration sites and the number of transgene copies which have
inserted. The uncertain nature of the integration process involved with transgenic
modification can prove to be a significant drawback. It has been noted that the
location of integration can have a very significant influence, termed positional
effect, on the levels of expression achieved from the transgenic construct.
Integration may take place inside the coding sequence of a native gene,
disrupting transcription and thereby contributing an additional phenotype to the
mouse (Palmiter and Brinster, 1986; Fukushige and Sauer, 1992). An additional
limitation of this approach is the inability to efficiently delete expression; while
some techniques exist by which transgenic manipulation could reduce or
counteract native expression of a particular gene, transgenics cannot efficiently
generate null alleles. The ability to efficiently delete or replace specific genomic
sequences is termed gene targeting.
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1.5.2 Site-specific alteration of the mouse genome to produce disease models;
Gene targeting
Altering the genome in a targeted manner requires the harnessing of native
cellular mechanisms, some knowledge of the region of genome to be changed
and the isolation of cells which can be used to carry the genetic alterations into
adult mice. Cells can and do undergo a process of DNA strand exchange between
regions of similar sequences referred to as homologous recombination (HR). In
eukaryotes this process takes place during gametogenesis where sister chomatids
exchange DNA, while in both prokaryotes and eukaryotes HR is involved in the
repair of DNA which has suffered mutation or breakage (Bollag et al., 1989).
The exact mechanistic processes involved in HR are still not fully understood but
a number of models have been proposed. The first model involves the generation
of a single stranded DNA molecule with a free end from one of the homologous
pair sequences which proceeds to invade the double strand of the target
molecule. The displaced DNA strand from the target molecule forms what is
referred to as a D-loop; a loop of single stranded DNA which degrades to its own
free end which then invades the "attacking" DNA double strand (Meselson and
Radding, 1975). The ligation of both of the invading single strands to the free
end of the target strands creates a Holliday junction, a structure which can
migrate along the DNA molecules, exchanging material and eventually resolve
itself in one of two manners leaving behind strand exchange products (see figure
1.5) (Holliday, 1964). The second model of HR requires the double strand
breakage of one of the pairs of homologous molecules. One of the free ends thus
created invades the unbroken DNA molecule, resulting in the formation of a D-
loop. In this case the D-loop formation does not degrade; both strands making up
the D-loop act as templates for the cellular DNA replication machinery. The
result of this replication is the formation of two Holliday junctions; each capable
of migrating and resolving in two ways, leaving a total four possible
recombination products (see figure 1.6) (Szostak et al., 1983).









Figure 1.5: One model of the process of homologous recombination. In this model
A) recombination is initiated by a single strand nick in one of the participating
sequences. The nicked strand is displaced from its complementary sequence by DNA
repair synthesis and B) invades the homologous double stranded DNA of the other
molecule. C) The invading strand continues displacing its homologous sequence
which is degraded creating an asymmetric heteroduplex. D) The free ends of the
newly synthesised and partially degraded strands are ligated together forming a
Holliday junction which can migrate along the DNA molecules. E) The first possible
resolution of the Holliday junction produces gene conversion areas as well as
crossover segments. F) The second mode of resolution of the Holliday junction
involves cutting of the crossed strands ( without isomerisation) producing only gene
conversion products.
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Figure 1.6: Homologous recombination; the double Strand Break model
Figure 1.6: A second model of the process of homologous recombination. In this
model A) recombination is initiated by a double strand break in one of the
participating sequences. B) A single strand from the broken molecule then invades
the homologous double stranded DNA of the other molecule. C) Repair processes
extend the invading single strand, displacing it's homologous sequence from the
invaded molecule. D) Repair of the broken molecule and ligation of the free ends
results in the formation of 2 Holliday junctions. E) The two Holliday junctions may
resolve in 4 manners involving simple resolution without junction isomerisation (1),
resolution following isomerisation of one of the junctions (2,3) or resolution
following isomerisation ofboth junctions (4).
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Whatever the exact mechanism of HR, the common factor is the presence in
close proximity of two DNA strands of very similar sequence. Because of this
requirement for homology the alteration of a particular gene or other genomic
structure through HR by necessity requires some knowledge of the sequence of
the DNA to be affected. General gene targeting approaches used to generate
knock-out mutations of specific genes use arms of homology, regions of
sequence identical to the target region, in conjunction with one or more
selectable markers and elements designed to interrupt the coding sequence.
Successful knock-out HR replaces one or both genomic copies of a target with
the selectable marker allowing isolation of successful recombinants.
Modifications to this strategy have been developed, some using a second round
of HR, to generate subtle mutations in target genes or to remove the selection
marker to prevent it contributing a phenotype to the animal ultimately produced
(Askew et al., 1993; Stacey et al., 1994).
While the process of HR can generate the desired mutations they are of little use
if the cells thus modified cannot generate whole animals. Of primary importance
to the creation of models of human disease through specific alterations of target
genes was the isolation and development of a culture system for cells which
retain totipotency following genetic manipulation. The use of fertilised eggs in
the generation of transgenics does not allow for the screening of large numbers
of possible recombinants prior to gestation. Embryonal Stem (ES) cells prove to
have the properties needed to generate recombinants, screen possible cells and
finally generate an entire engineered mouse. These cell lines are isolated from
peri-implantation mouse blastocysts; under standard culture conditions these
cells differentiate spontaneously into a variety of cell types, underlining their
totipotency (Evans and Kaufman, 1981). ES cells plated onto feeder cell layers or
grown in media conditioned by Buffalo Rat liver (BRL) cells were able to remain
undifferentiated and could be grown, passaged and maintained in culture
relatively easily (Smith and Hooper, 1987). Eventually a single cytokine was
found to be largely responsible for the maintenance of this state, Leukaemia-
inhibiting Factor (LIF); addition of recombinant LIF to ES cell media allows the
cells to remain undifferentiated (Williams et al., 1988; Moreau et al., 1988).
Importantly, these cells can maintain a normal karyotype and can colonise
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various tissues to generate chimeric animals when injected into a mouse
blastocyst (Gossler et al., 1986). ES cells are injected or electroporated to
introduce the recombination construct and cells having undergone the expected
HR are selected and screened. Cells which are found to have the correct genetic
alterations are then cultured and introduced into blastocysts; if the introduced ES
cells colonise the germline progenitor cells of the chimeric mouse, the genetic
alteration can be passed on to generate an animal which contains the manipulated
DNA in every cell.
1.5.3 Conditional Gene Targeting
In the search for methods of even finer control of gene expression in vivo a
number of systems were discovered and developed to allow inducible control of
gene knock-out or activation. Two systems have become widely used in a
number of model organisms and cell lines; the FLP/frt system, isolated from
Saccharomyces cerevisie and the Cre/loxP system discovered in the
bacteriophage PI (Broach and Hicks, 1980; Abremski et al., 1983).
1.5.3.1 Background: The FLP/frt system
Both the Cre/loxP and the FLP/frt systems rely on specific DNA sequences and
on an enzymatic recombinase capable of recognising these sequences. The FLP
recombinase, a member of the integrase family, is encoded on the 2pm circle
plasmid of Saccharomyces cerevisie and is involved in its replication cycle
(Volkert and Broach, 1986a; Volkert et al., 1986b). The specific DNA
sequences, frt sites, are 48bp motifs, composed of two 13 base pair direct repeats
separated by 1 base, an 8bp spacer element and a third 13 basepair
complementary repeat (Meyer-Leon et al., 1984). Three Flp proteins bind to
these sequences, in a specific order, binding first to the central 13 basepair motif,
followed by binding to the more upstream 13bp repeat and finally to the most
downstream repeat (Andrews et al., 1987). This sequential binding introduces a
significant bend, greater than 144°, to the DNA (Schwartz and Sadowski, 1990).
This bending allows protein interactions between the Flp molecules on paired frt
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sites, the end result being a site-specific cleavage and exchange which results in
the excision of the DNA sequence between frt sites (Amin et al., 1991; Amin et
al., 1990; Jayaram, 1994).
1.5.3.2 Background: The Cre/LoxP system
The second commonly used recombinase/site system is the Cre/loxP system
(Abremski and Hoess, 1984). The Cre recombinase (causes recombination) of
bacteriophage PI functions during the replicative cycle of the phage to
circularise monomeric genomes out of the concatameric replication product
(Segev and Cohen, 1981). The LoxP sites (/ecus of crossover) are composed of
two 13bp inverted repeats flanking a central spacer region of 8bp (Hoess et al.,
1982; Hamilton and Abremski, 1984). Each of the 13bp repeats binds a Cre
molecule during the process of recombination. The spacer region provides a
region of DNA bending, allowing two loxP sites on the same DNA molecule to
be brought together and made to interact as well as conferring directionality on
the loxP site (see figure 1.7a)(Guo et al., 1997; Lee and Saito, 1998).
Additionally, the spacer region imparts control over which loxP sites may
recombine; several mutant loxP sites have been created bearing altered spacer
sequence which will not efficiently react with each other or with wild-type loxP
sites but will efficiently recombine with themselves (Araki et al., 1997; Lee and
Saito, 1998; Lee and Park, 1998). The functional conformation of the Cre and the
loxP sites during recombination reactions consists of 4 Cre molecules (2 per loxP
site) and 2 loxP sites brought into parallel positions by bending of the DNA
molecule or by alignment of separate DNA molecules (Hoess et al., 1987; Guo et
al., 1997). The tetrameric structure then introduces sharp bends in the loxP site
spacer regions, thereby positioning the cleavage and ligation sites of the DNA
molecule(s) into the active sites of the recombinases (Guo et al., 1997). A set of
nucleophilic attacks catalysed by conserved tyrosine residues takes place,
ultimately resulting in strand exchange and completed recombination (see figure
1.7b) (Guo et al., 1997). There are a number of possible outcomes of this
reaction, depending on the orientation of the loxP sites and the number of
molecules involved. When the loxP sites contained in the same DNA molecule
are oriented in the same direction the intervening DNA sequence (referred to as
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being/lanked by loxP sites or floxed) is circularised and liberated from the parent
molecule (see figure 1.8). LoxP sites in opposite orientation in the same DNA
molecule can result in two reactions; the inversion of the intervening sequence on
Cre mediated recombination or the creation of dicentric chromosomes during
mitosis (Lewandoski and Martin, 1997). Alternatively, with loxP sites on
separate DNA molecules, Cre mediated recombination will result in the co-
integration of the two molecules. Importantly, this reaction appears to be carried
out without the use of ATP or co-factors and functions in a number of organisms,
including a wide variety of eukaryotes (Hoess and Abremski, 1985; Sauer, 1987).
These characteristics make the Cre/loxP system a very useful tool for the
manipulation of gene expression and the development of disease models.
1.5.3.3 Manipulation of the genome using the Cre/LoxP system
The flexibility of the Cre/loxP system makes it useful in a number of different
gene modification strategies. The applications with the most potential, perhaps,
are those which aim to use the site-specific recombinase to alter the expression of
a particular gene in a precise tissue type at a specified time (see figure 1.9). In the
drive to achieve this level of control a number of factors have had to be
addressed and dealt with; most importantly developing the ability to control the
location of Cre activity and/or expression and the generation of strains of model
organisms bearing the desired genomic alterations.
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Figure 1.7: A) The sequence of the native LoxP site. B) A representation of the
recombination reaction. The tyrosine 324 residue of the Cre recombinase initiates a
nucleophilic attack on the phosphate bond of the 5' guanine residue of the loxP site
spacer region of one of the DNA strands. The hydroxyl groups of the liberated
DNA ends subsequently attack the tyrosine/phosphate bond generating a pair of
DNA strand crossovers. The tyrosine 324 residue then attacks the same guanine
residue in the remaining DNA strand and the hydroxyl groups again attack the
tyrosine/phosphate bond, resolving the DNA strand crossovers.
Figure1.7:TheCre/loxPrecombinationmechanicsandtloxPs qu e
Figure 1.8: Cre mediated excision of a loxP flanked (floxed) DNA sequence
Figure 1.8: A model of Cre-mediated recombination/excision of a stretch of floxed
DNA A) The sequence to be excised is flanked by 34bp loxP sites (black
arrowheads) in the same orientation within the DNA molecule. B) The Cre
recombinase brings the loxP sites together in a parallel manner and initiates the
recombination reaction (see figure 1.7 for details). C) Following recombination the
stretch ofDNA originally flanked by loxP sites is excised as a closed loop containing
one loxP site while the parent molecule retains the second loxP site within its






Figurel.9:The generation of global, tissue specific and/or time specific null
phenotypes by Cre recombination.
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1.5.3.4 Regulating the expression and/or activity of the Cre recombinase
A number of strategies have been developed to control both the location of Cre
expression or delivery as well as its activity in situ, many of which have been
used in vivo to achieve genomic modifications. Some of the tools and techniques
employed to achieve this specificity include the delivery of Cre coding sequence
in viral systems, the use of tissue-specific or inducible promoters to drive Cre
expression and the use of Cre fusion proteins which can be ligand activated.
The delivery of Cre coding sequences directly to tissues in vivo or to cell cultures
in vitro can take place in a number of different manners. The most widely
employed method appears to be the use of a viral mediated system. The most
successful systems to date involve the use of modified adenovirus vectors. In
general a segment of the viral genome is deleted (the El or E3 genes most
commonly) and replaced with the Cre coding sequence under the control of a
strong promoter (Anton and Graham, 1995; Sakai et al., 1995). The resultant
virus is replication deficient but still capable of infecting a wide range of cell and
tissue types. The infected cells maintain the virus delivered DNA sequences
episomally for a short period before being degraded but this transient expression
of Cre recombinase may be sufficient to bring about the desired alteration in
target gene function. This system has been used with success in CV1 cell lines
where high efficiency of infection has been achieved and recombination has been
clearly and consistently achieved (Kanegae et al., 1995). In vivo the situation is
more difficult to control as the presence of an immune system in experimental
organisms, as well as a large number of cell types for which adenovirus displays
varied tropisms, can result in suboptimal infection efficiencies and alteration of
phenotypes (Yang et al., 1994; Yang et al., 1996; Wang et al., 1996). Despite
these difficulties a number of mouse lines bearing loxP altered target genes have
been successfully infected with these altered adenovirus constructs. The high
affinity for hepatocytes displayed by adenovirus makes the liver a prime target
for the use of this recombination system. Intravenous administration of Cre
encoding adenoviruses has been used to achieve both the activation and deletion
of genomic targets in the liver, with a relatively low background of
recombination occurring in other tissues (Wakita et al., 1998; Rohlmann et al.,
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1998; Stec et al., 1999). More specific administration of Cre carrying
adenoviruses can also be used: for example, this system has been used to
introduce active Cre genes and induce recombination in the epithelium of the
murine colorectum through enema application (Shibata et al., 1997). Other virus
systems have also been used to deliver Cre genes into target cells; these include
Herpes Simplex (HSV) and retrovirus species, each with their own spectrum of
efficiency and tissue tropism (Brooks et al., 1997; Choulika et al., 1996).
An alternative to administering Cre coding sequence to genomically altered
organisms is the generation of a transgenic line which expresses Cre recombinase
in the tissues of interest and crossing this strain to a loxP altered line. The
resultant offspring will express Cre, and subsequently undergo genomic
recombination reactions, only in the desired locations. A number of mouse lines
have been generated to date which express Cre only in particular tissues or sets
of tissues, which include thymocytes, cardiac myocytes, pancreatic cells,
hepatocytes and the mammary gland among many others (Orban et al., 1992;
Agah et al., 1997; Ray et al., 1999; Wagner et al., 1997; Selbert et al., 1998) (see
also http://www.jax.org/pub-cgi/imrpub.sh?objtype=rptquery). One of the
potential benefits of this system, an advantage which many of the Cre/loxP
systems have been designed to include, is the ability to knock-out or turn on a
gene which may prove lethal if altered globally rather than in an isolated manner.
Some difficulties may arise when attempting to use this system, however, as
many of the promoters which have specific tissue activity in adult animals may
prove to be active in a different location during embryogenesis. This has been
noticed in platelet endothelial cell adhesion molecule-1 driven Cre expression
and nestin driven Cre expression, where tissue specificity in the adult was
accompanied by more global activity in the developing embryo (Terry et al.,
1997; Betz et al., 1996). The study of genes involved in the process of
embryogenesis, however, may require very early alterations in expression. A
number of mouse strains have been engineered to express Cre during
development, including Wntl promoter driven Cre targeting to the developing
neural tube (Danielian et al., 1998).
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The use of tissue-specific promoters to drive Cre expression provides a large
degree of spatial, and possibly some temporal, control over the recombination
process. In order to more specifically regulate the timing of Cre expression or
activity in a model organism there are two possible strategies used currently; the
use of ligand inducible promoter elements to specifically start or stop Cre
expression or the generation of Cre fusion proteins which can be made active
through the application of exogenous signals (Sauer, 1998). Inducible promoters
exist which will either activate or silence on the presence of an exogenous ligand.
A tetracycline dependant Cre expression mouse strain has been developed in
which, in the presence of tetracycline, Cre expression is suppressed to very low
levels. On withdrawal of the exogenous signal Cre expression is driven in a
global manner and genomic recombination takes place (Gossen and Bujard,
1992; St-Onge et al., 1996). Alternatively Cre expression can be driven by the
presence of an applied ligand; Cre expression has been driven by promoters
induced by the presence of interferon a, the synthetic hormone RU 486 and the
insect hormone ecdysone (Kuhn et al., 1995; Kellendonk et al., 1999;
Kellendonk et al., 1996; Feil et al., 1996). In all of these systems the application
of the ligand rapidly and reversibly induces the expression of the Cre gene in a
global manner.
The alternative ligand activation system involves fusing the Cre coding sequence
with an element encoding a ligand-binding domain from an unrelated protein.
The fused peptides generally, in the absence of their specific ligand, sterically
interfere with the binding of the active sites of the fused Cre protein with the
target loxP sites by binding members of the heat shock protein (HSP) family
(Picard et al., 1990). In the presence of the proper ligand the HSP is displaced
from the fused peptide sequence, allowing the interaction of the Cre active site
and the loxP sequences. Several of these fusion proteins have been developed,
most often employing native or mutated steroid binding domains (Ligand
Binding Domains or LBD's). The constructs include Cre fusions with the native
LBD of the glucocorticoid receptor which responds to a number of natural and
synthetic steroids as well as an altered glucocorticoid receptor LBD which
responds only to the synthetic steroid RU 486, making in vivo control more
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accurate as natural steroids will not prematurely activate Cre activity (Dias et al.,
1998; Kellendonk et al., 1996; Indra et al., 1999). Cre has also been fused to the
LBD of the mouse and human oestrogen receptors (CreER), in a mutated form
which binds only to derivatives of the synthetic hormone tamoxifen (4-hydroxy
tamoxifen most commonly) and is used successfully to generate recombination in
double transgenic mice (loxP and CreERtamoxifen) by application of tamoxifen
to the skin (Zhang et al., 1996; Feil et al., 1997; Brocard et al., 1997; Vasioukhin
et al., 1999). Importantly, the tissue-specific promoter strategy for generation of
spatially controlled Cre expression has been successfully combined with the use
of inducible Cre fusion proteins to generate a recombination competent mouse
strain which can be activated in both a location and a time specific manner
(Kellendonk et al., 1999).
1.5,3.5 Site-specific insertion
As previously mentioned, Cre recombinase will catalyse the integration of two
DNA molecules if they each contain one LoxP site. This capability of the
recombinase can be used to site specifically insert DNA sequence into, for
example, a chromosome which has previously been engineered to contain a loxP
site (Sauer and Henderson, 1990). The genomic loxP site(s) can be introduced
into an organism through homologous recombination, as mentioned previously,
to generate altered sites in known positions or by random integration through
illegitimate recombination to generate a number of sites throughout the genome
(Sauer, 1998). The main benefit of this technology is the ability to efficiently and
reproducibly insert construct DNA sequence into a stable, predetermined
genomic location, circumventing or controlling for positional effects. Indeed, this
method was used to explore the effects of integration position on transcription
from Lactose Z (LacZ) and Neomycin (Neo) resistance cassettes in the mouse
genome (Fukushige and Sauer, 1992).
Additionally, avoidance of position effects allowed by site specific insertion of
DNA into the genome can be used to more accurately investigate the effects of
cis-acting elements on promoter activity. The insertion of marker genes and/or
enhancer/repressor elements in defined locations allowed detailed study of the
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Locus Control Region enhancer element of the human (3-globin gene as well as
helping to clarify environmental responses of the minimal p53 promoter
(Bouhassira et al., 1997; Bethke and Sauer, 1997).
1.5.3.6 Site specific excision of LoxP flanked DNA sequences
More common than the use of Cre technology in the targeted insertion of DNA
sequences is the use of recombination to excise loxP flanked DNA, either
exogenous sequence or endogenous genetic material. This specific deletion of
sequence can be used in at least two ways; first to activate transcription from a
desired locus and secondly to stop transcription from a gene of interest by
physically removing some or all of the coding sequence from the targeted
genome.
1.5.3.6.1 Activation of expression through excision (Floxed stop)
The strategy for activation of target genes through expression of Cre
recombinase generally involves the insertion into the genome of a transgene
bearing the gene of interest and a suitable promoter separated by a loxP flanked
inactivation cassette (floxed STOP cassette). This technique was used to target
the expression of the SV40 large T antigen to the mouse eye lens; the transgene
construct consisting of the lens specific murine a-crystallin promoter, a floxed
cassette consisting of stuffer DNA and a polyadenylation signal and finally the
SV40 large T antigen coding sequence (Lakso et al., 1992). The transgenic line
generated using this construct did not exhibit SV40 large T antigen expression in
any tissue. This line was subsequently crossed to another transgenic line, one
expressing the Cre recombinase from a global promoter. The resultant offspring
underwent excision of the floxed STOP cassette in all tissues but the expression
of the SV40 large T antigen was confined to the lens because of the tissue
specificity of the promoter used to drive its expression (Lakso et al., 1992). This
Cre-mediated activation of expression has since been used to instigate expression
from a number of other genes including hepatitis B genes and bcl-2 (Shintani et
al., 1999; Sato et al., 1998).
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1.5.3.6.2 Inhibition of expression through excision (Gene deletion)
Most frequently, the inhibition of expression from an allele using the Cre/loxP
technology involves the excision of the floxed gene of interest from the genome.
An organism containing a floxed copy of the gene of interest is generated using
transgenic or knock-out technology; this strain can then be crossed onto a line
bearing a deletion in the gene of interest to generate a model system with one or
more functional floxed copies of the gene to be selectively deleted, in addition to
either one or two null alleles of the same gene. This line can then be crossed to
Cre expressing mice, possibly bearing tissue-specific or ligand activated Cre's to
generate what are effectively null alleles in a highly controlled manner.
This technology has been used in the generation of inducible knock-out
phenotypes in very specific tissue or cell types. One of the earliest applications of
this technique was the ablation of the DNA polymerase (3 gene in T-cells in the
mouse, followed closely by the deletion of the same gene in a ligand inducible
manner (Gu et al., 1994; Kuhn et al., 1995). While these mice displayed no
observable phenotype, they did effectively demonstrate the feasibility of the
applied technology.
Importantly, the degree of tissue and time control afforded through the use of
Cre/loxP allows the study of inactivation of genes which would prove lethal in a
traditional knock-out model. Included among the genes whose functions have
been studied using this system is the murine Ape gene. Mouse lines containing an
Ape gene bearing a loxP flanked exon 14 were generated and backcrossed to
generate a line bearing two floxed copies of the Ape exon 14 (Shibata et al.,
1997). While mice homozygous for truncation mutations of the Ape gene are
embryonic lethal, failing to develop beyond gastrulation, the floxed exon 14 Ape
line proved viable and apparently free of phenotype. Upon administration
through enema into the colon of adenoviruses encoding Cre recombinase, the
floxed sequences were excised, resulting in truncated coding sequences; 80% of
these mice rapidly developed colorectal adenomas underlining the tumour
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suppressor function of murine Ape (Shibata et al., 1997). This mechanism
allowed the study of early events in the development of colorectal carcinogenesis
and successfully overcame the problem of embryonic lethality posed by
homozygosity for traditional mutations in the Ape gene.
1.6 Project Aims
The use of adenovirus to induce Cre-mediated gene excision gives impressive
control over the time and location of gene expression. Even more precise control
over this process may be achieved through the development of inducible, tissue-
specific Cre expression transgenic mouse lines. One of the goals of this project
was to work towards the development of an intestinal specific Cre expressing
transgenic mouse. Expression of the Cdx-1 murine homeobox gene is limited, in
the adult mouse, to the stem cells and proliferative compartment of the crypts of
the distal small intestine and the large intestine (see section 3.1). Cre expression
driven by the Cdx-1 promoter would confine recombination-mediated excision of
floxed sequences to the actively dividing cells of the intestinal crypt. In an effort
to produce Cdx-l/Cre expression mice, novel Cdx-1 promoter sequence was to be
isolated and characterised in vitro, while work was to be carried out towards the
development of a bacterial artificial chromosome (BAC) based transgene vector.
One of the primary targets for gene excision using a Cdx-1 promoter driven Cre
recombinase would be the Ape gene. A previously generated mouse strain
bearing a floxed human APC cDNA expression vector was crossed onto a mouse
line bearing the well characterised germline truncation mutation (Mi/j) in Ape.
The resulting progeny were to be characterised by comparison of survival times,
tumour spectrum and screening for altered embryogenesis to determine if the
introduced transgenic material had a significant influence on the Min phenotype.
Additional factors contributing to the development of colorectal tumours in
humans include deficiencies in DNA mismatch repair processes. As mentioned
previously, recent work has shown that levels of Ape are significantly increased
in a number of cell types on exposure to the methylating agent MNNG and that
this upregulation was dependant on the presence of functional p53 tumour
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suppressor protein (Jaiswal and Narayan, 1998). It has been shown that p53
stabilisation following MNNG exposure is, in certain systems, dependent on the
presence of the DNA mismatch sensor protein MSH2 (Hickman and Samson,
1999). A further aim of this project was to assess changes following MNNG
exposure in the levels of the Ape target protein (3-catenin, an indirect measure of





Chapter 2 - Materials and methods
2.1 Basic cloning Methodology
2.1.1 Agarose Gel Electrophoresis of DNA
Agarose gel concentrations used varied from 0.5% to 4% w/v in TBE (see
appendix 1) depending on the size of the DNA molecules to be resolved. TBE
gels were prepared by boiling an appropriate mass of agarose powder (Sigma) in
TBE buffer until dissolved and supplementing with O.lmg/ml ethidium bromide
(EtBr). DNA samples (volumes ranged from 2-50pl) were mixed with one sixth
volume of 6x loading buffer (see appendix 1) and loaded directly onto the gel.
Molecular weight markers (Markers II, II VI and/or X, Roche) were diluted in
loading buffer and run parallel to DNA samples. Electrophoresis was carried out
in IX TBE at 50-150V for periods of 30 minutes to 12 hours and visualised using
UV light on a transilluminator (Herolab, gel documentation equipment).
2.1.2 Restriction Digest Analysis of Plasmid DNA
Suitable amounts of DNA (O.lpg-lOjig) were mixed with 0.1 volumes of lOx
reaction buffer (supplied by the manufacturer, Roche or New England Biolabs)
and 0.1 volumes of 10X Bovine Serum Albumin (BSA) as suggested in the
manufacturer's instructions. 0.05-0.1 volumes of appropriate restriction
endonuclease (Roche, New England Biolabs), depending on the concentration
supplied, were added to the reaction mix and any remaining volume was made up
with ultrapure deionised water (dH20) which was prepared using the MilliQ
system (resistivity of >18MQ-cm); volumes of restriction reactions varied from
10-100p.l. Restriction enzymes were stored at -20°C in buffers containing 50%
glycerol and kept on ice while in use. Sufficient enzyme was used to ensure
complete digestion. 1 unit of enzyme being the amount required to digest lpg of
pBR322 plasmid DNA to completion in 1 hour. The amount of enzyme was kept
below 10% of the final reaction volume as glycerol can interfere with enzymatic
activity. The digests were incubated for l-24hrs at the temperature recommended
by the manufacturer, varying from 25-50°C (Roche, New England Biolabs).
Double digests were either performed in a buffer/temperature combination giving
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efficient digestion with both enzymes or were done sequentially with an
intermediate phenol:chloroform clean-up step. For phenohchloroform clean up
an equal volume of liquid phenol pre-equilibrated with Tris buffer (Fisher) was
added to the reaction mixture, gently vortexed and spun briefly at 10,000g. The
upper phase was removed to a clean tube and an equal volume of chloroform-
isoamyl alcohol (24:lv/v) was added, gently vortexed and spun briefly at
10,000g. The upper phase was again removed to a clean tube, 0.1 volumes of 3M
sodium acetate (pH 5.5) added, followed by 2 volumes of 100% ethanol. The
mixture was incubated at -70°C for 30 minutes then spun at 10,000g at 4°C for
10 minutes. The supernatant was poured off and the tube air dried for 30 minutes.
A volume of dH^O appropriate for the next digestion step was then added and the
tube vortexed gently to solubilise the DNA. Digestion reactions were visualised
on agarose gels to verify complete cutting.
2.1.3 Extraction of DNA Fragments from Agarose Gels
The QIAEX H Gel Extraction Kit (Qiagen) was used for the purification of DNA
fragments from agarose gels. DNA was digested with appropriate restriction
endonucleases and electrophoresed on an agarose-TBE gel containing EtBr. The
bands were visualised with long-wavelength UV light and excised in a minimal
volume from the gel with a clean scalpel and placed in a pre weighed 1.5ml
Eppendorf centrifuge tube. The gel slice was weighed and 300pl of supplied
QX1 buffer was added per lOOmg of gel slice to solubilise the agarose, dissociate
DNA binding proteins from the DNA fragment and give a suitable pH to allow
absorption of the DNA fragment to the QIAEX II silica particles. 10-30pl of
QIAEX II particles, depending on the amount of DNA in the excised gel
fragment, were added and the sample incubated at 50°C for 15 minutes with
mixing at regular intervals. Following solubilisation and adsorption of the DNA
to the QIAEX II silica particles, the sample was centrifuged at 10,000g for 1
minute. The resin pellet was washed once with the solubilisation buffer and
twice with the supplied PE wash buffer before being air-dried for 15 minutes. To
elute the DNA, the pellet was resuspended in 20pl of 20mM Tris at pH 8.0.
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DNA samples extracted from gels in this manner were electrophoresed to
determine concentration and used immediately or stored at -20°C.
2.1.4 Dephosphorylation of DNA fragments
The 5' terminal nucleotides of DNA fragments were dephosphorylated using
shrimp alkaline phosphatase, this step is included to increase ligation efficiency
by preventing recircularisation of the vector (SAP, United States Biochemical). 1
unit of SAP was added to the DNA in lx reaction buffer (20mM Tris-HCl pH
8.0, lOmM MgCE) or included in a restriction digest reaction. The reaction was
incubated at 37°C for 1 hour then heated to 65°C for 30 minutes to inactivate the
enzyme.
2.1.5 Blunting of restriction generated overhangs
In some cases the 5' or 3' overhangs created in the course of restriction digestion
were "blunted" prior to the ligation step. Two protocols were used, depending on
whether the overhang to be eliminated was 3' or 5'. In the case of a 5' overhang
the large fragment of DNA polymerase I termed the Klenow enzyme (New
England Biolabs), was used. 1-5 units of enzyme per pg of DNA and 0.1
volumes of 0.5mM dNTP (Gibco) mix were added directly to a completed
restriction digest and incubated at 37°C for 30 minutes. In the case of 3'
overhangs the T4 DNA polymerase was used to blunt DNA fragments. This
polymerase displays a 3' to 5' exonuclease activity and blunts DNA fragments
by removing the 3' bases rather than filling in the overhang. 3-5 units of T4 DNA
polymerase per pg of DNA, 0.1 volumes of 4.0mM dNTP mix, 0.1 volumes of
0.5mg/ml BSA and 0.1 volumes of T4 DNA polymerase reaction buffer (see
appendix 1) were added directly to completed digestions and incubated for 20
minutes at 12°C followed by heat inactivation by incubation at 75°C for >15




Concentrations of both vector and insert were calculated by determining the mass
of DNA in a given sample volume. A given volume of sample was gel
electrophoresed (see above) and compared against suitable mass markers (Low
Mass and High Mass Markers, Life Technologies) or by diffusion into EtBr
plates. EtBr plates consist of petri dishes containing 1% agarose in lx TBE
buffer supplemented with O.lmg/ml of EtBr. l-2pl of sample and l-2pl of
standard DNA diluted to a number of known concentration were pipetted onto
plate pre-warmed to 37°C to speed DNA uptake. When the DNA solutions were
fully absorbed, the plates were viewed under UV light and comparison between
unknown and known DNA concentrations used to determine sample
concentration.
Ligations were prepared with lOOng of linearised, dephosphorylated vector and
insert was added to a 1:1 or 1:3 molar ratio. Ligation reactions were carried out
using two different commercial systems. In the first system the total volume of
the ligation reaction was made up to 20 pi with dH20. This was then added
directly into a tube of dehydrated Ready-To-Go™ T4 DNA ligase (Pharmacia
Biotech). The ligation reaction was incubated at room temperature for 5 minutes,
mixed by gentle pipetting and then transferred to a 16°C water bath for overnight
incubation. In the second ligation system 1 Weiss unit (equivalent to 67 cohesive
end ligation units) of T4 DNA ligase (NEB) and 2pl of lOx reaction buffer
(500mM Tris-HCL (pH 7.6), lOOmM MgCl2, 10mM ATP, lOmM DTT, 50%
polyethylene glycol-8000) were added and the reaction made up to a total
volume of 20pl with sterile deionised water. Again, ligation reactions were
incubated for 5 minutes at room temperature and then overnight at 16°C.
Ligation controls were also set up that contained no insert but only
dephosphorylated vector.
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2.1.7 Transformation of Bacteria with Plasmid DNA
Aliquots of TOP10 One Shot™ ultracompetent E.coli K12 derived cells
(Invitrogen) were removed from storage at -70°C and thawed on ice. Plasmid
DNA was added directly onto the cells and then mixed by pipeting. The cells and
the DNA were incubated on ice for 30 minutes, heat shocked in a water bath at
42°C for 45 seconds and returned to ice for a further 5 minutes. 250-500pl SOC
media (see appendix 1) was added to the tube, which was then incubated at 37°C
for 1 hour in an orbital incubator at 225rpm.
Electrocompetent cells were generated using an osmotic shock method. Single
colonies were picked and grown in an orbital incubator overnight at 37°C in 5ml
of L-broth supplemented with the appropriate antibiotic. This started culture was
used to inoculate 250-500ml of antibiotic supplemented L-broth which was
placed in a 37°C orbital incubator and monitored for Optical Density at 600nm
(OD600). Preparations of cells containing the pBAD-Reda(3y plasmid were
supplemented with 0.5% w/v arabinose at an OD600 of 0.2. When culture OD600
reached 0.4-0.5, indicative of log growth phase, the culture vessel was placed in
an ice-water bath in the cold room and left to cool for 20 minutes. From this
point all manipulations were preformed in the cold room with precooled glass
and plasticware. Cells were harvested in precooled bottles and rotors by
centrifugation at 10,000g for 10 minutes at 4°C. The broth supernatant was
removed and discarded and the cell pellets were resuspended in an equal volume
of ice-cold dH20, followed by recentrifugation at the previous conditions. The
cells were then resuspended in 0.5 volumes (relative to the original culture
volume) of ice-cold dH20 and pelleted as before. This pellet was then
resuspended in 0.5 volumes of ice-cold 10% glycerol in dH20 and recentrifuged.
This step was repeated in some preparations. The supernatant was removed and
the cells resuspended in 0.25 volumes of ice-cold 10% glycerol in dH20 and
again centrifuged. The supernatant was poured off and the cells resuspended in
the small volume of remaining 10% glycerol. This resuspension was aliquoted
into 50pl volumes in precooled sterile Eppendorf tubes and snap frozen using dry
ice/ethanol baths or liquid nitrogen.
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Transformation by electroporation was carried out using a GenePulser (BioRad)
connected to a Pulse Controller (BioRad). Aliquots of cells (50pl) were thawed
on ice, mixed with 2-5pl of DNA solution. The cell/DNA mixture was then
pipetted into prechilled 2mm electroporation cuvettes (Equibio). Electroporations
were carried out at 2.5kV, 25pFD and 200£2. 500pl of SOC media (see appendix
1) was added to the cell/DNA mixture immediately following electroporation.
The cell suspension was then incubated at 37°C for 1 hour in an orbital incubator
at 225rpm. The transformed bacteria from both protocols were then plated onto
Luria Broth (LB)-agar plates (Luria broth supplemented with 2% w/v bacto-agar)
containing appropriate selection antibiotics (see appendix 1).
2.1.8 Preparation of Plasmid DNA
2.1.8.1 Small Scale Plasmid Preparation
Small scale preparations of plasmid DNA were purified from transformed
bacterial cells with the QIAGEN QIAprep Spin Miniprep kits in accordance with
the manufacturer's instructions. This "miniprep" method is a modification of the
procedures described in Sambrook et al. (Sambrook et al., 1989). A single
bacterial clone was picked from a LB-agar plate using a sterile p200 pipette tip.
The clone was transferred to a Falcon 2059 tube containing 5 ml of LB (see
appendix 1) supplemented with appropriate antibiotics and incubated in an
orbital incubator (225rpm) at 37°C overnight. 1.5ml of the overnight bacterial
culture was placed in a 1.5ml Eppendorf microcentrifuge tube and spun at 13,000
rpm for 2 minutes. The supernatant was discarded and bacterial pellets were
resuspended in 200|il of resuspension buffer (50mM Tris-HCl, pE17.5, lOmM
EDTA, 100pg/ml RNase A). RNase A was added to this solution to avoid RNA
contamination in later nucleic acid purification steps. Bacterial lysis was
accomplished by adding 200pl of lysis solution (0.2M NaOH, 35mM SDS) and
mixing by inversion. The lysis reaction is subsequently neutralised by addition
of 280pl of neutralisation buffer (1.32M potassium acetate, pH 4.8) and again
mixing by inversion. This latter step produces a protein precipitate, subsequently
removed by centrifugation at 10,000g for 1 minute. Supernatants were
transferred to QIASpin filter tubes and placed in collection tubes; the liquid was
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passed through the filter by centrifugation at 10,000g for 1 minute. 500pl of
wash buffer (80mM potassium acetate, 8.3mM Tris-HCl pH 7.5, 40p.M EDTA,
55% (v/v) ethanol) was added to the QIASpin filter tube followed by
centrifugation for 1 minute at 10,000g. The collection tubes were emptied and
the filter tubes spun again for 1 minute atl0,000g. QIASpin filter tubes were
placed on fresh 1.5ml Eppendorf tubes and 50pl of elution buffer (lOmM Tris
pH 8.5) was added to each tube. The tubes were incubated at room temperature
for 5 minutes. The QIASpin/Eppendorfs were spun at 10,000g for 1 minute. The
elute containing the DNA was used immediately or stored at -20°C.
2.1.8.2 Large Scale Plasmid Preparation
Large-scale isolation of plasmid DNA was carried out using the QIAGEN
Plasmid Maxi Kit (Qiagen), the HYBAID Quickflow Maxi Kit (Hybaid) or the
Nucleobond Maxi Kit (Clontech) according to the manufacturer's instructions.
The general protocol consists of inoculating a conical flask containing 100-
500ml of LB, supplemented with the appropriate antibiotics with bacteria from
suitable miniprep cultures. The bacteria were grown at 37°C for 12- 16 hours in
an orbital incubator at 225 rpm, harvested by centrifugation (10,000g for 10
minutes at 4°C, Sorvall GSA rotor, Centrikon H-40IB), resuspended and lysed
and neutralised in manufacturer supplied solutions as for the miniprep method.
Protein precipitate was removed by centrifugation at 12,000g for 30 minutes at
4°C (Sorvall SS-34 rotor, Centrikon H-401B). Supernatants were added directly
to QIAGEN-tips, HYBAID columns or Nucleobond columns and allowed to pass
through the DNA binding resin by gravity flow. Columns with bound DNA were
washed with the supplied buffers twice prior to elution of DNA. DNA was
remove from the column using a supplied elution buffer and 0.7 volumes of
isopropanol were added. The DNA was collected by centrifugation at 12,000g
for 15 minutes at 4°C (Sorvall SS-34 rotor, Centrikon H-401B). DNA pellets
were washed with 70% ethanol and recentrifuged. The final DNA pellet was
dissolved in 100-250pl of TE buffer (lOmM Tris-HCl, pH7.5, ImM EDTA) or
20mM Tris pH 8.0, in accordance with manufacturer's instructions.
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2.1.8.3 Preparation of BAC DNA
Preparations of BAC DNA follow a protocol developed by Davidson et al.
(Davidson et al., 1999). BAC isolation is carried out using the Q-tip 500
(Qiagen) plasmid extraction kit. Each extraction requires eight Q-tips and an
additional 40ml each of Resuspension, Lysis and Neutralisation solutions (see
appendix 1) and 180ml extra buffer QC (see appendix 1). Each extraction
requires 2.5 litres of bacterial culture, which should be grown from a single
colony derived from a plate that has been freshly streaked out from the original
bacterial stock. A single colony was picked and used to inoculate 5ml of L-broth
o
containing 20pg/ml chloramphenicol. This starter culture was grown at 30 C for
6 to 8 hours and subsequently used to inoculate 500ml of L-broth again
o
supplemented with 20jlg/ml chloramphenicol and allowed to grow at 30 C over
night. Cells were centrifuged, the supernatant removed and, if required, stored at
-20°C.
Cells were resuspended in a total of 120ml of Resuspension buffer, lysed by the
addition of 120ml of Lysis buffer and incubated at room temperature for 5 to 10
minutes with gentle mixing by inversion. The lysis reactions were stopped by the
addition of 120ml of Neutralisation buffer, followed by inversion mixing. The
resulting solution was divided into centrifuge bottles and spun at 7,000g for 30
minutes in a Sorvall RC-5B rotor at room temperature to precipitate proteins.
During this centrifugation step 8 Q-tip columns were pre-equilibrated with 10ml
each of buffer QBT (see appendix 1). The supernatant from the centrifugation
was filtered through four layers of gauze and 45ml loaded onto each column. The
columns were washed with three aliquots of 30ml of buffer QC (see appendix 1).
Columns were eluted with 15ml of buffer QF (see appendix 1) and the eluates
combined in 50ml conical tubes. BAC DNA was precipitated by the addition of
20ml of room temperature isopropanol to each tube and centrifuged at 3250 rpm
in a Sorvall RT7 with swinging bucket rotor for 30 to 60 minutes at 4°C. The
pelleted BAC DNA in each tube was washed with 20ml of 70% ethanol and
recentrifuged for 15 minutes. Pellets were drained and air-dried before being
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resuspended in 195pil of ultra-pure water. To reduce genomic DNA
contamination, 1 Opil of lOmM ATP solution, 25pl of lOx Plasmidsafe buffer and
5 to 10pl of Plasmidsafe enzyme were added to each 195|itl resuspension and
allowed to digest overnight at 37 C while the BAC DNA solubilises. The
resulting BAC DNA solutions were combined into two Eppendorf tubes and
extracted once with an equal volume of phenol/chloroform and ethanol
precipitated (see section 2.1.2). The BAC DNA pellets were each dissolved in
200pl TE (see appendix 1) and allowed to dissolve overnight.
2.1.8.4 Preparation of bacterial glycerol stocks
Single clones were used to inoculate 5ml of Luria Broth supplemented with the
appropriate antibiotic and grown overnight at 37°C in an orbital incubator.
Bacteria were harvested by centrifugation at 13,000rpm for 3 minutes in a bench-
top microfuge followed by removal of excess media. The pellet was resuspended
in 750pl of autoclaved 50% Luria Broth:50% autoclaved glycerol and placed into
a CryoTube™ (Nunc) prior to storage at -70°C.
2.1.9 Sequencing of Plasmid/PCR DNA
Where only short stretches of sequence needed to be determined, plasmid DNA
was sequenced using the T7 Sequenase® quick denature plasmid sequencing kit
(Amersham Life Sciences). This protocol is based on the chain termination
method originally described by (Sanger et al., 1977). Sequencing involves
denaturing 0.5-3pg of plasmid DNA, in a volume of 8pl, by the addition of
NaOH (supplied by the manufacturer) to a final concentration of 0.2M. 2pmol of
sequencing primer (chosen using the Primer3 web software, see below) was
added to the reaction mix. The samples were then incubated for 10 minutes at
37°C before being incubated on ice. The reaction mix was then returned to
neutral pH by the addition of HC1 (supplied by the manufacturer) to a
concentration of 0.2M. Finally 2 pi of 5x plasmid reaction buffer (see appendix
1) was added and the samples were left to anneal for 10 minutes at 37°C and
once again placed on ice. To the cooled reaction mixture 0.1M dithiothreitol, lx
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labelling mix (see appendix 1), 5pCi (35S) dATP (0.5p.l) and 1 pi of Sequenase®
enzyme (diluted 1:8 in enzyme dilution buffer, see appendix 1) were added. The
reaction mixtures were then vortexed gently and incubated at room temperature
for 5 minutes. 3.5pl of this labelling reaction was then added to each of 4 0.5ml
Eppendorf tubes, each containing 2.5pl of one of the dideoxynucleotide
termination mixes (see appendix 1) and incubated at 37°C for 5 minutes. The
chain termination reactions were each stopped by addition of 4pl of sequencing
stop solution (supplied by manufacturer, see appendix 1). Individual chain
termination reactions were then run out side by side at 70W for 1-2 hours on
prewarmed 6% acrylamide, 6M urea 0.4mm sequencing gels (see appendix 1).
lxTBE or lx glycerol tolerant running buffer were used for electrophoresis. Gels
were washed twice with 10% methanol/10% acetic acid in dfEO and removed to
3MM Whatman filter paper, vacuum dried at 80°C and placed into film cassettes
with X-ray film (Kodak BioMaxMR X-ray film, Kodak Eastman Corporation)
for 2-3 days.
Where longer stretches of sequence were to be determined automated
fluorescence label sequencing was carried out by DNAShef (Royal Infirmary of
Edinburgh, Haematology Department).
2.1.10 Southern Blot/Dot Blot hybridisation
For southern blot analysis -10 pg of the DNA to be probed was digested with the
appropriate restriction enzymes (see above). Following digestion, the samples
were subjected to electrophoresis on a TBE-agarose gel (see above) at low
voltage (40V) overnight at 4°C. Images of the electrophoresed DNA were
captured on a UV transilluminator (see above) for later comparison. Transfer of
the DNA to the nylon membrane was improved by partial depurination ('acid
nick') of the DNA prior to transfer. Partial depurination was achieved by
soaking the gel for 10 minutes in 0.2M HCI. The gel was then rinsed in
deionised water and the DNA was transferred immediately. DNA was transferred
from the gel onto a positively charged nylon membrane (Zeta-Probe® GT,
BioRad). 0.4M sodium hydroxide was used as the transfer buffer and transfer
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was carried out overnight. After transfer the membrane was subsequently rinsed
in 2xSSC (see appendix 1), air-dried UV crosslinked (Spectrolinker XL-1500
UV Crosslinker, Spectronics Corp.). Dot blot membranes for Bacterial Artificial
Chromosome (BAC screening) were obtained from Research Genetics.
Membranes were stored between sheets of Whatman 3MM paper at room
temperature until required.
25-50ng of clean probe DNA in 1 lp.1 of dH20 (gel extracted restriction fragment
or PCR product) was radiolabeled with 32P-dCTP using High Prime enzyme
32
(Boehringer Mannheim) by addition of 4pl of enzyme and 5|al of P-dCTP
followed by incubation at 37°C for 20 minutes. Labelled probe was separated
from unincorporated nucleotides using a Sephadex G50 column (Pharmacia).
20pl carrier salmon sperm DNA (lOmg/ml) was mixed with radiolabeled probe
and added to the column. Unincorporated nucleotides were eluted by addition of
400pl TE (lOmM Tris pH 8, ImM EDTA) buffer which was allowed to enter the
column by gravity flow and a further 400pl TE was added to elute the purified
probe. The elutes were collected in 1.5ml Eppendorf tubes and the quality of
radiolabelling was assessed by Geiger Counter comparison of the counts/minute
recorded from both elution products. Labelled probe was only used if it had
incorporated >50% of the radionucleotides.
Hybridisation buffer (see appendix 1) was preheated to 68°C to ensure all
components were in solution. lOmls buffer was transferred to a hybridisation
tube (Hybaid) containing the nylon membrane to allow the membrane to
equilibrate. Membrane and buffer were incubated with rotation at 68°C for 1
hour in a hybridisation oven (Hybaid). Following this prehybridisation step, the
400pl of TE containing the appropriate radiolabeled probe was added to the
hybridisation tube. The membrane was incubated with the radiolabeled probe in
hybridisation buffer overnight at 68°C. The membrane was then washed twice
for 15 minutes in 2xSSC supplemented with 0.1% sodium dodecyl sulphate
(SDS), once for 30 minutes in lxSSC/0.1% SDS and once for 10 minutes in
0.1xSSC/0.1% SDS, all at 68°C. Following these washes the membrane was
removed from the hybridisation tube, sealed in a plastic bag, and exposed to MR
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X-ray film (Kodak) in an autoradiography cassette. Autoradiography cassettes
were stored at -70°C for 2-5 days, depending on signal strength.
Autoradiography films were developed (Hyperprocessor, Amersham) and
compared with the gel image or dot blot grid supplied by the manufacturer.
2.2 PCR reactions
2.2.1 Reaction Conditions
PCR reactions were carried out in 0.5ml thin-walled microcentrifuge Eppendorf
tubes in a standard thermocycler (Hybaid Omnigene, Hybaid). Reaction volumes
of 25pl and/or 50pl were used and all reactions were overlaid with 25pl of
autoclaved paraffin oil. All reagents were obtained from Life Technologies. Four
reaction master mixes of varying magnesium concentrations and additives were
used; their recipes are listed in the following table.
Table 2.1: PCR master mix recipes
1.0 mM Mg 1.5 mM Mg 2.0 mM Mg 1.5 mM Mg +
reaction mix reaction mix reaction DMSO reaction
mix mix
dH20 195.5pl 193pl 190.5pl 180.5pl
lOx PCR buffer 25pi 25pi 25pl 25pl
W1 detergent 12.5JU.1 12.5pl 12.5pl 12.5pl
DMSO Opl Opl Opl 12.5pl
Mg (50 mM) 5pi 7.5pl lOpl 7.5pl
dNTP (10 mM) 8pl 8pl 8pi 8pi
primer (lOOpM) 2pl each 2pl each 2pl each 2pl each
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2.2.2 Primer Design
For most reactions primers were chosen from a number of primer pair options
supplied by Primer3, a web base primer design software program
(http://www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi). Primers were
chosen to avoid secondary structure and primer dimerisation and to have very
similar melting temperatures. Some sets of genotyping primer pairs and reaction
conditions were taken from the referenced publications. Primer pairs and the
optimal reaction conditions are listed in the following table: Hot start reactions
included the addition of 1.5pl of 1:10 dilution of Taq polymerase in dH20 once
tube temperature had reached 94°C.
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Table 2.2: PCR reaction primers and conditions































































































































































































































72°C -2 minutes 30 cycles
94°C -30 seconds
72°C -5 minutes

































72°C-1 minute 32 cycles
94°C -30 seconds
72°C -5 minutes
followed by BamHI digestion
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2.3 Tissue culture
2.3.1 Derivation of cell lines
The human colorectal cell lines used were obtained from the European Cell
Culture Collection. These include DLD-1, HT 29, HCT116 and SW 480 cell
lines (see table 2.3 for references and ATCC numbers). HM-1 ES cells were
obtained from Dr. Nathalie Sphyris. Murine embryonic fibroblasts were
generated from various mouse lines on site. Pregnant female mice were
sacrificed at day 12-14 of gestation and the whole womb removed and placed in
a petri dish containing PBS (see appendix 1). The embryos were then
individually removed from the womb and separated from the placental tissue
using watchmaker forceps, dipped briefly in 70% ethanol to remove
contaminating bacteria and placed in a fresh petri dish. Each embryo was
mechanically disrupted using new, sterile scalpels, with a small tissue sample
taken for genotype analysis where necessary. The disrupted embryo was then
suspended in 5ml of 0.2pm filter sterilised 2.5% trypsin (DIFCO) in dfEO,
prewarmed to 37°C. This suspension was incubated at 37°C for 5 minutes and
gently mixed by regular inversion. The trypsin was then neutralised by the
addition of 10ml of prewarmed media (see section 2.3.2). The suspension was
then centrifuged at lOOOg for 3 minutes to pellet the separated cells. The
supernatant was carefully removed either by pouring or by pipette and the cell
pellet resuspended in 10ml of prewarmed media. This was then poured into a
10cm petri dish and placed in a tissue culture incubator (see section 2.3.2).
Primary wild type murine colonocytes were supplied by Robert Morris and were
isolated using the protocol developed by Booth et al. (Booth et al., 1995).
Briefly, to seed four 24-well plates 3 adult mice were sacrificed and their colons
excised, flushed and placed into Hanks' Balanced Salts Solution (HBSS). The
colons were slit open longitudinally and dissected into small pieces. The colon
fragments were washed in 50ml HBSS and then mechanically disrupted in a petri
dish with a scalpel. The disrupted tissue was then placed into 25ml culture media
(see table 2.3) supplemented with 75U/ml collagenase and 20pg/ml dispase and
incubated with gentle shaking for 2-3 hours at 37°C. The tissue solution was then
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transferred to a 30ml Universal tube and allowed to gravity settle for 45 minutes
to pellet undigested tissue. The top 22ml of the suspension, containing the
isolated crypts was removed and retained. The remaining 3ml of suspension was
supplemented with 22ml of fresh media and resuspended and pelleted to collect
any remaining crypts. The collected crypt suspensions were diluted with an equal
volume of culture media supplemented with 2% D-sorbitol to aid buoyancy and
centrifuged at 200-300rpm in a Harrier 18/80 centrifuge (Sanyo) for 2 minutes.
The supernatant, containing single cells and bacteria was removed and the pellet,
containing whole crypts was resuspended in a further 50ml of D-sorbitol
supplemented media and recentrifuged; this washing step was repeated 4-5 times.
The pellet was finally resuspended in an appropriate amount of culture media and
plated into collagen coated tissue culture plasticware. Collagen coatings were
added to the culture vessels by adding sufficient 200pg/ml acidified collagen
solution to the vessel to cover the culture surface and leaving it overnight. The
collagen solution was aspirated and the vessel allowed to air dry prior to crypt
plating. Colonocyte cultures were fed every 3-4 days when half of the media
volume was removed and replaced with fresh culture medium.
2,3.2 Thawing, media and incubation conditions
To thaw cell lines for culture, aliquots of cells stored in CryoTube™ vials (Nunc)
were thawed with agitation in a prewarmed 37°C waterbath. The rapidly thawed
cell suspensions were then dispersed into 10 mis of the appropriate culture media
(see table 2.3) and spun at lOOOrpm for 4 minutes. The media was aspirated and
the cells resuspended in a further lOmls of media. This suspension was placed
into the appropriate culture vessel.
All cell lines used were incubated at 37°C in 5% CO2 and 100% humidity in
Sanyo CO2 incubators. Cells were cultured in plasticware (flasks and petri
dishes) supplied by Nalge-Nunc or Greiner. ES cell culture vessels were
pretreated by incubation for 30 minutes with an appropriate volume of 0.1%
swine skin gelatine (Sigma) in PBS. All cells were removed from plasticware for
passaging by removal of culture media, washing with warm PBS and application
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of an appropriate amount (enough to just cover the cells) of 0.25%
Trypsin/EDTA solution (Life Technologies) prewarmed to 37°C. The cells were
incubated in the trypsin solution until the monolayer detached and fresh
prewarmed culture media was added to neutralise the trypsin. The resulting cell
suspension was diluted and split into the appropriate number of culture vessels.
The media used for each of the cell lines used are listed in the following table:
Table 2.3: Cell culture media
Cell line Culture Media Reference and
ACTT number
HCT 116 BHK-21 medium with 2.0mM L-glutamine
(Gibco)




SW 480 Leibovitz's medium with 2mM L-glutamine
(Gibco)




DLD-1 RPMI 1640 medium with 2mM L-glutamine
(Gibco)
+ 1.5g/L sodium bicarbonate
+ 4.5g/L glucose
+ lOmM HEPES
+ 1 .OmM sodium pyruvate (Gibco)




HT-29 McCoy's medium with 1.5mM L-glutamine
(Gibco)






BHK-21 medium with 2.OmM L-glutamine
(Gibco)
+ lx MEM Non-essential amino acids (Gibco)
+ 1 .OmM sodium pyruvate (Gibco)














BHK-21 medium with 2.OmM L-glutamine
(Gibco)
+ lx MEM Non-essential amino acids (Gibco)
+ l.OmM sodium pyruvate (Gibco)
+ 5% FCS (Sigma)
+ 5% normal calf serum (NCS, Gibco)
+ 0.2mM (3-mercaptoethanol (Gibco)
+ 1:1000 Leukaemia-inhibiting factor (LIF)
(Gibco)
N/A
(Kitani et al., 1996)
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2.3.3 Harvesting cells for protein
Cells to be harvested for protein analysis were washed twice with ice-cold PBS
after removal of culture media. A minimal volume (0.5-2ml) of ice-cold RIPA
buffer (see appendix 1) was then added to the cells. The cells were removed from
the plastic surface into the RIPA buffer using a cell-scraper (Nalge-Nunc) and
the resulting suspension was collected in a 1.5ml Eppendorf tube. The tubes were
then immediately frozen, either in an ethanol/dry ice bath or in liquid nitrogen.
The suspension was thawed on ice and the cells and DNA mechanically
disrupted by being passed through a succession of gradually narrower syringe
needles (21,23,25 and 26 gauge). Samples were stored at -70°C.
2.3.4 Chemical treatment of cells
Cells to be treated with MNNG were serum starved (culture media supplemented
with 0.5% foetal calf serum) for 18 hours prior to the addition of the methylating
agent. 0.050g of MNNG were dissolved in 0.340ml of dimethylsulfoxide
(DMSO) to generate a 1.0M solution. This solution was diluted in culture media
supplemented with 0.5% serum to concentrations of 25pM and 50pM; untreated
cells were fed culture media containing similar amounts of MNNG-free DMSO.
Cells were left incubating at 37°C for 15 hours and then washed and harvested as
previously outlined. Media containing MNNG and PBS used to rinse MNNG
treated cells were collected in disposable plastic universal tubes (Falcon) and
sealed with parafilm before being double sealed in collection bags prior to
incineration. Plasticware that came into contact with MNNG was double bagged
before being disposed of by incineration.
2.4 Immunoblotting
2.4.1 Tissue sample preparation
Intestine samples were removed from the sacrificed animals and frozen in 1.5ml
Eppendorf tubes in liquid nitrogen. Samples to be prepared were placed in a
mortar prechilled with liquid nitrogen and ground into a fine powder with a
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pestle. This powdered tissue was placed in a 25ml universal tube and 2ml of ice-
cold RIPA (50mM NaCl, 1% NP-40, 12mM deoxycholate, 3mM SDS, 50mM
Tris pH 7.5) buffer was added. The samples were then mechanically
homogenised and centrifuged in 1.5ml Eppendorf tubes at 10,000g for 2 minutes
at 4°C to pellet cell debris. The supernatant was removed to a fresh Eppendorf
tube and passed through a 25-gauge syringe needle to shear remaining DNA.
Samples were stored at -70°C.
2.4.2 Protein quantification
Quantification of protein concentration in cell and tissue lysates was carried out
using the BCA protein Assay Kit (Pierce). Briefly, fifty parts BCA reagent A
(see appendix 1) were mixed with one part BCA reagent B (see appendix 1) to
create the working BCA reagent solution. A protein concentration standard curve
was generated by preparing a set of dilutions (5, 2.5, 1.25, 0.625, 0.3125 and 0
mg/ml) of Bovine Serum Albumin (BSA, supplied) in sterile test tubes. 0.1ml of
1:10 dilution of each sample to be assayed was placed in a test tube. 2.0ml of the
working BCA reagent solution was added to each test tube, mixed and incubate
at 37°C for 30 minutes. At the end of this incubation the tubes were cooled to
room temperature and the absorbance at 562nm of each solution determined
relative to a water blank. A standard curve was generated from the 562nm
absorbance of the known BSA concentration samples and the protein content of
each of the cell or tissue lysates determined by comparison to the standard curve.
2.4.3 Protein electrophoresis
0.3 volumes of 4x SDS-Sample Loading buffer (Novex, see appendix 1) were
added to the quantified protein samples. The samples were heated to 70°C for 15
minutes and then vortexed briefly. SDS-polyacrylamide gel electrophoresis was
accomplished on precast 10% Tris-Glycine gels in a XCell II™ tank (Novex). A
volume of sample in loading buffer containing 20pg of total protein (5-25pl) was
added to each of the wells and electrophoresed at 150V in parallel with a
molecular weight marker (Kaleidoscope Prestained Standards, BioRad) in MOPS
SDS running buffer (Novex, see appendix 1) at room temperature for 1 hour.
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2.4.4 Protein Transfer
Protein was transferred onto Hybond™ECL™ nitrocellulose membranes
(Amersham) via electrophoresis at a constant current of 250mA per gel for 90
minutes in transfer buffer (see appendix 1). Transfer was carried out at 4°C in a
BioRad wet blotting apparatus. Following transfer gels were stained in GelCode
(Pierce) to determine transfer efficiency and to check loading levels in the
individual wells. Gels were placed in 15 ml of stain solution in a Coplin jar and
gentle rocked for l-2hours then destained in dH20 for 2-6 hours. Destained gels
were place on 3MM Whatman filter paper and dried in a vacuum apparatus.
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2.4.5 Antibody incubation
Protein blots were transferred to 50ml centrifuge tubes with 10ml of blocking
solution (10% non-fat dried milk powder (w/v) in TBST, see appendix 1) and
placed on a roller mixer. Blots were blocked in this solution for 1 hour at room
temperature. Following blocking, 5|il of primary antibody solution (anti-(3-
catenin, Upstate Biotechnologies or Transduction Laboratories) was added to the
blocking solution and the blots incubated in the same manner for 1 hour at room
temperature or overnight at 4°C. The primary antibody solution was then poured
off and the blot washed 4 times in 10ml TBST at room temperature. The blot was
then incubated with 5pl of HRP-conjugate secondary antibody solution (anti-
light chain IgG, name of company) in 10ml of 10% Marvel (Nestle, UK) in
TBST (see appendix 1) at room temperature for 1 hour. The blot was washed as
above prior to signal detection.
2.4.6 Signal detection
Signals were detected using the ECL™ Chemiluminescent detection system
(Amersham). For each blot 1ml of each of the two reagents solutions were mixed
just prior to application. The blot was placed on an acetate transparency, protein
upwards, and the mixed reagent solution pipetted onto its surface. The reagents
were left in contact with the blot for 1 minute then poured off. A second acetate
transparency was laid on top of the blot and this sandwich then placed in a film
cassette. The blot was then overlaid with ECL™ film (Amersham) for periods of
30 seconds to 10 minutes, depending on signal intensity. Films were developed
(Hyperprocessor, Amersham), digitally scanned (DeskScan II, Hewlett Packard)
and bands quantified with densitometry software (Aida, Microsoft).
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2.7 Introduction of DNA into cultured mammalian cells
2.7.1 Microinjection
2.7.1.1 DNA preparations
DNA for microinjection was diluted to 125ng/jil in lx injection buffer (see
appendix 1) to a final volume of 10(il. The DNA dilutions were spun at 10,000g
for 3 minutes to pellet any debris which may clog the injection needle. 2pl of the
DNA/buffer solution was placed into the tip of the microinjection needles
(Original Femtotips, Eppendorf) using drawn loading pipette tips (Eppendorf).
2.7.1.2 Injection conditions
Microinjections were carried out on a Zeiss Axiovert SI00 Microscope using an
Injectman control console and a Transjector Injection system (both from
Eppendorf). Injection conditions for the cell lines use were as follows:
Table 2.4: Microinjection conditions
Cell line Injection pressure Injection time
HCT 116 130 hPa 0.3 seconds
Primary murine
colonocytes
100 hPa 0.1 seconds
2.7.2 Transfection
2.7.2.1 Calcium phosphate transfection
Transfection was carried out using a method described in Maniatis (16.33).
Plasmids to be transfected into mammalian cells were linearised with an
appropriate restriction enzyme digest followed by phenol: chloroform extraction.
The precipitated plasmid DNA was resuspended in the appropriate amount of
sterile O.lx TE (pH 8.0) to give a concentration of 40|ig/ml.
Cell lines were plated in 60mm petri dishes 12 to 24 hours prior to transfection.
Plasmid DNA was prepared to give a solution volume of 220pl at 40pg/ml and
250pl of 2 x HBS were added. 31 pi of 2M CaCF was slowly added to this
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solution during continuous but gentle vortexing. The resulting solution was
incubated at room temperature for 25 minutes or until a faint precipitate could be
seen. 0.5ml of this DNA solution was added drop-wise to each cell culture dish
containing 1ml of medium with continuous gentle agitation. 4ml of prewarmed
media was then added to each dish and the cells allowed to incubate for 24 hours.
After this period the medium was removed, the cells washed in PBS and re-fed
with 5ml of media. For selection of G418 resistant clones the cells were
trypsinised and replated at low densities and media containing the appropriate
concentration of G418 (see table 2.5). The cells were kept under G418 selection
for up to 14 days.
Table 2.5: G418 selection concentrations





2.7.2.2 Liposome mediated transfection
Optimal DNA (pg) to FuGene (pi) transfection reagent (Roche) ratios for the
individual cell lines used in transfection experiments were determined by
transfection with the positive control pCMV-GFP reporter plasmid. DNA:reagent
ratios of 1:6, 1:3 and 2:3 (recommended by the manufacturer) were used initially
with 0.3pg of DNA being applied to a 75% confluent well of a 24-well plate
(Nunc or Grenier). Transfection solutions were prepared by placing the
appropriate amount (3 or 6pl) of reagent into room temperature media to a
volume of lOOpl. 1 or 2pg of plasmid DNA was added to the FuGene/medium
solution and gently mixed followed by incubation at room temperature for 30
minutes. Following the incubation 30pl (for 1:6 or 1:3 ratios) or 15pl (for 2:3
ratio) of the solution was added with shaking to each well (containing 1ml of
medium). Further experiments varied the amount of transfection solution, and
therefore amount of plasmid DNA, which was added to each well. Optimal
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transfections were obtained using a 1:6 ratio and lpg of DNA for cell lines, 2pg
of DNA for primary colonocytes and lpg for murine ES cells.
2.8 Animal work
2.8.1 Tissue processing
Animals showing signs of illness were sacrificed by cervical dislocation and
immediately dissected. Organs collected (kidney, liver, spleen, mammary gland
and pancreas) were placed immediately in Formalin (see appendix 1), wax
embedded, sectioned to 3pm and haematoxylin and eosin stained. Intestines were
dissected out of the animals intact and flushed with water to remove waste
material. The large and small intestines were then separated, placed on Whatman
3MM paper and cut open along their length. The opened intestines, still on 3MM
filter paper, were placed in a tray containing Methocarn (see appendix 1) and left
to fix for 3-12 hours. The intestine samples were then "swiss-rolled" by winding
onto the end of watchmaker forceps and skewered by a syringe needle. These gut
rolls were submerged in Formalin (see appendix 1), wax mounted, sectioned to
2pm and stained with haematoxylin and eosin. Tissue sections were visually




For the harvest of embryos for prenatal phenotype examination, virgin females
were caged with males and were examined daily to check for the presence of a
post-coital (pc) plug. On the appropriate day (8-10 days pc) the pregnant females
were sacrificed by cervical dislocation and the uterus immediately dissected out
and placed in ice-cold PBS. Dissection of embryos from the maternal tissue and
placenta was carried out in a petri dish containing ice-cold PBS. Yolk sac
samples were retained for DNA extraction and genotyping of individual embryos
where appropriate. Embryos were examined under a binocular dissection
microscope (Heerbrug) for any gross anatomical abnormalities and to more
accurately establish developmental stage. Embryos were then fixed in formalin






Chapter 3 - Time and tissue-specific gene deletion
3.1 Background
While the Min mouse model and other murine APC mutants, such as the APC
1638N line, have provided considerable detail regarding the genetic progression
from normal tissues to neoplastic colorectal tumours these models have certain
limitations (Smits et al., 1998). As discussed in chapter 1, the heterozygous loss
of APC function in all tissue types during the entire lifetime of a mouse does
generate an animal model of tumour formation similar to the rare human
condition FAP, but does not adequately model the more common condition of
sporadic colorectal carcinoma. Tumour formation in the mouse is predominantly
in the small intestine, while in the human small intestinal tumours are very rare
compared to tumours of the large intestine. In order to better understand the
formation of sporadic colorectal lesions it would be useful to possess an animal
model that more closely resembles the human phenotype. One way to achieve
this would be to be able to control more precisely where and when the murine
APC gene is lost. The aim of this project was to generate an intestinal stem cell
specific inducible Cre mouse strain, with the intention of crossing it to a
transgenic mouse strain containing one or more copies of a floxed wildtype Ape
gene compensating for homozygous Min mutations. On induction of Cre
recombinase activity, the floxed Ape genes would be excised only in the stem
cells and proliferative compartment, hopefully resulting in a phenotype
resembling that observed in the human sporadic colorectal cancer patient. A
floxed Ape / ApcM,n/M'n mouse strain has been developed and it has been shown
that introduction of Cre coding sequence into the intestinal epithelial cells of
these mice using engineered adenovirus results in rapid formation of polyps and
eventually adenomas (see section 1.5.3.6.2) (Shibata et al., 1997). However, as
the Cre-adenovirus does not only infect stem cells, some of the polyps or
adenomas may arise from older cells which have accumulated mutations capable
of influencing tumour formation and progression. Additionally, the number of
tumours formed following adenovirus Cre delivery was very small when
compared with the number of cells infected using a related adenovirus encoding
the LacZ gene. The difference in the frequency of polyp formation compared
with the frequency of adenovirus infection in the intestinal epithelium suggests
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that either recombination is not occurring in an efficient manner or that loss of
Ape function alone is insufficient to cause polyp formation. While it is known
that most intestinal tumours contain alterations to both copies of the Ape gene
and that early adenomas may be wildtype for a number of other tumour
suppressor genes, the use of adenovirus Cre delivery does not answer the
question of whether these Ape mutations alone are sufficient to initiate and
maintain tumour formation (Lamlum et al., 2000).
Mouse strains have previously been developed which express the Cre
recombinase in the epithelium of the intestine in both inducible and constitutive
manners (Saam and Gordon, 1999). In the constitutive expression mouse line the
control of Cre transcription is placed under the control of the Fatty Acid Binding
Protein (Fabp)\ expression of Cre from this promoter appears to be limited to the
epithelial cells of most of the length of the mouse small intestine. In the inducible
recombination mouse the reverse tetracycline (tet) transactivator sequence is
under the control of the Fabp promoter while Cre expression occurs from a
minimal human cytomegalovirus (CMV) promoter, itself under the control of a
tet operator sequence, at another transgenic locus. In this system, expression of
the tet transactivator is limited to the small intestinal epithelium; administration
of the tetracycline analogue doxycycline activates this transcription factor which
then binds to the tet operator and provokes expression of the Cre coding
sequence, thereby also limiting Cre expression to the small intestinal epithelium.
Analysis of these mouse strains crossed onto floxed reporter strains indicate that
when Cre is under the constitutive control of the Fabp promoter, Cre
recombination can be observed prenatally from day 13.5 post-conception while
in the inducible mouse strain recombination occurs with high efficiency after
administration of doxycycline. The presence of the recombined allele is
detectable up to 60 days after the cessation of doxycycline treatment despite the
high cell turn-over rate of the intestinal epithelium, indicating that the Fabp
promoter is active in cells with proliferative potential (Saam and Gordon, 1999).
While this model will prove useful for the investigation of the effects of gene
removal in the developing (in the case of the constitutively expressed Cre) and in
the adult (in the inducible Cre mouse) intestine, it has not been clearly
established whether the Fabp promoter initiates expression in the stem cells of
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the intestinal crypts. The ability to induce Cre recombination in the crypt stem
cells would allow for the expansion of clonal populations derived from the
altered progenitor cells.
In order to generate such a model organism, tissue-specific promoter elements
are required to target the inducible Cre expression to the desired cells. No
intestinal stem cell specific promoters have been identified to date; the closest
candidate gene proved to be Cdx-1, a murine homeobox gene, which is expressed
biphasically in the lifetime of the mouse (Meyer and Gruss, 1993). Cdx-1 is first
expressed in the mouse embryo prior to the gastrulation stage (-day 7.5) in the
primitive streak, with expression becoming more global later in embryogenesis.
In the adult mouse Cdx-1 expression is limited to the intestinal epithelium, in a
gradient increasing from the proximal small intestine to the distal large intestine
and is expressed in detectable levels in the stem cells and proliferative
compartments of the crypts (see figure 3.1) (Subramanian et al., 1998). The early
embryonic expression of Cdx-1 would prove to be a problem if used to drive
native Cre expression in a floxed APC cross line, as APC null homozygosity is
embryonic lethal and premature excision of the APC gene in all tissues as a result
of Cre activation would result in embryo death (Moser et al., 1995). To avoid the
premature excision of APC in this crossed line, the Cre coding sequence is fused
to a mutated human oestrogen-binding (ERtm) element coding sequence, the
resulting fusion protein termed CreERtm. This element is normally bound to a
heat shock protein thereby sterically hindering the active site of the Cre
recombinase, but will recognise and bind the synthetic hormone tamoxifen (tm);
binding of tamoxifen displaces the heat shock protein from the oestrogen-binding
element, thereby restoring Cre recombinase activity (Feil et al., 1996). The
combination of the tissue-specific Cdx-1 promoter elements with the tamoxifen
inducible Cre would allow control of APC excision in a time and tissue
dependant manner, allowing for better modelling of the formation of human
sporadic colorectal adenomas and the investigation of whether APC inactivation
alone is sufficient to cause tumour formation.
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Figure 3.1: Expression pattern of Cdx-1 in the murine colonic crypt







Figure 3.1: Cdx-1 expression is limited, in the adult mouse large intestine, to the
proliferative compartment and stem cells of the colonic crypts. Cdx-1 expression is
also detected at lower levels in the small intestine, again in the proliferative
compartment.
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3.2 Isolation of Cdx-1 tissue-specific promoter sequence
3.2.1 BAC screening
The initial step in generating an intestinal specific inducible Cre mouse line was
the identification and cloning of the Cdx-1 promoter elements needed to confer
tissue-specific promoter activity. At the time of the commencement of this
project approximately l.lkb of sequence upstream of the transcription start site
of Cdx-1 had been published and was available from GenBank (Hu et al., 1993).
This short stretch of sequence had been engineered into a construct to drive
expression of a Chloramphenicol Acetyltransferase (CAT) reporter gene when
transiently transfected into a number of colorectal adenoma derived cell lines
(Hu et al., 1993). Levels of transcription generated using this short promoter
sequence were extremely low and only produced measurable levels of reporter
protein when a strong viral enhancer (SV40 enhancer) was present in the reporter
construct (Hu et al., 1993). This l.lkbp of published Cdx-1 promoter sequence
did not appear able to drive significant levels of reporter transcription in the
absence of an exogenous enhancer and did not appear to contain an endogenous
enhancer, although it was found to contain an orientation independent silencer
element and a silencer blocking element. (Hu et al., 1993). While the published
sequence did contain a number of transcriptional control elements, it was still
possible that the published Cdx-1 promoter did not contain all the elements
necessary to confer the precise tissue-specificity required; transcription factor
binding sites might exist upstream of this initial 1.1 kb of promoter sequence
which are vital to producing not only reasonable levels of transcription but the
observed expression pattern.
The first step in generating constructs driven by the Cdx-1 promoter was
therefore the isolation of a significant amount of sequence upstream of the Cdx-1
transcription start site. A number of methods for isolating sequence immediately
upstream of the published Cdx-1 promoter sequence were investigated, including
genome walking and inverse PCR. While some sequence was successfully
isolated and sequenced using an inverse PCR method (see figure 3.2) the lack of
suitable restriction sites near the 5' limit of the known Cdx-1 sequence limited
the viability of finding large amounts of new sequence. Screening available
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genome libraries using probes based on the published Cdx-1 sequence was
determined to be the most reliable way to isolate the desired elements.
Ultimately, it was decided to screen a Bacterial Artificial Chromosome (BAC)
library to isolate clones containing murine Cdx-1 sequence (Shizuya et al., 1992).
The very large insert sizes in these pBeloBACll constructs (>100kb) would
maximise the chances of the known Cdx-1 sequence being contained in the same
clone as the unknown upstream sequence of the Cdx-1 promoter region (Monaco
and Larin, 1994). The initial stages of BAC screening involve PCR reactions;
BAC DNA was obtained from Research Genetics and screened by PCR for the
presence of exon 1 of Cdx-1 using primers and conditions optimised by Dr. Jane
Armstrong (figure 3.3, see section 2.2.2 for PCR conditions). The genomic
mouse DNA inserts in these BAC constructs were derived from the CJ73 cell
line which was derived from the 129SV mouse strain. DNA samples were
organised in superpools of DNA derived from a large number of clones and
pools containing a much smaller number of BAC DNA samples. Once the
correct pool of BAC DNA had been identified a membrane corresponding to this
DNA sample was obtained for the final round of BAC library screening. This
membrane contained DNA dot blots from 384 BAC host clones and was
hybridised to a PCR amplified Cdx-1 exon 1 DNA probe by Dr. Sula Corbet.
Two BAC clones were identified as positive for the presence of Cdx-1 exon 1,
BACs 219 and 538 (see figure 3.4).
3.3 Construction of BAC based targeting and transgenic vectors
In order to maximize the amount of upstream Cdx-1 sequence included in the
transgene construct it was decided to employ a relatively recently developed
technology to build a Cdx-1 driven CreERtm transgene in parallel with the more
traditional subcloning methods. A method for the rapid modification of BAC
sequence based on the viral Redoc-P-y recombination-inducing proteins has been
used to introduce changes into specific locations in BACs without the need to
purify large quantities of BAC DNA or indeed remove the BAC from its host
bacteria (Muyrers et al., 1999). The method employs an inducible Reda-P-y
expression plasmid, which is first introduced into the BAC host organism by
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electroporation (see section 2.1.7). The plasmid is induced by the addition of
arabinose to the culture media which results in the high level expression of Reda
to complement the constitutive expression of Redp/Redy and these "activated"
recombination competent cells are harvested and made electrocompetent (see
figure 3.5, section 2.1.7). The recombination competent BAC host bacteria are
then electroporated with a linearized vector containing sequence to be inserted
into the BAC along with a selection cassette to screen for bacteria containing
recombinant BACs. This sequence to be introduced is flanked with short
stretches of DNA (40-150bp) homologous to the region of the BAC to be
targeted for insertion (see figure 3.6 for overview). The recombination-induction
of the Reda-P-y proteins and the ability to select for recombinants using an
antibiotic system should make this process very efficient.
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Figure 3.2: Inverse PCR for the isolation of upstream Cdx-1 promoter sequence
A)
new upstream Cdx-1 sequence
Avrll (- 2845)
































Figure 3.2: A) Schematic of the region amplified in the inverse PCR of circularised
Avrll digested mouse genomic DNA showing the locations of the PCR primers as
well as the the subsequently identified location of the upstream Avrll site. B) UV gel
image of a representative PCR product generated from the inverse template. Lane 1:
High Mass Marker (Gibco). Lane 2: Inverse PCR product of 2.8 kb generated from
Avrll digested/circularised mouse genomic DNA. Lane 3: Marker VI (Roche). C)
Sequence derived from the pCR 2.1 cloned inverse PCR product.
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Figure 3.3: Cdx-1 exonl PCR for screening of BAC library
A)
Sphl (1249)
Notl (1174) Pvull (1491)

































Figure 3.3: A) Schematic of the published Cdx-1 promoter region and exonl,
showing some relevant restriction sites and the location of primers used to amplify
the exonic sequence. B) Gel electrophoresis of representative PCR reaction of the
first exon of Cdx-1. Lane 1: Low Mass Ladder (Gibco). Lane 2: PCR product
produced in a 25pi reaction. Lane 3: PCR product produced in a 50pl reaction. C)
Analytic digests of the PCR product to confirm the correct amplification of exon 1 of
Cdx-1. Lane 1: Marker VI (Roche). Lane 2: BspEI digestion of the amplified 400 bp
exon 1 sequence showing the expected bands at 123 and 277 bp. Lane 3: Undigested
exon 1 PCR product. Lane 4: Pvull digestion of the amplified 400 bp exon 1
sequence showing the expected bands at 186 and 214 bp.
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Figure 3.4: A) A representative 400 bp PCR reaction screening for the presence
of the first exon (exon 1) of the murine Cdx-1 gene within the BAC DNA pools
provided. Lane 1: Marker VI (Roche). Lane 2: Cdx-1 exon 1 PCR of negative
BAC DNA pool 2F. Lanes 3-4: Positive DNA pools 8B and 4C respectively.
Lane 5: A negative control reaction using dH20 in the place of template DNA.
B) An autoradiograph of a membrane dot blotted with the DNA from BAC
clones making up the positive DNA pool. The membrane was hybridized with a
PCR amplified 400 bp stretch of exon 1 of murine Cdx-1. The positive clone
gives a strong signal and is found at position H8, corresponding, in this case, to
BAC clone 219.
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Figure 3.5: Induction of the Reda protein in bacteria by exposure to arabinose
- 25 kDa
Figure 3.5: A GelCode (Pierce) stained SDS-PAGE electrophoresis gel of total
proteins isolated from bacterial host cells containing the pBAD-Reda/p/y
recombination inducing plasmid. The expression of the Reda protein is under the
control of an arabinose inducible promoter (Clontech). Lane 1: Broad Range Pre-
Stained Protein Standards (BioRad). Lane 2: Total proteins isolated from BAC 219
hostis. colicells cultured in the absence of arabinose. Lane 3: Total proteins isolated
from BAC 219 host E. colicells cultured in LB media supplemented with 0.2% w/v
arabinose showing the induction of the 25 kDa Reda protein.
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Figure 3.6: An overview of the strategy for the creation of a BAC based gene
targeting construct for the expression of inducible Cre recombinase under Ccbc-l
promoter control using the Red a/(3 recombination technique. Floxed Neo
resistance cassettes were cloned into a vector containing the promoterless
CreERtm fusion protein coding sequence. The CreERtm and resistance cassette
were excised from the plasmid backbone and inserted into the sequence of a short
stretch of cloned Cdx-1 sequence containing the transcription start site. The
resulting plasmid was be linearised and transfected into bacteria containing a
Bacterial Artificial Chromosome (BAC) encoding the entire murine Cdx-1
promoter sequence and an activated Red a/p plasmid. The CreERtm Neo plasmid
underwent recombination with the wild type sequence of the BAC producing a
Cre expression construct under the control of the entire Cdx-1 promoter. To create
an analogous transgene construct the Neo gene was not flanked by loxP sites but
the strategy remained the same.
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3.3.1 Subcloning of CreERtm coding sequence
The coding sequence of the Cre recombinase fused to that of a human oestrogen
receptor altered to preferentially bind the synthetic hormone tamoxifen, CreERlm,
was obtained from Dr. Tom Gardner. This plasmid, termed Cre5 (see figure
3.7a), contained a number of stretches of sequence which would have interfered
with the construction or function of the final BAC targeting vector, making it
necessary to subclone the coding sequence into another vector. The CreERlm
coding sequence was excised from the Cre5 plasmid by a double digestion with
Spel and NotI, followed by gel extraction of the 2840 bp fragment containing the
CreERtm sequence (figure 3.7b). This fragment was cloned into the pBlueScript
(pBS) (Stratagene) vector, which had been digested with the same enzymes and
treated with SAP to prevent recircularisation. The result was a "clean" CreERlm
coding sequence vector, pBSCre without the viral promoters and stretches of
unknown sequence found in the original Cre5 plasmid (figure 3.8).
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Figure 3.7: A) A vector schematic of the Cre5 vector, constructed by Dr. Tom
Gardner, coding the CreERtm fusion protein. B) Electrophoresis gel showing the
NotI/ Spel digest of the Cre5 vector for gel extraction and subcloning of the Cre¬
ERtm fusion ORF into the pBlueScript backbone. Lane 1: Marker 2 (Roche). Lane 2:
Cre5 digested with Notl/Spel. The DNA fragment encoding the CreERtm protein is
present in the 2.8 kb band indicated.
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Figure 3.8: A) A vector schematic showing the CreERtm coding sequence cloned
into the pBlueScript (pBS) plasmid backbone. B) Gel image of the pBSCre plasmid
prepared for the next cloning step. Lane 1: High Mass Marker (gIBCO). Lane 2:
pBSCre digested with Spel giving a single band at 5.8 kb representing the linearised
plasmid. The digestion was supplemented with SAP to prevent recircularisation in
subsequent cloning stages.
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3.3.2 PCR generation ofmutant floxed and native kanamycin/neomycin
resistance cassettes
In addition to the CreER"11 coding sequence it was necessary to generate an
appropriate antibiotic selection cassette. Two uses for the recombination altered
BAC were envisioned at the inception of this project; the use of a full length
linearised BAC construct as a random integration transgene and, should
appropriate "trimming" digests prove possible, as a targeting vector for the
replacement of one native copy of Cdx-1 in murine embryonic stem (ES) cells
with the Cdx-1 promoter driven CreERtm recombinase. Because of the need to
select for recombinant BACs in prokaryotic hosts as well as possibly needing to
select for ES cells which had undergone recombination, the selection cassette
chosen for use in the BAC based construct was a Neo gene driven by both
prokaryotic and eukaryotic (Herpes Simplex Virus-Thymidine Kinase or HSV-
TK) promoter sequences. The resulting cassette gives resistance to the antibiotic
Kanamycin in the E. coli K12 derivative cells used during the cloning stages of
construct building and would impart resistance to G418 in ES cells which had
successfully integrated the altered BAC (Southern and Berg, 1982).
Two cassettes containing the Neo resistance gene were generated by PCR from a
commercially available vector (pGFP-Nl, Clontech). The first cassette contained
only the promoter and resistance coding sequences mentioned above while the
second cassette generated was flanked by loxP sites containing a single basepair
mutation in the spacer region (see section 2.2.2 for primers). This single base
change results in loxP sites which will preferentially recombine with each other
rather than with native loxP sites (Lee and Saito, 1998). The inclusion of these
loxP sites would allow for the removal of the selection cassette from
recombination positive "knock-out" ES cells by transient transfection with a Cre
coding plasmid driven by a strong promoter (Abuin and Bradley, 1996).
Removal of the selection cassette may prevent read through from the selection
cassette promoter into sequence downstream of the targeted gene and
additionally stops the constitutive transcription and translation of resistance
markers in any animal generated using the targeted ES cells; both situations
which may result in phenotype unrelated to the desired genomic alterations.
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Mutated loxP sites were used to prevent Cre mediated recombination between
the single loxP site remaining in the altered Cdx-1 allele following selection
cassette excision and the native loxP sites flanking genes of interest in mice to
which the Cdx-1 -Cre mouse may be crossed, thereby preventing possible large
genomic rearrangements. This loxP flanked selection cassette would, however,
not be appropriate for use in the random integration transgenic approach as the
presence of multiple sites of integration and/or concatamer integration events
could result in multiple undesired recombination events upon Cre induction. The
Neo resistance cassette without loxP sites was therefore generated for use in the
transgenic BAC construct while the mutant loxP cassette was generated for use
in the targeting BAC construct.
Resistance cassette amplification reactions, both with and without loxP sites,
were incubated with Dpn I, a methylation dependant restriction enzyme,
following amplification to cleave any template plasmid present in the PCR
reaction. The cassettes were then cloned into the pCR 2.1 vector (Invitrogen),
resulting in the plasmids pCRNeo and pCRLoxNeo (see figures 3.9 and 3.10). As
the pCR 2.1 cloning vector contains a native Kanamycin selection cassette the
PCR generated cassettes were cut out with a Spel / Xbal double digest and
cloned into the pBlueScript vector, which contains only the Ampicillin resistance
gene, to test for functionality of the PCR generated Neo gene, the resulting
vectors referred to as pBSNeo and pBSLoxNeo (figures 3.11 and 3.12). Both the
floxed and the non-floxed cassettes successfully conferred kanamycin resistance
to E. coli host strains.
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Figure 3.9:A) A vector schematic showing the non-floxed Neo resistance cassette
cloned into the pCR 2.1 plasmid backbone. B) A representative PCR product. Lane
1: Kilobase Ladder (New England Biolabs). Lane 2: Negative control using dH20
instead of template DNA. Lane 3: 1.9 kb Neo PCR product. C) An analytic digest of
the cloned Neo PCR product. Lane 1: Marker II (Roche). Lane 2: EcoRI digest of the
pCRNeo plasmid. The EcoRI digest liberates the 1.9 kb resistance plasmid from the
3.9 kb pCR backbone. Lane 3: Marker VI (Roche).
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Figure 3.10: A) A vector schematic showing the floxed Neo resistance cassette
cloned into the pCR 2.1 plasmid backbone. B) A representative PCR product. Lane 1:
Marker VI (Roche). Lane 2: 1.9 kb LoxNeo PCR product. Lane 3: Negative control
using dH20 instead of template DNA. C) An analytic digest of the cloned LoxNeo
PCR product. Lane 1: Marker II (Roche). Lane 2: EcoRI digest of the pCRLoxNeo
plasmid. The EcoRI digest liberates the 1.9 kb resistance plasmid from the 3.9 kb
pCR backbone.
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Figure 3.11: Subcloning of the native Neo cassette
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Figure 3.11: A) A vector schematic showing the Neo resistance cassette cloned
into the pBlueScript plasmid backbone. B) An analytic digest of the correct
pBSNeo plasmid. Lane 1: Marker VI (Roche). Lane 2: pCRNeo digested with
Xbal/Spel. This double digestion liberates the Neo cassette from the pCR 2.1
backbone giving bands of 1.9 and 3.9 kb. Lane 3: pBSNeo digested with Xbal/Spel.
This double digestion liberates the Neo cassette from the pBS backbone giving
bands of 1.9 and 2.9 kb, showing the successful subcloning of the resistance
cassette. Lane 4: Marker II (Roche).
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Figure 3.12: A) A vector schematic showing the LoxNeo resistance cassette cloned
into the pBlueScript plasmid backbone. B) A gel image of an analytic digest of the
correct pBSLoxNeo plasmid. Lane 1: pBSLoxNeo cut with Xbal/Spel. This double
digestion liberates the 1.9 kb LoxNeo resistance cassette from the 2.9 kb pBS
backbone. Lane 2: The 3.9 kb pCR 2.1 vector, from which the LoxNeo fragment had
been subcloned, cut with Xbal to generate a single linearised DNA molecule. Lane 3:
Marker VI (Roche). Lane 4 Marker II (Roche).
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3.3.2.1 in vitro Cre recombination
Following testing for the functionality of the generated kanamycin resistance
cassettes the recombination competence of the mutant loxP sites introduced into
one of the cassettes was tested using an in vitro Cre recombination reaction
followed by a diagnostic restriction digest. 5pg of the pBSLoxNeo prep were
incubated with lOju.1 of Cre-maltose binding protein fusion protein preparation
(supplied by Sharon Sheahan, 20mg/ml) in Cre reaction buffer (see appendix 1)
in a total volume of 30|il (Kolb and Siddell, 1997). The reaction was incubated at
37°C for 1.5 hours and the DNA subsequently phenol-chloroform extracted and
resuspended in 20pl of TE buffer. A fraction of the recombined DNA was set
aside for gel electrophoresis without digestion and the remaining fraction was
digested with Eagl. This restriction enzyme cleaves the kanamycin resistance
cassette, generating a 1.9kb linear fragment which will not appear if Cre
recombination is unsuccessful. Restriction enzyme digested and uncut plasmid
DNA fractions were gel electrophoresed for analysis and banding patterns
consistent with successful in vitro Cre recombination were observed (figure 3.13)
indicating that the introduced mutant loxP sites were capable of interacting.
120













% t -1.8 kb
1 1 1 -1.2 kbp 1 -1.0 kb
Figure 3.13: A) A vector schematic showing the LoxNeo resistance cassette cloned
into the pBlueScript plasmid backbone, before and after recombination following in
vitro Cre treatment. B) A gel image showing an analytic Eag I digest of the correct
pBSLoxNeo plasmid with and without Cre treatment. Lane 1: Marker II (Roche).
Lane 2: pBSLoxNeo digested with EagI following Cre treatment. The presence of a
band at 1.9 kb indicates that some fraction of the original plasmid has undergone the
expected recombination reaction prior to digestion. Lane 3: pBSLoxNeo digested
with EagI without prior Cre treatment. Note the absence of the 1.9 kb band. Lane 4:
pBS digested with EagI giving a single 2.9 kb band representing the linearised
plasmid. Lane 5: The LoxNeo PCR product of 1.9 kb. Lane 6: Marker VI (Roche).
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3.3.3 PCR and cloning of arms of homology
The final components of a construct for recombination alteration of BAC 219 are
the stretches of sequence homologous to the region of the BAC to be replaced:
the arms of homology. To generate an appropriate set of homologous sequences
for Reda-(3-y mediated recombination, a PCR was performed across a region of
the published Cdx-1 sequence containing the transcription start signal (figure
3.14, chapter 2 for PCR conditions and primers). The PCR amplified Short-Cdlx-
1 sequence (278bp) was cloned into the pCR 2.1 vector (Invitrogen), giving
pCRSCdx (see figure 3.15), and sequenced by DNAShef (Royal Infirmary,
Edinburgh, UK) to determine the fidelity of the PCR reaction. The sequence was
determined to be identical to the corresponding published sequence of murine
Cdx-1 and therefore suitable for use in the generation of arms of homology for
Reda-fTy mediated BAC recombination. To facilitate further cloning and
screening steps, the Short-C<ix-7 sequence was cut out of the pCR 2.1 vector
using a SacI/EcoRV double digest and cloned into the corresponding sites of
pBlueScript (Stratagene) giving pBSSCdx (figure 3.16). The amplified Short-
Cdx-1 sequence contains a unique SphI site, at position +73 relative to the
transcription start site and 22bp upstream of the translation start site, which was
used to introduce the CreERtm and Neo coding sequences into the Short-Cdx-1
sequence.
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Figure 3.14: A) A schematic representation of the region of published murine Cdx-1
promoter to be amplified as Short-Cdxl, showing the location of the PCR primers
and some of the restriction sites within the region. B) Electrophoretic gel image of an
example of the amplified product Short-Cdxl, 278 bp in length. Lane I: Marker VI
(Roche). Lane 2: Short-Cdxl PCR product. C) A gel image of an analytic digest of
the amplified Short-Cdxl product. Lane 1: Marker VI (Roche). Lane 2: Digestion of
the correct PCR product with Notl results in the generation of fragments of 148 bp
and 130 bp in size. Lane 3: Undigested Short-Cdxl PCR product.
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Figure 3.15: Cloning of Short Cdx-1 PCR














Figure 3.15: Cloning of Short Cdx-1 PCR A) A schematic vector map of the
Short-Cdxl PCR product cloned into the pCR 2.1 vector backbone. B) A restriction
digest showing the successful cloning of Short-Cdxl into pCR 2.1 Lane 1: Marker
VI (Roche). Lane 2: An analytic EcoRI digest of the cloned Short-Cdxl fragment
within pCR 2.1. The EcoRI digest liberates the 278 bp Short-Cdxl DNA sequence
with 12 basepairs ofvector from the 3.9 kb plasmid backbone.
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Figure 3.16: Subcloning of Short Cdx-1 PCR
A) CDX1 short PCR £CO r | (3227)
Sphl (3166)


















Figure 3.16: Subcloning of Short Cdx-1 PCR A) A vector map of the Short-Cdxl
PCR product subcloned into the pBS vector backbone. B) An analytic restriction
digest showing the successful subcloning of the Short-Cdxl sequence into
pBlueScript. Lane 1: Low Mass Marker (Roche). Lane 2: An EcoRI digestion of the
correct plasmid. The EcoRI digest liberates the 300 bp subcloned Short-Cdxl
fragment from the 2.9 kb pBS plasmid backbone. Lane 3: pBS linearised by EcoRI
digestion for size comparison. Lane 3: The 278 bp Short-Cdxl PCR product. The
subcloned fragment is slightly larger as it carries short flanking sequences from pCR
2.1.
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3.3.4 Construction and screening of final BAC targeting vectors
The three component fragments; the CreERtm coding sequence, the floxed or
native selection cassette and the Short-Cda>7 arms of homology were then
assembled into the complete BAC targeting vector. The pBSCre construct was
cut with Spel and treated with Shrimp Alkaline Phosphatase (SAP). The pBSNeo
and pBSLoxNeo constructs were digested with Xbal / Spel (which produce
compatible overhang ends) to liberate the resistance cassettes which were gel
extracted (see figure 3.17). The pBSCre Spel linearised fragment and resistance
cassette Xbal / Spel fragments were ligated and the resulting transformed
colonies were screened by NotI / Bglll digest for the presence of pBSCreNeo and
pBSCreLoxNeo plasmids of the correct orientation (see figures 3.18). With the
Neo resistance cassette inserted in the appropriate direction the entire CreERtm-
Neo coding sequence could be liberated from the pBS backbone with a NotI
digest, giving a band of 4902 bp (with loxP sites) or 4834 bp (without loxP sites)
(figure 3.19). The NotI digest was supplemented with T4 DNA polymerase to
generate blunt ended fragments and the digest run out for gel extraction of the
CreERtm-Neo DNA fragment.
The arms of homology were prepared for insertion of the Cre containing cassette
by SphI digest of the pBSSCdx construct, supplemented with T4 DNA
polymerase and SAP to generate a blunt ended molecule incapable of self-
ligation. This was then ligated to the blunted NotI pBSCreNeo and
pBSCreLoxNeo fragments. The resulting plasmids were transformed into TOPIO
E. coli cells (Invitrogen) and colonies resistant to both kanamycin and ampicillin
(the resistance gene present in the pBS backbone) were picked and grown for
screening. Plasmids derived from these resistant bacteria were digested with Not
I and Bgl II to check for the presence of the expected CreERtm-Neo sequence
flanked by Cdx-1 promoter arms of homology and to determine the orientation of
the blunted NotI CreERtm-Neo fragment within the plasmid (figure 3.20).
Once the appropriate homology arm flanked CreERtm-Neo plasmids
(pBACtargetLox and pBACtarget) had been identified and isolated they were
digested with Seal, which cut these constructs once to give linearised vectors.
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This linearization increases the frequency of recombination in the BAC host as
well as preventing intact circular plasmid from persisting within BAC host cells
and becoming a source of false positives upon antibiotic selection for resistant
recombinants. The linearised plasmids were gel extracted to remove any uncut
DNA (figure 3.21). The clean linearised plasmids were then electroporated into
previously prepared recombination competent (Reda induced) BAC 219 cells
(section 2.1.7).
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Figure 3.17: A) Vector schematics of the previously described pBSCre,
pBSLoxNeo and pBSNeo resistance cassette plasmids. B) Gel image of the
linearised pBSCre and the resistance cassette fragments to be cloned together to
generate the CreERtm/resistance cassette plasmids. Lane 1: High Mass Marker
(Roche). Lane 2: An Spel digest of the pBSCre which results in its linearisation,
giving a single band on 5.8 kb. Lane 3: A gel extraction of the 1.9 kb Spel/Xbal
fragment of pBSLoxNeo plasmid which contains the floxed resistance cassette.
Lane 4: A gel extraction of the 1.9 kb Spel/Xbal fragment of pBSNeo plasmid
which contains the non-floxed resistance cassette.
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Figure 3.18: Cre/Neo constructs
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2980 bp
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1.5 kb- 1517 bp
1.0 kb
Figure 3.18: A) Vector schematics showing the CreERtm coding sequence and the
Neo resistance cassettes (floxed and native) cloned into the pBlueScript plasmid
backbone. B) An electrophoretic gel showing the banding pattern of analytic digest
of the pBS CreNeo and pBSCreLoxNeo plasmid. Lane 1: Marker II (Roche). Lane 2:
pBSCreNeo digested with Notl/Bglll showing the expected bands at 1.5, 3.0 and 3.2
kb. Lane 3: pBSCreLoxNeo digested with Notl/Bglll showing the expected bands at
1.5, 3.0 and 3.25 kb. With the Neo cassette inserted in the wrong orientaion NotI /
Bglll digest would give bands of 4816(floxed)/4884(unfloxed), 1517 and 1352
basepairs.F
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Figure 3.19: A) A vector schematic showing the pBSCreLoxNeo and pBSCreNeo
plasmids. B) An electrophoretic gel showing the banding pattern of a Notl digest of
the pBSCreNeo and pBSCreLoxNeo plasmids. Lane 1: Marker II (Roche). Lane 2:
pBSCreNeo digested with Notl showing the expected bands at 2.9 and 4.8 kb. Lane
3: pBSCreLoxNeo digested with Notl showing the expected bands at 2.9 and 4.8 kb.
C) Preparation of the pBS-SCdx plasmid. Lane 1: Kilobase marker (NEB). Lane 2:
Uncut pBS-SCdx plasmid. Lane 3: pBS-SCdx plasmid cut with SphI resulting in a
linear molecule. T4 DNA polymerase was used to blunt the vector ends in
preparation for this cloning step.
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Figure 3.20: BAC targeting vectors
Cdx-1 homology arm
TK PolyA









































1.5 kb -1.6 kb
Figure 3.20: A) A vector schematic showing the pBACtarget" and pBACtargetLox
plasmids. B) An electrophoresis of analytic digests of the blunt cloned plasmids
plasmids. Lane 1: Lane 1: Kilobase marker (NEB). Lane 2: pBACtarget digested
with Bglll and Notl. With the blunted Notl cassette inserted in the correct orientation
the expected bands are of 1584 and 6363 bp. Lane 3: A Bglll/NotI double digest of
the pBACtarget construct with the blunted Notl insert in the wrong orientation; in
this plasmid the expected bands are of 3261 and 4686 bp. Lane 4: A Bglll/NotI digest
of the pBACtargetLox plasmid. The expected bands are of 1584 bp and 6431 bp.
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Figure 3.21: A) A vector schematic showing the pBACtarget and pBACtargetLox
plasmids which have been linearised by digestion with Seal. B) An electrophoresis
of the Seal digested plasmids. Lane 1: Kilobase Marker (New England Biolabs).
Lane 2: Seal digest ofpBACtarget. Lane 3: Seal digest ofpBACtargetLox.
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Initial electroporations of BAC 219/Reda cells with linearised pBACtarget and
pBACtargetLox failed to produce colonies on LB plates supplemented with
20p.g/ml kanamycin. The incorporation of the Neo gene into the BAC would
result in only one copy of the resistance gene persisting within the cell, as
opposed to the multiple copies present inside host bacteria when the gene is
present in a traditional high copy number plasmid, such as the pBS plasmid used
as a backbone for the targeting constructs. This marked reduction in copy
number may result in a lower threshold of resistance to kanamycin; to
compensate, the cells from further electroporations were plated on LB plates
containing reduced concentrations of kanamycin. Electroporated and mock
electroporated (electroporation without DNA) BAC host bacteria were spread on
LB plates containing 1, 2, 5, and 10pg/ml kanamycin. Colonies were observed
on lpg/ml and a reduced number on 2|ig/ml plates in both the positive and
negative electroporations. No bacteria grew on plates supplemented with 5 or
10|ig/ml kanamycin, regardless of the presence of either linearised BAC
targeting construct in the electroporation. Further experiments showed that a very
small number of colonies (1-5) grew on plates supplemented with 3(ig/ml
kanamycin, again apparently independent of the presence of the targeting
construct in the electroporation. The small number of colonies found on these
3pg/ml kanamycin plates, both positive and negative, were screened for the
presence of the recombination modified BAC. As the isolation of BAC construct
in quantities suitable for analysis by restriction digest is a relatively time
consuming process, the possible targeted BAC clones were screened by PCR
with primers located in the sequence to be inserted into the BAC and within the
Cdx-1 sequence previously confirmed to be contained within BAC 219 in such a
manner that the product from the unaltered BAC and that generated from the
targeted BAC are of different sizes, 950 and 1550 bp respectively (figure 3.22,
section 2.2.2 for PCR primers and conditions). All colonies isolated from these
initial electroporation experiments proved to contain the unmodified BAC 219.
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PCR screen primer 4
integrated BAC target floxed
Figure 3.22: A) A vector schematic showing the expected products after Reda/p
mediated recombination of the "BAC target" and "BAC target floxed" sequences
into BAC 219.
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The lack of expected recombination products from the electroporations could
have had several causes. The first possibility investigated was the level of
electroporation competence of the BAC 219 host cells. These cells were made
electrocompetent by a commonly used osmotic shock protocol (see section
2.1.7). This protocol had proved relatively inefficient (~5xl03 colonies/pg of
plasmid DNA) for preparing BAC 219 hosts for the introduction of the inducible
pBAD-Reda(3y recombination plasmid; the additional requirement of a
recombination event in the attempt to create modified BACs would lower the
number of resistant colonies generated in an electroporation with a given amount
of DNA. The osmotic shock protocol was altered in an effort to improve the
electroporation competence of the BAC 219 hosts; additional resuspension steps
(see section 2.1.7) with both dFLO and 10% glycerol improved the
electroporation efficiency slightly (~lxl04 colonies/pg of pBS DNA), as did the
use of lOmM CaCl2 in place of dH20 for one of the resuspension steps
(~1.25xl04 colonies/pg of pBS DNA), although these additional steps reduced
the amount of bacterial prep which could be recovered and aliquoted.
Electroporations using linearised pBACtarget and pBACtargetlox with these
more electrocompetent bacteria produced slightly higher numbers of colonies
resistant to 3pg/ml kanamycin, however all of these colonies proved to contain
unmodified BAC 219 when screened by PCR. Another possible cause of the
inability to generate recombination altered BAC constructs could lie in the Neo
resistance cassette used in the pBACtarget vectors. This resistance cassette did,
however, successfully generate kanamycin resistance in all host bacteria used in
the various cloning stages involved in construction of the final pBACtarget and
pBACtargetlox vectors, suggesting that the cassette was functional and being
expressed at sufficient levels to provide resistance to 20p,g/ml kanamycin when
present within a cell on a high copy number plasmid.
Variation of the electroporation parameters (see section 2.1.7) failed to increase
the efficiency of the transformation. Lowering of the electroporation voltage to
2.3kV from the recommended 2.5kV, the maximum potential generated with the
electroporation apparatus available, resulted in a small decrease in the
135
transformation efficiency, while variation in the capacitance and/or resistivity of
the system resulted in very large reductions in efficiency.
An additional consideration was the possibility that the Reda protein was not
being induced to sufficient levels in the BAC 219 hosts prior to the osmotic
shock treatment. To check for induction of the Reda protein, 1.0 ml aliquots of
the BAC 219 host culture were taken at 30 minute intervals following the
addition of 0.2% L-(+)-arabinose (w/v) to the culture medium. Protein
preparations were made by the pelleting of bacterial cells at 10,000g for 2
minutes in a benchtop microcentrifuge, followed by resuspension in lOOpl of
SDS-protein loading buffer. The bacterial cells were lysed by placing the
samples in a boiling water bath for 5 minutes after which the protein samples and
appropriate molecular weight markers were electrophoresed on a 10%
acrylamide gel. The separated proteins were stained with GelCode (Peirce). A
clear increase of the intensity of a band corresponding to the apparent molecular
weight of Reda (25kDa) was seen in protein samples collected as little as 1 hour
and continuing at least 2 hours following the addition of arabinose to the
bacterial culture when compared to a sample collected immediately prior to the
addition of the pBAD inducer (see figure 3.5). This indicates that production of
the Reda protein was being successfully induced in the BAC 219 host cells well
within the 2 hours between addition of arabinose to the culture medium and
harvesting of the cells for osmotic shock treatment. While this would appear to
indicate that the Reda protein was present in significant quantities in the BAC
host bacteria, this gives no indication of the quantities or indeed the presence of
the Red(3 or Redy proteins. The genes encoding these two viral proteins were
under the control of constitutive prokaryotic promoters, EM7 and Tn5
respectively, both strong promoters (Goldstein and Doi, 1995). It is possible that
the levels of transcription from these promoters, and hence the concentrations of
the RedP and Redy proteins, were too low to achieve a significant rate of
recombination in arabinose activated BAC host cells electroporated with the
BAC targeting vectors. Alternatively, mutations in the constitutive promoters, or
in any of the protein coding sequences, could have resulted in a lack of
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functional recombination promoting proteins. While these possibilities seem
unlikely, they could not be ruled out.
A further consideration for electroporation efficiency is the concentration and
quality of the DNA used in the electroporation. The Seal linearised pBACtarget
and pBACtargetlox plasmids were gel extracted using the QIAEX II gel
extraction kit (Qiagen) in order to prevent electroporations from being
contaminated with uncut plasmid. The gel extraction of the 8kb DNA molecules
resulted in relatively low yield (-50%), the DNA concentrations of the extracted
preparations were typically between 0.25 and 0.4p,g/pl despite efforts to improve
yield. This concentration is relatively low but within the limits for
electroporation experiments. To determine if increased DNA concentration
would produce better electroporations, pBACtarget and pBACtargetlox were
digested overnight with a large excess (20 units/pg) of Seal to reduce the amount
of uncut plasmid and the digests were phenokchloroform extracted. The pelleted
DNA was resuspended in a minimal volume (lOpl) of lOmM Tris (pH 8.0). This
resulted in DNA concentrations of l-2pg/pl; electroporations using this
concentrated DNA prep again produced a slight increase in the number of
colonies resistant to 3pg/ml kanamycin, although all colonies screened by PCR
contained unmodified BAC 219. In order to determine if the increase in colonies
resistant to 3pg/ml kanamycin were the result of contamination of the DNA prep
with uncut plasmid a selection of the resistant colonies were screened by PCR for
the presence of the Neo resistance gene. The presence of the Neo resistance
coding sequence in a number of the colonies which also contained unmodified
BAC 219 suggested that these bacteria were indeed taking up contaminating
uncut plasmid from the phenokchloroform DNA prep.
In order to achieve higher concentrations of linear BAC target sequence without
the uncut plasmid contamination a PCR reaction was designed to generate a BAC
targeting molecule similar to the cloned pBACtarget. Primers were designed
which contained 40bp Cdx-1 arms of homology (5' and 3') in addition to
sequences designed to anneal to the ends of the CreERtm / Neo resistance coding
sequence. The PCR reaction would use the pBSCreNeo plasmid as a template
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(see figure 3.18), generating high concentrations of linear DNA molecules
containing the CreERtm-Neo sequence flanked by short arms of homology. A
consideration in performing this PCR reaction was the introduction of sequence
errors by the high temperature polymerases commonly used in PCR reactions.
Mutations in the Neo resistance gene would be relatively unimportant, as non¬
functional Neo coding sequence would be selected against on introduction into
bacterial hosts. Mutations in the Cre coding sequence would be of greater
consequence, however, as these alterations may lower or negate the function of
the resulting Cre protein but would not be detected without considerable
sequencing or functional analysis. In an effort to reduce the possibility of
polymerase error, the proofreading high temperature polymerase Pfu was used in
this PCR reaction. A number of reaction conditions were used in an attempt to
generate the appropriate BAC targeting molecule, however no product was
detected. The difficulty in amplifying this product may have been due to the high
secondary structure present in the upstream primer sequence; the translation start
site of Cdx-1, the most appropriate location to attempt to place the translation
start site of the CreERtm-Neo sequence, is found just downstream of a GC repeat
island (see appendix 2). This DNA motif, common to many eukaryotic promoter
sequences, meant that the primer designed to overlap this area could self-anneal,
as well as being able to anneal to other copies of the same primer. A number of
variations in the annealing temperature of the PCR reaction sequence were used
in an effort to overcome the effects of this poly-GC sequence but no annealing
temperature resulted in detectable levels of product.
A further issue is the linearisation of the pBACtarget(lox) plasmids prior to
electroporation into the activated BAC host bacteria. The rate of homologous
recombination promoted by a bacterial system analogous to the phage system
used in this experiment is known to be increased by the proximity of double
strand breaks to the region of homology (Keim and Lark, 1990). Using PCR to
generate a BAC targeting construct leaves DNA strand ends very near the arms
of homology; the plasmid vectors used here were linearised using a restriction
digest which leaves substantial (l-2kb) stretches of DNA between the restriction
generated strand ends and the arms of homology. This may have significantly
reduced the efficiency of the recombination reaction; unfortunately the nature of
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the pBACtarget(lox) vectors prevented further digests to remove this "extra"
sequence prior to electroporations.
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3.4 Discussion
The inability to detect the expected recombination products from a large number
of electroporations highlights some of the potential difficulties arising from using
this system. There are a number of factors which should be taken into
consideration before attempting to generate altered BAC construct by
recombination. The first is the selection of an appropriate antibiotic resistance
cassette. The BAC host bacteria used in this series of experiments have a small
degree of natural resistance to kanamycin which only became apparent when the
concentrations of the antibiotic were lowered to compensate for the single copy
of the Neo resistance gene expected to be present within the targeted BAC. This
small natural resistance resulted in relatively large numbers of untransformed
colonies growing on plates intended to select for recombinants; colonies resulting
from the relatively rare recombination events may have been "hidden" amongst
these unrecombined colonies. It proved impossible to find an antibiotic
concentration which would return colonies from electroporations involving DNA
while fully inhibiting growth in mock-electroporated controls. It is possible that
other antibiotic resistance cassettes would have more fully inhibited growth of
non-recombinants at the low concentrations needed to allow growth of cells
containing BACs bearing a single copy of the cassette.
Another consideration for future efforts to create BAC based constructs through
recombination is the ability to generate concentrated, high quality linearised
targeting DNA preparations. PCR reactions can generate the required
concentrations and Dpnl (a methylation dependant restriction enzyme) digestion
of the amplification reaction can be used to eliminate the methylated template
plasmid DNA. However PCR reactions may introduce changes to the sequence to
be recombined into the BAC. This may not be crucially important if the material
to be introduced into the BAC consist solely of a selectable marker, but it
becomes more important if the sequence contain other genes which are not so
easily tested for their ability to generate functional protein product. The use of
proofreading polymerases may partially circumvent this problem but may still
require time consuming sequencing reactions to verify crucial sequence integrity.
Additionally, if the sequence to be inserted into the BAC does not contain an
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endogenous promoter and is intended to make use of promoter material already
present within the sequence of the BAC, the design of efficient PCR primers may
be hindered by the presence of repetitive motifs in some promoter sequences.
The ability to generate BAC based transgenes within their bacterial hosts though
induced recombination holds much promise. BAC based transgenes may be large
enough to escape the positional effects which can alter the efficiency of
expression from smaller, traditional transgenes. The amount of sequence present
within BACs, up to 120kb in some cases, may also allow the creation of
transgenes based on genes or promoters whose sequence has not been fully
described, as was the intention in this effort to generate a transgene based on the
promoter of the Cdx-1 murine homeobox gene. While these features make the
building of transgenes using in vivo recombination systems and BAC construct
attractive, the nature of the transgenic material and the careful choice of selection






Chapter 4 - Evaluation ofmurine Cdx-1 promoter sequence
4.1 Background
The construction of the BAC 219 based transgene discussed in the previous
chapter would have allowed for the transcription of the CreERtm recombinase to
be placed under the control of a large stretch of the native murine Cdx-1
promoter sequence. It is hoped that this would allow for an accurate reproduction
of the time and tissue specificity of the Cdx-1 expression patterns, thereby
imparting an important degree of control over the activity of the Cre
recombinase. In parallel with the efforts to alter BAC 219 to include Cre coding
sequence, a more traditional transgene construct was prepared by Dr. Sula Corbet
and Dr. Jane Armstrong using a subcloned fragment of BAC 219.
The Cdx-1 promoter has been partially characterised in at least three separate
studies, two of these studies have been published since this project was begun. In
the first, the stretch of sequence 1040bp in length immediately upstream of the
transcription start site was used to drive expression of a chloramphenicol
acetyltransferase (CAT) based reporter construct in a number of human derived
colorectal carcinoma cell lines as well as murine NIH 3T3 cells (Hu et al., 1993).
Using a series of deletion constructs as well as subcloned stretches of the 1040bp
and sequence analysis, a number of transcriptionally important motifs were
identified; these include a silencer element found between -589 and -380, a
silencer blocking element between -1040 and -887 and a positive control
element found between -47 and +66, all positions relative to the transcription
start site (Hu et ah, 1993). This last positive element was the only one of the
identified elements to confer cell type specificity; the element preferentially
drove transcription in epithelial cell lines (see figure 4.1) (Hu et al., 1993). While
information regarding the functionality of this short stretch of promoter was
gained, the levels of expression given by this short stretch of sequence were
extremely low, suggesting that more promoter was necessary to drive adequate
transcription or that the cell lines used in the experiment were capable of down
regulating the activity of the Cdx-1 promoter; downregulation of Cdx-1
transcription has been observed in a number of epithelial derived human cell
lines (Mallo et al., 1997).
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In the second study a larger stretch of sequence, comprising some 3621bp
upstream of the transcription start site, was used in the construction of a number
of luciferase based reporter plasmids which were transfected into wild type and
Tcf-4 deficient murine ES cells as well as undifferentiated rat embryonic
endoderm (Lickert et al., 2000). An analysis of the sequence of this stretch of
DNA had revealed, in addition to the elements described in the earlier study, four
perfect TCF/LEF binding sites (base pair motif CTTGA(T)A(T)) (see figure 4.1).
The presence of these sequence motifs suggested that the expression of Cdx-1
was on some level under the control of the Wnt signalling pathway. In this study
the experiments focussed on the role of these transcription-factor binding sites in
the control of transcription from the Cdx-1 promoter. Each of the TCF/LEF sites
were in turn removed and/or mutated to abrogate Tcf binding. Changes in the
levels of reporter protein generated from the various plasmids revealed the
contributions of each of the TCF/LEF sites to overall transcriptional level
alterations induced by Tcf binding and transactivation. The results suggested that
the two TCF/LEF binding motifs nearest the transcription start site at positions -
113 and -82 contributed most strongly to the transactivation effects of Wnt
signalling, while the two more distant elements at positions -1923 and -950
contributed considerably less to Wnt activation of Cdx-1 transcription (Lickert et
al., 2000).
The third and most recent investigation reveals another transcription factor
influencing expression driven by the Cdx-1 promoter sequence (Houle et al.,
2000). Similarities between the altered vertebral specifications seen in Cdx-1
mutant mice and the phenotype of mice mutant for retinoic acid response
elements (RAREs) suggested a possible overlap in the functions of homeobox
genes and retinoic acid responsive genes. While no consensus RARE was found
in the sequence of the Cdx-1 promoter, application of retinoic acid to a number
of cell types resulted in specific upregulation of Cdx-1 levels. The 15bp
(AAGGGTCGTGACCCT) element within the Cdx-1 promoter responsible for
the binding of retinoic acid was found at -512 relative to the transcription start
site. This lies within the silencer element identified in the initial isolation and
characterisation of the Cdx-1 mRNA and genomic promoter. Interestingly
another study has shown that [3-catenin signalling through the TCF/LEF pathway
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can be inhibited by the presence of retinoic acid and that (3-catenin is capable of
binding the retinoic acid receptor RAR (Easwaran et al., 1999a). Because Cdx-1
regulates homeobox genes which themselves are not responsive to concentrations
of retinoic acid, the suggestion is that Cdx-1 acts as a transducer of the retinoic
acid signals to influence vertebral patterning through regulation of these
homeobox genes.
In the present study a large stretch of the DNA immediately upstream of the
transcription start site, representing some 6.7kb of sequence, was analysed for
relevant promoter elements while reporter constructs based on the Enhanced
Green Fluorescent Protein (EGFP) were constructed using DNA fragments of up
to 4.3kb in length. These stretches of promoter DNA were all derived from the
BAC clone 219.
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Figure 4.1: published Cdx-1 promoter elements
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Figure 4.1: Schematic of the previously described regulatory elements of the Cdxl
promoter. The investigated elements include 4 TCF/LEF binding sites, a novel
retinoic acid response element, a orientation independent silencer and its blocking
element and an element giving epithelial cell type transcription specificity. The 5'
end of the diagram indicates the limit ofpreviously characterised sequence.
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4.2 Mapping of newly isolated upstream Cdx-1 promoter sequence
The first step to isolating novel sequence upstream of the Cdx-1 gene was to
construct a map of restriction sites within BACs 219 and 538, both of which
were determined to contain Cdx-l sequence by PCR and hybridisation (see
section 3.2.1). To this end Drs. Sula Corbet and Jane Armstrong digested BAC
219 and 538 DNA preparations with a number of single or paired restriction
enzyme reactions. The resulting fragments of BACs 219 and 538 were then run
out and visualized on an ethidium laced agarose gel (see figure 4.2a). The pattern
of the digestion products allowed a rough map of restriction sites to be generated
and similarities confirmed that the two BACs were overlapping clones, as would
be expected if both contained Cdx-1 exonic sequence as previously determined.
The BACs both appeared to contain at least lOOkb of sequence; in order to
determine which of the bands produced in the various restriction digests
contained the desired sequence the gel was blotted and probed with the DNA
sequence of Cdx-1 exon 1 by Dr. Sula Corbet. A number of bands hybridised to
this probe (see figure 4.2a, red) indicating that they contained at least the
sequence of the first exon of Cdx-1. The restriction map of the known promoter
sequence and the first exon allowed for the determination of which bands would
prove to contain a relatively large amount of more upstream sequence. It was
ultimately decided that a band generated from the BAC 219 Xhol digestion,
approximately 7.1kb in size, provided the best target for subcloning. The band
proved reasonably seperated from other bands resulting from the same digest
allowing for gel extraction and was confirmed by PCR to contain the first exon
of Cdx-1 (see figure 4.2b). The genomic sequence downstream of the Cdx-1
promoter contains an Xhol site at position +640 relative to the transcription start
site; as a result the band of 7.1kb produced by the Xhol digest would contain
approximately 5.8kb of sequence upstream of the -1040 position, which was the
limit of sequence data at the start of this project (GenBank). The 7.1kb BAC 219
Xhol band was gel extracted and cloned into the corresponding site of the pGEM
commercial plasmid vector (Promega) by Dr. Sula Corbet. Drs. Jane Armstrong
and Sula Corbet have since used this subcloned section of BAC 219 in the
construction of a CreER"11 transgene while this project used the pGEM-XhoI
sequence to investigate the properties of the Cdx-1 promoter.
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4.3 Subcloning and sequencing of pGEM-XhoI
The restriction digestion of the BAC 219 and 538 provided some degree of
mapping of the construct but further mapping was necessary in order to use the
subcloned fragment of BAC 219 for subsequent investigations, including
sequence analysis and reporter construct assembly. The pGEM-XhoI construct
was prepared and digested with a number of individual endonucleases as well as
in double digestions using Xhol in conjunction with a second restriction
endonuclease. A number of the individual digestions were able to provide
information on orientation of the fragment within the pGEM backbone, while the
double digests with Xhol provided the approximate locations of restriction sites
within the subcloned BAC fragment. Further double digests allowed for more
accurate placement of sites relative to one another (see figure 4.3a). This more
accurate map was then able to form the starting point for subcloning sections of
the BAC 219 Xhol fragment in order to efficiently sequence its entire length as
well as allowing the simultaneous construction of several EGFP based reporter
vectors.
Initial sequencing of the pGEM-XhoI plasmid was done using a primer within
the known Cdx-1 promoter sequence and a primer within the pGEM plasmid
backbone sequence at the upstream end of the Xhol fragment (DNAShef, Royal
Infirmary, Edinburgh). Further sequencing was done using the same plasmid
backbone primer following digestion of the pGEM-XhoI plasmid with SacI and
EcoRI and subsequent religations. These digestions removed portions of the
upstream Xhol fragment sequence and allowed determination of internal
sequence. Subsequent sequencing was performed using primers complementary
to this newly determined internal sequence. The DNA sequence data was
compared and aligned to reconstruct the full length of the BAC 219 Xhol
fragment (see figure 4.3b, appendix 2 for full sequence data).
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Figure 4.2: BAC subcloning
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Figure 4.2: A) EtBr stained gel showing the banding patterns following digestion
of BACs 219 and 538 with the restriction endonucleases indicated above the
appropriate lanes. The bands common to both BACs suggest that they contain
significant amounts of identical sequence other than that of the construct backbone.
Lanes 1 and 20 contain Marker II (Roche). The gel image is overlaid with a false
colour representation of the bands observed following southern hybridization of the
BAC 219 and 538 digests using Cdxl exon 1 as the probe sequence. B) PCR
confirmation of the 7.1 kb Xhol band found in both the BAC 219 and BAC 538
digestions as containing Cdx-1 exon 1. The Xhol bands at —10.0 kb, 7.1kb and 6.0
kb were gel extracted and used as template for the PCR amplification (see section
2.2.2) of Cdx-1 exon 1. Only the 7.1 kb band (indicated by the blue arrow) gives the
correctly sized band. Lane 1: Low Mass Marker (Gibco). Lane 2: Cdx-1 exon 1
PCR reaction using gel extraction of 6.0 kb BAC 219 Xhol band. Lane 3: Cdx-1
exon 1 PCR reaction using gel extraction of 7.1 kb BAC 219 Xhol band. Lane 4:
Cdx-1 exon 1 PCR reaction using gel extraction of 10.0 kb BAC 219 Xhol band.
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Figure 4.3: A) Gel image of some of the restriction digests of pGEM-XhoI plasmid
used to determine the orientation of the insert within the plasmid backbone as well
as determining the number and the approximate positions of various sites within the
insert itself. Lane 1: Kilobase Marker (Gibco). Lane 2: NotI digest, the presence of
the 665 basepair band shows insert orientation within the pGEM plasmid. Lane 3:
Notl/SacI digest. This digest liberates the insert from the 3.2 kb pGEM backbone,
again shows the NotI 665 basepair fragment and reveals one SacI site within the
BAC 219 insert sequence, which cuts the insert into 4.5 and 1.9 kb fragments. Lane
4: Notl/BamHI digest of pGEM-XhoI. The expected band at 645 bp (20 less than
the 665 bp NotI fragment) appears, the pGEM backbone and a portion of the insert
run at just over 4.0 kb and the digest shows the presence of 2 more BamHI sites
within the remaining BAC 219 insert sequence which give bands of -2.7, 1.5 and
1.0 kb. Lane 5: Notl/EcoRI digest of pGEM-XhoI. This digest again liberates the
insert from the 3.2 kb pGEM backbone and shows the NotI 665 basepair fragment.
Additionally 2 EcoRI sites are shown to exist within the BAC 219 sequence, cutting
the insert into 4.2, 1.8 and 0.5 kb fragments. Lane 6: Sail digest of pGEM-XhoI, a
single Sail site exists in the pGEM multiple cloning site and no Sail sites appear
within the subcloned insert sequence. Lane 7: Sall/EcoRI digest. The pGEM
backbone and some of the insert travel at 5.6 kb while the insert is cut into 4.2 and
0.5 kb fragments. Lane 8: Sall/BamHI digest. This digest liberates the pGEM vector
(3.2 kb) and reveals the approximate locations of the BamHI sites within the insert
sequence. Lane 9: Marker II (Roche). Lane 10: Marker VI (Roche). B) A vector
schematic of the BAC 219 7.1 kb Xhol fragment cloned into the pGEM plasmid
backbone, showing the positions of some restriction endonuclease sites as
determined by the described digests in conjunction with derived sequence data.
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4.4 Reporter plasmid construction
The newly derived upstream Cdx-1 promoter sequence contained all of the
transcriptional mediating elements described in earlier studies (see section 4.1).
In addition to the described elements, a fifth perfect TCF/LEF binding site, not
reported previously, was found at position -3957 relative to the transcription start
site. In order to investigate transcription initiation from the newly isolated Cdx-1
sequence a number of reporter construct were assembled for use in in vitro
studies. A number of reporter systems were considered and compared for use in
the Cdx-1 promoter characterisation experiments. The most suitable reporter
system proved to be one based on the EGFP gene. The EGFP gene is a
specifically mutated version of the Green Fluorescent Protein (GFP) originally
isolated from the jellyfish Aequorea Victoria (Cormack et al., 1996; Prasher et
al., 1992). The GFP gene encompasses 714bp encoding a protein of 238 amino
acids which fluoresces green at 508nm under stimulation with UV light
(absorption wavelengths of 395 and 470nm). A number of features of GFP make
it useful as a reporter system; the GFP protein appears to be relatively non-toxic
in a large number of cell type, it fluoresces without the need for cellular co-
factors and GFP fusion proteins (both N- and C- terminal) retain the ability to
fluoresce enabling tracking of specific proteins within a cell (Wang and
Hazelrigg, 1994). These properties have been retained and added to in the
enhanced version of the GFP protein. EGFP remains relatively non-toxic and can
form C- and N-terminal fusion proteins without loss of chromophore activity. Its
absorption spectrum has been shifted to 488nm by two amino acid changes
(Phe64 to leucine and Ser65 to threonine) while the emission spectrum remains
similar to that of native GFP, with the major peak at 508nm (Cormack et al.,
1996). The transition to Leu64 and Thr65 also boosts the level of fluorescence
and prevents the incidence of photobleaching making EGFP a more sensitive
marker protein than GFP (Cormack et al., 1996). Further alterations of the
original GFP sequence includes silent alteration of a large number of codons to
human preference versions and the addition of a Kozak sequence in order to
increase expression of the EGFP protein in many mammalian cell types (Kozak,
1987a; Kozak, 1987b). The EGFP coding sequence has been incorporated into a
number of commercially available vectors for use in expression and localisation
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studies. A vector encoding a promoterless version of EGFP, pEGFP-1
(Clontech), was used as the backbone for construction of the Cdx-1 reporter
constructs and as a negative control for expression studies (see figure 4.4).
Analysis of the newly isolated Cdx-1 promoter sequence revealed an SphI site at
position -4186 relative to the transcription start site. Another SphI site is found
within the published sequence, at position +73 relative to the transcription start
site and 22bp upstream of the translation start site. The sequence between these
two SphI contains all the published Cdx-1 promoter elements as well as the
newly identified fifth TCF/LEF binding motif, while excluding the translation
start site (+95) (see figure 4.5a). The 4.2kb SphI fragment of Cdx-1 promoter was
chosen as the starting point for the construction of the various Q/x-i-EGFP
reporter plasmids.
4.4.1 Construction of pEGFP-Sph
Digestion of the pGEM-XhoI plasmid with SphI liberates the 4.2kb Cdx-1
promoter sequence from the 3.2kb pGEM backbone and 2.5kb of the 5' end of
the BAC 219 Xhol fragment (see figure 4.5b). Unfortunately, the pEGFP-1
plasmid does not contain a site within the multiple cloning site upstream of the
EGFP coding sequence which generates ends compatible with those generated on
SphI digestion. To clone the 4.2kb SphI fragment into the pEGFP-1 vector the
digestion was supplemented with dNTPs and T4 DNA polymerase in order to
generate a blunt ended molecule. This fragment was cloned into the blunt Smal
site found in the pEGFP-1 multiple cloning site and the resulting plasmids
screened for the presence and orientation of the 4.2kb SphI Cdx-1 promoter
fragment (see figure 4.6). The resulting 8.2kb plasmid, pEGFP-Sph, contains the
EGFP coding sequence under the control of all 5 TCF/LEF binding motifs as
well as all other published promoter elements.
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Figure 4.4: pEGFP-1 reporter vector backbone
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Figure 4.4: A) A vector schematic of the pEGFP-1 vector, encoding the Enhanced
Green Fluorescent Protein (EGFP) sequence downstream of a multiple cloning site.
There is no native promoter driving EGFP expression from this vector. The Smal
and EcoRI sites were used for the insertion of various portions of the murine Cdx-1
promoter. The NotI site was used for analytic digests of the Ccfr-7-EGFP constructs.
B) Gel image of a Smal digest of the pEGFP-1 plasmid. Lane 1: Kilobase ladder
(NEB). Lane 2: Smal digestion ofpEGFP-1.
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Figure 4.5: Subcloning of pGEM-XhoI
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Figure 4.5: A ) A vector schematic of the BAC 219 7.1 kb Xhol fragment cloned
into the pGEM plasmid backbone. B ) Digestion of the pGEM-XhoI plasmid with
Sphl liberates a 4.13 kb section of the subclone Cdx-1 promoter sequence from the
pGEM backbone. The digestion was supplemented with T4 DNA polymerase and
lOmM nucleotides in order to generate blunt ended DNA molecules. Lane 1:
Kilobase ladder (NEB). Lane 2: pGEM-XhoI Sphl digestion showing 4.13kb Cdx-1
promoter fragment.
Figure 4.6: pEGFP-Sphl reporter vector
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Figure 4.6: A) A vector schematic of the 4.13 kb SphI fragment of the pGEM-
BAC 219 Xhol construct cloned into the Smal site ofpEGFP-1. The SphI fragment
was blunted with T4 DNA polymerase prior to ligation into the blunt Smal site.
This section of the murine Cdx-1 promoter contains 5 perfect TCF/LEF binding
motifs. B) Gel electrophoresis of the Cdx-1 pEGFP-Sph vector after restriction
enzyme digestion. Lane 1: Kilobase ladder (NEB) Lane 2: Notl digest of the
pEGFP-Sph vector showing the expected bands at 7.5 kb and 819 bp.
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4.4.2 Construction of pEGFP-LongEco and pEGFP-ShortEco
The 4.2kb SphI Cdx-1 promoter fragment cloned into the pEGFP-1 vector
contains 2 EcoRI sites, one at position -2308 and the other at position -1781
relative to the Cdx-1 transcription start site. The EcoRI site at position -2308 lies
downstream of the TCF/LEF site at position -3957 while the restriction site at
position -1781 lies downstream of the TCF/LEF binding site at position -1923
relative to the Cdx-1 transcription start site (see figure 4.1, 4.6a). The pEGFP-
Sph vector contains an EcoRI site at 8191. The location of the EcoRI sites within
pEGFP-Sph enables portions of the 4.2kb SphI Cdx-1 promoter fragment to be
removed; with a partial digestion and religation it was possible to generate the
pEFGP-LongEco and pEGFP-ShortEco Cdx-1 promoter plasmids
simultaneously. The pEFGP-LongEco plasmid contains the EGFP coding
sequence under the transcriptional control of 238lbp of the Cdx-1 promoter, this
2.4kb contains 4 TCF/LEF binding motifs, the retinoic acid response element, the
epithelial specific promoter element and the silencer/silencer blocking elements
(see figure 4.7). pEGFP-ShortEco contains 1854bp of Cdx-1 promoter containing
the same elements although only 3 TCF/LEF binding motifs (see figure 4.8).
4.4.3 Construction of pEGFP-SCdx
A lack of suitably compatible restriction site necessitated the use of PCR in order
to generate a shorter Cdx-1 promoter segment to drive EGFP transcription. The
pBS-SCdx plasmid generated to provide homology arms for the BAC targeting
vectors (see figure 3.16) contains a short PCR generated stretch of the Cdx-1
promoter. Digestion of the pBS-SCdx plasmid with SphI supplemented with T4
DNA polymerase followed by digestion with EcoRI generates a 232bp fragment
of the Cdx-1 promoter containing the positive epithelial promoter element and 2
TCF/LEF binding sites. This fragment was cloned into the Smal/EcoRI digested
pEGFP-1 to generate the 4383bp pEGFP-SCdx (ShortCdx) plasmid (see figure
4.9). The Cdx-1 promoter sequences contained within the four CJv-7-EGFP
reporter plasmids are summarised in figure 4.10.
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The pCMV-GFP plasmid was used as a positive control for transfections and
microinjections; the strong cytomegalovirus viral promoter efficiently drives
transcription in a wide range of mammalian cells (see figure 4.11). GFP and
EGFP are excited by similar wavelengths so detection of GFP in positive control
experiments would affirm that the apparatus used to detect fluorescence were
working properly.
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Figure 4.7: pEGFP-LongEco reporter vector
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Figure 4.7: A) A vector schematic of the SphI fragment of the pGEM-BAC 219
Xhol construct cloned into the Smal site of pEGFP-1 after the removal of a 1.8 kb
EcoRI restriction fragment and subsequent religation. The resulting portion of the
murine Cdx-1 promoter contains 4 perfect TCF/LEF binding motifs. B) Gel
electrophoresis of the pEGFP-LongEco vector after restriction enzyme digestion.
Lane 1: Kilobase ladder (NEB) Lane 2: NotI digest of the pEGFP-LongEco vector
showing the expected bands at 5.7 kb and 819 bp.
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Figure 4.8: pEGFP-ShortEco reporter vector
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Figure 4.8: A) A vector schematic of the SphI fragment of the pGEM-BAC 219
Xhol construct cloned into the Smal site of pEGFP-1 after the removal of a 2.3 kb
EcoRI restriction fragment and subsequent religation. The resulting portion of the
murine Cdx-1 promoter contains 3 perfect TCF/LEF binding motifs. B) Gel
electrophoresis of the pEGFP-ShortEco vector after restriction enzyme digestion.
Lane 1: Kilobase ladder (New England Biolabs) Lane 2: NotI digest of the pEGFP-
ShortEco vector showing the expected bands at 5.15 kb and 819 bp.
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Figure 4.9: pEGFP-SCdx reporter vector
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Figure 4.9: A) A vector schematic of the Short Cdx-l PCR cut with EcoRI/SphI
and cloned into the EcoRI/Smal sites of pEGFP-1. This portion of the murine Cdx-
1 promoter contains 2 perfect TCF/LEF binding motifs. B) Gel electrophoresis of
the vector after restriction enzyme digestion. Lane 1: Kilobase ladder (New
England Biolabs) Lane 2: NotI digest of the pEGFP-SCdx vector showing the
expected bands at 3.63 kb and 819 bp.
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Figure 4.10: Summary of Cdx-1 reporter promoter sequences
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B) Sph I (-4186) EcoR I (-2308) EcoR I (-1781) Sph I (+73)
pEGFP-Sphl
C) EcoR I (-2308) EcoR I (-1781) Sph I (+73)
pEGFP-LongEco





Figure 4.10: Schematics of the full Cdx-1 Xhol promoter sequence showing known
promoter elements and the shortened promoter fragments built into the pEGFP-1
promoterless reporter vector. A) 6.4 kb of sequence upstream of the start of Cdx-1
transcription were isolated from BAC 219. The sequence contains a retinoic acid
binding sequence, a silencer element, a silencer blocking element, a positive
epithelial specific element and 5 perfect TCF/LEF binding motifs. B) The longest
section of the isolated sequence cloned into the pEGFP-1 vector. The SphI digest
fragment contains all the previously identified promoter elements as well as at least
one newly identified TCF/LEF binding site. C) Truncated promoter sequence Long
EcoRI. This sequence contains only 4 of the TCF/LEF binding sites while retaining
the other identified elements. D) Truncated promoter sequence Short EcoRI. The
sequence contains 3 TCF/LEF binding sites as well as all other identified promoter
elements. E) Truncated promoter sequence Short Cdx-1. This sequence was
generated by PCR from genomic template. It contains 2 TCF/LEF motifs and the
epithelial specific element but lacks the retinoic acid response element and both the
silencer and silencer blocking sequences.
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Figure 4.11: pCMV-GFP positive control reporter vector
A)












Figure 4.11: A) A vector schematic of the pCMV-GFP plasmid. This plasmid
served as a positive control during the Ccbc-1 EGFP transient transfection
experiments. B) Gel electrophoresis of the pCMV-GFP vector after restriction
enzyme digestion. Lane 1: Kilobase ladder (New England Biolabs) Lane 2: BamHI
digest of the pCMV-GFP plasmid showing the expected single band of 4.7 kb.
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4.5 Introduction of pEGFP-Cdx-i plasmids into mammalian cells
To study the contribution of the Cdx-1 promoter elements to overall levels of
transcription the various pEGFP-Cdx-1 vectors were introduced into a variety of
mammalian cell lines. Initial experiments involved the human colorectal
carcinoma derived cell lines HCT 116 and SW 480 and further experiments were
performed using primary murine colonocytes and murine ES cells.
4.5.1 Microinjections
The used of microinjection as a means of introducing DNA into cells in vitro has
some advantages over other methods. The technique can be very efficient, as
robust cells will tolerate the procedure quite readily and up to 100% of cells
within a particular region may be injected. Microinjection also allows for more
consistent control over the amount of DNA entering any particular cell, as DNA
concentrations are controlled for copy number and a precise amount of material
is injected into each cell. The relative consistency in the number of DNA
molecules introduced into a cell as well as the high efficiency make comparison
of levels of transfection from the reporter constructs more immediately
quantitative, at least on a relative scale. One disadvantage of microinjection is the
relative harshness of the procedure, fragile cell lines or primary cultures may not
be able to withstand even the most mild injection pressures and may rupture
immediately or die soon after microinjection. Additionally cell morphology can
make microinjection very difficult; rounded cells tend to be difficult to inject
while flat epithelial cells are significantly easier to successfully microinject. As
SW 480 cells tend towards a more rounded morphology microinjections were
carried out on HCT 116 cells and primary murine colonocytes as their
morphology makes them considerably easier to accurately inject.
HCT 116 and primary murine colonocytes were plated into 5cm culture dishes in
preparation for microinjections as the angle of the injection needle and apparatus
makes injecting into wells awkward. The human cell line was allowed to reach
75% confluency prior to injecting while the murine colonocytes were injected 3-
5 days after isolation and plating. Control and reporter plasmid preparations were
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diluted to achieve consistent plasmid copy number per unit volume in injection
buffer (see appendix 1). In some applications a fluorescent tracer dye can be
added to the injection buffer in order to check that the injection has succeeded in
introducing material into the cell: in this case, as the dye can persist for 24-48
hours depending on the cell injected and may mask the fluorescence (or lack
thereof) generated by transcription from the reporter plasmids, the injections
were carried out without adding the tracer dye. The relative plasmid size and
final DNA concentration in the injection medium for both reporter and control
constructs are given in table 4.1
Table 4.1: Plasmid DNA concentrations for microinjections
Plasmid Size (bp) DNA concentration in injection medium
pCMV-GFP
(positive control) 4728 125ng/|il
pEGFP-1





Microinjections were preformed using the apparatus and protocols previously
described (see section 2.7.1) and the injected cells monitored at intervals under
normal phase contrast and UV illumination for up to 48 hours following the
introduction of DNA.
While the HCT 116 human cell line proved able to tolerate the microinjection
procedure, the primary murine colonocytes seemed too fragile to undergo
injection and survive for the periods needed to observe possible low level EGFP
expression from the reporter plasmids. HCT 116 cells injected with the positive
control pCMV-GFP reporter plasmid were observed to fluoresce when UV
illuminated at intervals over the full monitoring period, indicating that the
injected cells were surviving the procedure and persisting in culture (see figure
4.12). The HCT 116 cells microinjected with Cdx-l-EGFP reporter plasmids
failed to show any signs of fluorescence over the period of observation (48
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hours). That the cells appeared to survive the microinjection procedure and
remain healthy indicated that the failure to observe fluorescence was not due to
cell death but instead due to insufficient expression from the reporter plasmids.
Primary murine colonocytes were observed to fluoresce following injection with
the pCMV-GFP positive control plasmid beginning 3 hours post injection but
these cells appeared to die by 6-8 hours after introduction of plasmid DNA. This
short time period appears to be insufficient to observe EGFP at the levels of
transcription supported by the Cdx-1 fragments built into the reporter construct.
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Figure 4.12: Microinjection of HCT 116 cells
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Figure 4.12: A) Phase contrast image of HCT 116 human colorectal cell line
(200x). B) UV illuminated image of HCT 116 cells microinjected with the positive
control pCMV-GFP plasmid 48 hours post injection (200x). HCT 116 cells injected
with Cdxl-EGFP reporter plasmids showed no fluorescence above background in
the 48 hours following microinjection.
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4.5.2 Transfections
In addition to the microinjection procedures, a variety of cell types were
liposome transfected with the control and reporter constructs. While transfection
efficiencies can vary between cell types and from one plasmid to another making
accurate quantitative comparisons more difficult, the procedure is relatively mild
and fragile cells such as primary murine colonocytes or ES cells may survive
long enough to show evidence of Cdx-1 promoter driven EGFP transcription.
The ease with which the transfection reactions can be carried out as well as the
relatively small volumes and numbers of cells involved made it possible to run a
parallel transfection using the same plasmids but with the cell medium being
supplemented with lp.M retinoic acid (RA). As mentioned previously, various
concentrations of retinoic acid have been reported to upregulate expression from
the Cdx-1 promoter in murine embryos and embryonalcarcinoma cell lines. If the
levels of transcription driven by the Cdx-1 EGFP rporter constructs containing
the retinoic response element (RARE) incorporated into the EGFP reporter
plasmids were very low, the addition of RA to the medium may bring the levels
of fluorescence into the detectable range.
HCT 116, SW 480, murine ES cells and murine colonocytes were seeded into 24
well plates in preparation for transfection experiments. As in the microinjection
procedure the cell lines were allowed to reach 75% confluency prior to
introduction of plasmid DNA while the colonocytes were transfected 3-5 days
post plating. Transfections were carried out using FuGENE reagent (Roche, see
chapter 2 for protocol) and the optimal ratio of reagent to DNA determined to be
6p,l FuGENE: 1 jig DNA by transfection with the positive control plasmid pCMV-
GFP. This transfection ratio appeared to be optimal across all three cell types
although the amount of reagent:DNA added to a well varied from 12|il:2jig for
the colonocytes to 6|il:l|ig for the cell lines, the increased amount of transfection
mixture added to the colonocyte preparations did not appear to have any toxic
effect on the cells. The transfection efficiencies for the human derived cell line
HCT 116 and the ES cells were approximately 30%, while <10% of primary
murine colonocytes and SW 480 cells expressed GFP after transfection.
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Following administration of the transfection mixture the cells were monitored at
intervals for 48 hours under normal phase contrast and UV illumination.
4.5.2.1 HCT 116 cell line
HCT 116 cells began to show evidence of fluorescence in pCMV-GFP
transfected cells within 3 hours of application of DNA and continued in a
constant manner for at least 48 hours (see figure 4.13b and 4.13c) while Cdx-1-
reporter transfected populations began to show signs of fluorescence
approximately 36 hours following the introduction of DNA and continuing for at
least a further 12 hours (see figure 4.13). While relatively widespread
fluorescence was observed from the positive control pCMV-GFP construct the
fluorescence observed from Cdx-1 -promoter driven constructs was considerably
more dispersed. Small patches of cells were observed showing fluorescence in
those wells transfected with the minimal Cdx-1 -reporter, pEGFP-SCdx (see
figure 4.13e). As mentioned previously this plasmid contains only 2 TCF/LEF
binding motifs and the positive epithelial control element. Transfections with the
pEGFP-ShortEco and pEGFP-LongEco reporter plasmids failed to produce
fluorescence in the transfected HCT 116 cells in the 48 hours following
transfection and, again, the addition of lp.M retinoic acid to the culture medium
failed to produce any visible increase in fluorescence, despite the fact that these
plasmids contain the RARE. HCT 116 cells transfected with the pEGFP-Sph
reporter construct showed relatively widespread and intense fluorescence
beginning 36 hours post-transfection (see figure 4.13h). While this plasmid also
contains the retinoic acid response element, no change in fluorescence was
observed in cells incubated with lp,M retinoic acid.
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Figure 4.13:.A) Phase contrast image of HCT 116 human colorectal cell line
(200x). B) UV illuminated image of HCT 116 cells transfected with the positive
control pCMV-GFP plasmid 8 hours post transfection (200x). C) HCT 116 cells 48
hours after transfection with pCMV-GFP (200x). D) HCT 116 cells 48 hours after
transfection with the promoterless pEGFP-1 plasmid (200x). E) HCT 116 cells 48
hours after transfection with the pEGFP-SCdx plasmid showing low levels of
fluorescence (200x). F) Cells transfected with the pEGFP-ShortEco reporter. G)
HCT 116 cells transfected with the pEGFP-LongEco plasmid (200x). H) HCT 116
cells 48 hours after transfection with the pEGFP-Sphl plasmid showing relatively
high levels of fluorescence (200x). The cells transfected with pEGFP-ShortEco and
pEGFP-LongEco showed no fluorescence over background levels.
Figure 4.13: Transfections of the human derived HCT 116 colorectal cell line
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4.5.2.2 SW 480 cell line
SW 480 cells, when compared to HCT 116 cells, showed a reduced transfection
efficiency and were very slow growing. Transfection with pCMV-GFP resulted
in <10% of cells showing significant fluorescence 36 hours after transfections
(see figure 4.14b). SW 480 cells also differ from HCT 116 cells in morphology;
they tended to remain relatively rounded rather than showing the more regular
epithelial morphology of the HCT 116s (see figures 4.13a and 4.14a for
comparison). This rounded morphology made detecting low levels of
fluorescence difficult as rounded cells appear to "lens" and auto-fluoresce
significantly more than flat cell types, perhaps overwhelming GFP/EGFP
emission. Transfection with the Cdx-1 -reporter constructs did not appear to result
in fluorescence significantly greater than the background observed in the pEGFP-
1 promoterless negative control transfections, again regardless of RA application.
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Figure 4.14: Transfection of SW 480 cells
Figure 4.14: A) Phase contrast image of SW 480 human colorectal cell line (200x).
B) UV illuminated image of SW 480 cells transfected with the positive control
pCMV-GFP plasmid 48 hours post transfection (200x). No EGFP fluorescence was
observed in SW 480 cells transfected with the Q&-1-EGFP constructs
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4.5.2.3 Primary murine colonocytes
Transfection of colonocyte preparations achieved a variable efficiency, with
maximum transfection levels being ~10%. This variability may have been in part
due to the variability in plating density from one preparation to another and also
may have been influenced by the presence of fibroblasts within the platings. A
relatively large amount of debris was also present within the colonocyte
preparations and this debris showed a tendency to autofluoresce. Despite the
variability of transfections and the presence of autofluorescing debris, it was
possible to identify colonocytes expressing the pCMV-GFP reporter plasmid and
to distinguish them from the fibroblast contamination based on morphology.
Colonocytes containing the pCMV-GFP plasmid showed relatively high levels of
fluorescence; these fluorescing cells tended to occur in groups within islands
formed when the isolated colonic crypts adhered to the tissue culture vessel (see
figure 4.15b). Transfection with the promoterless pEGFP-1 plasmid failed to
produce fluorescence above the relatively high background within the 48 hours
of observation, as did transfection with the pEGFP-SCdx reporter construct (see
figure 4.15c and 4.15d). Very low levels of fluorescence were observed in the
colonocyte preps transfected with the pEGFP-ShortEco reporter while higher, but
still faint, fluorescence was achieved in isolated cells following transfection with
either the pEGFP-LongEco or pEGFP-Sph reporter constructs (see figure 4.15e
and 4.15f).
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Figure 4.15: A) Phase contrast image of murine primary colonocytes (200x). B)
UV illuminated image of murine colonocyte cells transfected with the positive
control pCMV-GFP plasmid 48 hours post transfection (200x). C) Murine
colonocytes 48 hours after transfection with the promoterless pEGFP-1 vector The
cells transfected with the negative control pEGFP-1 plasmid showed no
fluorescence over background levels (200x). D) Murine colonocytes 48 hours after
transfection with pEGFP-SCdx, no fluorescence above background was detectable
(200x). E) Murine colonocytes 48 hours after transfection with the pEGFP -
ShortEco plasmid; the image has been enhanced to show the very low level of
fluorescence presence in a small number of cells (200x). Fluorescence was lower
that that observed in transfections with pEGFP-LongEco or pEGFP-Sphl. F)
Murine colonocytes cells 48 hours after transfection with the pEGFP-LongEco
plasmid showing low levels of fluorescence (200x). G) Murine colonocytes cells 48
hours after transfection with the pEGFP-Sphl plasmid showing slightly higher
levels of fluorescence (200x).
Figure 4.15: Transfections of murine primary colonocytes
4.5.2.4 Murine HM-1 ES cells
Liposome mediated transfection of murine ES cells with the pCMV-GFP plasmid
resulted in an efficiency of -30%, comparable to that achieved in the HCT 116
cell line. The appearance of fluorescence from the positive control transfection
occurred within 3 hours of transfection, again comparable with the time frame
seen in other cell types. The appearance of fluorescence following transfection of
the Cdx-1-EGFP reporter plasmids, however, occurred much more quickly than
in the other cell type, with visible levels of fluorescence appearing as little as 12
hours following DNA application (see figure 4.16). Additionally, the intensity of
fluorescence provoked by the reporter plasmids was much higher in the ES cells.
The level of fluorescence increased from 12 hours to 24 hours and remained
relatively constant for the period up to 48 hours (see figure 4.16 and 4.17).
pEGFP-SCdx generated a relatively strong fluorescence in ES cells, while the
pEGFP-ShortEco reporter failed to produce any obvious fluorescence above
background levels (see figure 4.17c and 4.17d). The pEGFP-LongEco produced
the most intense fluorescence, while the pEGFP-Sph reporter provoked an
intermediate fluorescence response (see figure 4.17e and 4.17f). The addition of
lpM RA to the culture medium for the 12 hours following DNA transfection did
not appear to have any upregulating effect of transcription from the Cdx-1-EGFP
reporter plasmids, even with those reporter constructs which contained the
reported RARE. The levels of fluorescence actually appeared to be reduced when
compared to HM-1 cells which had not been treated with retinoic acid (see figure
4.18).
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Figure 4.16: A) Phase contrast image of the HM-1 murine stem cell line (200x). B)
UV illuminated image of HM-1 cells transfected with the positive control pCMV-
GFP plasmid 12 hours post transfection (200x). C) HM-1 cells 12 hours after
transfection with the promoterless pEGFP-1 plasmid (200x). D) HM-1 cells 12
hours after transfection with the pEGFP-SCdx plasmid showing low levels of
fluorescence (200x). E) HM-1 cells 12 hours after transfection with the pEGFP-
ShortEco plasmid showing no fluorescence above background (200x). F) The HM-
1 cells transfected with pEGFP-LongEco showed relatively high levels of
fluorescence (200x). G) HM-1 cells transfected with pEGFP-Sph again showing
relatively high levels of fluorescence (200x).
Figure 4.16: Activity of Cdxl-EGFP reporter constructs in ES cells
12 hours post-transfection
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Figure 4.17: HM-1 cells 24 hours post-transfection. A) UV illuminated image of
HM-1 cells transfected with the positive control pCMV-GFP plasmid 24 hours post
transfection (200x). The fluorescence is comparable and prehaps stronger than that
observed at 12 hours. B) HM-1 cells 24 hours after transfection with the
promoterless pEGFP-1 plasmid again showing very little background fluorescence
(200x). C) HM-1 cells 24 hours after transfection with the pEGFP-SCdx plasmid
showing higher levels of fluorescence than seen at 12 hours (200x). D) HM-1 cells
24 hours after transfection with the pEGFP-ShortEco plasmid again showing no
fluorescence above background (200x). E) The HM-1 cells transfected with
pEGFP-LongEco showing levels of fluorescence relatively higher than those seen
at 12 hours (200x). F) HM-1 cells transfected with pEGFP-Sph again showing
moderate levels of fluorescence (200x).
Figure 4.17: Activity of Cdxl-EGFP reporter constructs in ES cells
24 hours post-transfection
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Figure 4.18: Effect of incubation with lpM retinoic acid on expression from the
Cdxl-EGFP reporter plasmids in HM-1 ES cells. A) UV illuminated image of HM-
1 cells transfected with the positive control pCMV-GFP plasmid 12 hours post
transfection (200x). The fluorescence is comparable to that observed without
retinoic acid. B) HM-1 cells 12 hours after transfection with the promoterless
pEGFP-1 plasmid again showing very little background fluorescence (200x). C)
HM-1 cells 12 hours after transfection with the pEGFP-SCdx plasmid showing a
reduced fluorescence compared to similar timepoint without addition of retinoic
acid (200x). D) HM-1 cells 12 hours after transfection with the pEGFP-ShortEco
plasmid again showing no fluorescence above background (200x). E) The HM-1
cells transfected with pEGFP-LongEco showing lower levels of fluorescence than
those seen in untreated cells (200x). F) HM-1 cells transfected with pEGFP-Sph
again showing reduced levels of fluorescence (200x).
Figure 4.18: Effect of retinoic acid on activity of Cdxl-EGFP reporter
constructs in ES cells, 12 hours post-transfection
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4.6 Discussion
All homeobox genes code for proteins containing a cross-species conserved 61
amino acid helix-turn-helix homeobox domain, capable of binding to DNA and
through this interaction influencing transcription from target genes. These
homeobox genes are believed to be of central importance to the formation of
body-axis during embryogenesis in almost all animal species. For this reason the
understanding of the transcriptional control of homeobox genes could provide
important clues to the signals involved in the complex process of tissue
patterning in animal development. The method of transcriptional control of these
genes may be of importance for other reasons, as well. More recently it has been
shown that the regulation, or dysregulation, of certain homeobox genes may be
of importance in vertebrate animals beyond embryogenesis. A number of
homeobox genes have been found to demonstrate altered expression in neoplastic
tissues of both the human and the mouse, including kidney, breast and colorectal
lesions (Cillo et al., 1992; Jin et al., 1999; Vider et al., 2000). Altered
expression of several homeobox genes of the Hox family have also been found in
human leukaemias and lymphomas, indeed these genes appear to possess
oncogenic potential when overexpressed (Maulbecker and Gruss, 1993).
More specifically, the deregulation of the murine and human versions of Cdx-1
has been implicated in tumourigenesis. Overexpression and nuclear localisation
of Cdx-1 has been observed in epithelial cells in intestinal metaplasia of the
human stomach and oesophagus while Cdx-1 levels appear to be significantly
depressed in neoplastic regions of the large intestine (Silberg et al., 1997). Co-
transfection of the overexpression vectors for Cdx-1 and a related homeobox
gene, Cdx-2, into the colorectal derived cell line HT 29, shown to be deficient in
expression of these two genes, has demonstrated that their reintroduction
potentiates apoptosis and lowers motility and tumour formation in these cells
(Mallo etal., 1998).
The suppression of Cdx-1 expression in neoplastic regions of the large intestine
is very interesting given the recent demonstration that Cdx-1 is a target of the
Wnt/(3-catenin/TCF signalling pathway (Lickert et al., 2000). As previously
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mentioned the large majority of tumours arising in the colon carry mutations in
APC or P-catenin; these mutations either interrupt the ability of APC to bind P-
catenin and hence target the protein for degradation or result in P-catenin
molecules which are inherently resistant to APC induced phosphorylation
(Polakis, 1999). This mutation spectrum is reflected in the genotypes of cell lines
derived from human colorectal tumours (Dihlmann et al., 1997; Ilyas et al.,
1997). The result of these mutations is the accumulation of P-catenin within the
cell, ultimately resulting in transcriptional activation of targets of the TCF/LEF
class of transcription factors. The demonstration that Cdx-1 is a TCF/LEF target
gene coupled with the knowledge that accumulation of P-catenin and hence
transactivation of TCF/LEF targets is an early event in colorectal tumourigenesis
would suggest that Cdx-1 expression should rise during the initial stages of
transformation from normal tissue to neoplastic lesion. While increase in Cdx-1
is observed in gastric and oesophageal lesions this is not the case in the large
intestine. This suggests that some means of reducing or stopping expression from
the Cdx-1 locus must be able to override the influence of the increased TCF/LEF
transcriptional potential.
One possibility is that the Cdx-1 alleles suffer inactivation mutations early on in
the process of tumourigenesis. While no comprehensive study of Cdx-1 mutation
frequency in colorectal lesions has been performed, mice heterozygous for a null
mutation in the related Cdx-2 gene are prone to intestinal tumours and Cdx-2
mutations have been noted in a number of replication error positive (RER+)
human colorectal tumours, although the frequency of mutation seems to indicate
that Cdx-2 mutation does not contribute significantly to tumourigenesis (Yagi et
al., 1999). Cdx-1 heterozygous mice do not appear to show the same
predisposition to colorectal tumourigenesis. The relative rarity of Cdx-1
mutations in colorectal tumours suggests that some other means of Cdx-1
downregulation must be occurring in early neoplastic lesions of the large
intestine.
The other control elements identified in the Cdx-1 promoter sequence may play
some role in this downregulation. If Cdx-1 expression is driven by the presence
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of retinoic acid in normal cells, the loss of ability to respond to normal
physiological levels of retinoic acid could account for the observed drop in Cdx-1
levels. Interestingly, retinoic acid is essential for maintenance of epithelial cell
differentiation and appears to increase differentiation in a number of cancer-
derived cell lines, it has been used as a chemotheraputic to treat some types of
poorly differentiated cancers (Carter et al., 1996; Hansen et al., 2000). It is
possible that the observed reduction in Cdx-1 expression in early intestinal
lesions is indicative of a loss of retinoic acid responsiveness possibly preceding
some degree of dedifferentiation. The expression from the Cdx-1-EGFP reporter
plasmids did not increase at the dose previously reported to give maximal
upregulation in the mouse embryo and embryonalcarcinoma cells, despite the
fact that three of the reporter constructs contain the described retinoic acid
response motif. It is possible that HCT 116 cells and murine primary colonocytes
do not express the required retinoic acid binding protein to allow interaction with
the novel Cdx-1 retinoic acid response element. Embryonic stem cells more
closely resemble the embryonalcarcinoma cells in which the retinoic acid
dependant upregulation of Cdx-1 was initially observed and may be expected to
behave in a similar manner in response to retinoic acid. Despite their
resemblance to embryonalcarcinoma cells, the ES cells transfected with the Cdx-
7-EGFP reporter constructs showed reduced, rather than enhanced, reporter
expression upon treatment with lpM retinoic acid. Again, it is possible that the
protein responsible for the interaction of retinoic acid with the novel retinoic acid
response element found in the Cdx-1 promoter is not present in high levels within
ES cells. Perhaps more importantly, the ES cells responded to the presence of
retinoic acid by slowing their growth and differentiating to some degree; treated
wells were much less confluent after 2 days of observations than were
corresponding wells of ES cells which had not been exposed to retinoic acid. The
ability to actively drive transcription from the Cdx-7-EGFP reporter constructs
may depend to some extent on whether the transfected cells are actively growing
and dividing and so are susceptible to growth inhibition caused by retinoic acid
exposure. Alternatively, Cdx-1 expression may be downregulated during the
process of differentiation, so that the exposure to retinoic acid causes a reduction
in Cdx-1 expression by driving this process. The observed pattern of Cdx-1
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expression in the crypts of the murine intestine shows highest levels in the stem
cells and proliferative compartments, with expression falling away as cells move
out of this zone (Subramanian et al., 1998). It is possible that this observed
gradient of Cdx-1 expression is related to the differentiation state of the cells as
they migrate up the crypt wall and become progressively more differentiated.
High levels of expression are measured from the pEGFP-SCdx plasmid
transfected cells; this plasmid contains 2 TCF/LEF sites and the positive
epithelial element but does not contain the previously described silencer element.
Transfection with the pEGFP-ShortEco plasmid produced a lower level of
fluorescence intensity despite containing one more TCF/LEF binding site than
the pEGFP-SCdx plasmid. This may be due to the presence of the silencer
element within the pEGFP-ShortEco reporter construct, although this reporter
also contains the described silencer blocking element. The level of fluorescence
intensity in ES cells transfected with pEGFP-LongEco was higher than that
measured in the pEGFP-ShortEco transfected cells, while the pEGFP-Sph
transfected cells showed fluorescence intensity nearly equal that shown in the
pEGFP-SCdx transfections. The increasing amount of promoter sequence in
these reporters, perhaps most importantly the inclusion of additional TCF/LEF
binding sites, appears to overcome the transcription blocking effects of the
silencer element.
The differences in the expression levels observed between the various cell types
may highlight known mechanisms of Cdx-1 expression control, and in some
cases points to the involvement of other regulatory processes. The lack of
expression seen in the SW 480 cell line when compared to the HCT 116 cell line
has a number of possible explanations. Perhaps the most likely is simply the
reduced transfection efficiency seen in the SW 480 experiments, compounded by
the relatively high autofluorescent background caused by their rounded
morphology has created a situation where expression from the Cdx-1-EGFP
constructs is masked in the relatively few cells which have been successfully
transfected. Had the transfections of SW 480 cells proved as efficient and as easy
to observe as those involving HCT 116 cells, some differences in the levels of
expression from the Cdx-1 promoter in these two cell lines would have been
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expected. (3-catenin exists in a number of distinct pools within cells; some of the
protein is sequestered in its interactions with the membrane bound E-cadherin
molecule, some (3-catenin will be present in the nucleus in association with
transcription factors and there also exists a pool of (3-catenin associated with a-
catenin. The distribution of (3-catenin between these pools appears to vary from
cell line to cell line and distinct differences between the proportions of (3-catenin
in the various "pools" have been found in the colorectal carcinoma derived SW
480 cell line and the adenocarcinoma derived HCT 116 cell line when compared
to MDCK cells. (3-catenin in HCT 116 and SW 480 cells, in addition to being
present in much greater concentrations, appears to be found in a larger proportion
in a low molecular weight fraction; this appears to indicate a shift in the amount
of a-catenin associated (3-catenin relative to the fraction bound to E-cadherin or
nuclear pools (Stewart and Nelson, 1997). The relative amount of (3-catenin
represented in each of these pools differs between HCT 116 and SW 480 cells;
HCT 116 cells contain a larger proportion of E-cadherin bound (3-catenin. This
difference may reflect a variation in the fraction of (3-catenin which is free to
bind TCF/LEF transcription factors and hence participate in the upregulation of
Wnt target genes, such as Cdx-1. If high transfection efficiency had been
achieved in SW 480 cells, it is possible that higher expression levels would have
been observed. In HCT 116 cells significant expression was seen in cells
transfected with the shortest reporter construct, pEGFP-SCdx, and from those
transfected with the longest construct, pEGFP-Sph. The two intermediate
reporter construct, pEGFP-ShortEco and pEGFP-LongEco, showed very little
expression in HCT 116 cells. Expression from the pEGFP-SCdx reporter may be
being driven by the previously described positive epithelial element present in
the short stretch of the Cdx-1 promoter built into this reporter. Additionally, this
reporter construct does not contain the endogenous Cdx-1 silencer (or silencer
blocking element). The lack of transcription from pEGFP-ShortEco and pEGFP-
LongEco in HCT 116 cells may be caused by the presence of this endogenous
Cdx-1 silencer element within the two intermediate reporter constructs; the
silencer blocking element may not be able to completely overcome the
transcriptional downregulating effect of the silencer without the fifth TCF/LEF
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site or possibly other transcriptional elements found in the longer pEGFP-Sph
reporter construct.
The Cdx- 1-EGFP reporter containing the longest stretch of Cdx-1 promoter,
pEGFP-Sph, provokes much higher levels of EGFP expression in HCT 116 cells
when compared to the pEGFP-LongEco plasmid. As previously mentioned, the
pEGFP-Sph promoter region contains a fifth TCF/LEF binding site and as such
could be expected to drive the highest levels of transcription as TCF/LEF binding
is important in Cdx-1 expression control. Interestingly, in murine HM-1 ES cells
the highest levels of transcription are found in cells transfected with the pEGFP-
LongEco plasmid, despite the fact that this plasmid contains one fewer TCF/LEF
sites than pEGFP-Sph. An algorithm based search of the newly determined
upstream Cdx-1 sequence reveals a number of putative transcription factor
binding sites which may be responsible for this observed difference in expression
between murine ES cells and the HCT 116 human cell line (Matlnspector,
www.gsf.de/cgi-bin/matsearch.pl). Perhaps most interesting is the presence of a
c-myb binding site at -2426 relative to the transcription start site (see figure
4.19). This transcription factor is recognised as an oncogene and has been found
to be upregulated in a number of different cancer and tumour derived cell lines,
including colorectal cancers and colorectal cell lines (Ramsay et al., 1992;
Alitalo et al., 1984). C-myb controls the expression of a number of genes
important to cell cycle, apoptosis and also plays a role in the control of cell
differentiation (Ramsay et al., 2000; Thompson et al., 1998; Del Bufalo et al.,
1996). ES cells express only low levels of c-myb, while HCT 116 cells may, in
common with many colorectal derived cell lines examined to date, express very
high levels of this transcription factor (Dyson et al., 1989; Alitalo et al., 1984;
Untawale and Blick, 1988). High cellular levels of c-myb would be a potent
factor in driving the expression of genes responsive to c-myb signalling, of
which Cdx-1 is a candidate, and lead to higher expression from the reporter
construct containing the putative c-myb binding site in overexpressing cell lines.
This may explain the higher relative level of EGFP transcription seen in the HCT
116 cell line with the pEGFP-Sph reporter compared with expression levels from
the same reporter construct in HM-1 ES cells.
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Figure 4.19: Diagram showing the locations of the characterised transcription
factor binding sites in the murine Cdx-1 promoter region in relation to some
restriction enzyme sites used in the construction of the Cdx-1 -EGFP reporter
vectors. Also indicated are possible c-myb and CREB transcription factor binding
sites identified by algorithm searches.
Figure 4.19: Known and possible transcription factor binding sites in the
murine Cdx-1 promoter
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The low levels of expression from the Cdx7-EGFP reporters observed in the
primary colonocyte preparations might again be the result of poor transfection
efficiency coupled with high background masking low levels of EGFP
fluorescence. An additional factor may have been the age of the cultures when
transfected; the colonocyte preparations were generally transfected after 3 days
in culture, the stem cells and the cells of the proliferative compartment which
would be expected to express Cdx-1 may have begun to differentiate into more
mature, non-Cdx-1 expressing cells prior to transfection. There are also reports of
downregulation of Cdx-1 expression in colonic epithelium co-cultured with some
fibroblast cell lines; the primary cell preparations contained a significant amount
of fibroblast contamination which may have provoked a downregulation of Cdx-
1 expression in the cultured colonocytes (Duluc et al., 1997).
Algorithm searches of the newly determined upstream Cdx-1 sequence reveal
other potentially interesting transcription factor binding motifs, including a
number of putative cyclic-AMP responsive element binding (CREB) sites (see
figure 4.19). CREB plays a role in transcriptional regulation of a number of
genes important to cancer development and progression, as does its associated
protein and transcription factor CREB-binding protein (CBP). Notably, CBP
appears to play a role in inhibiting (3-catenin/TCF/LEF transcriptional activation,
the close proximity of a TCF/LEF binding site within the Cdx-1 promoter
sequence may indicate that CBP is capable of downregulating Cdx-1 expression
(Barker et al., 2000). Cdx-l is not the only homeobox gene to be known to
contain CREB sites within its promoter; the related mouse homeobox gene Cdx-
2/3 contains a CREB consensus site and the Drosophila cardiac homeobox gene
tinman depends on CREB sites within its promoter region to direct correct tissue-
specific expression (Lorentz et al., 1999; Venkatesh et al., 2000). Interestingly,
expression of the tinman homeobox gene is known to be modulated by wingless,
the Drosophila Wnt-1 homologue, suggesting another similarity with murine







Chapter 5 - Characterisation of a transgenic Floxed APC mouse line
5.1 Background
As outlined in the introductory chapter, the APC gene and its protein product
play a central role in the regulation of the Wnt-1 signalling pathway, a pathway
whose dysregulation is heavily implicated in the formation and progression of
colorectal tumours. The prevalence of APC mutations in spontaneous colorectal
tumours, as well as the phenotype displayed by human patients with germline
APC mutations, have pointed to APC mutations as early events in colorectal
neoplasia and work with the Min mouse and other genetically altered Ape
deficient strains have borne out this hypothesis. While these germline Ape
truncation strains have many features mimicking the rare human condition FAP
they are less accurate representations of the much more common phenomenon of
spontaneously arising colorectal tumours. Ideally an animal model in which the
Ape gene can be "switched off' at a precise time in the location most relevant to
successful mimicking of the human spontaneous tumour, the stem cells of the
large intestinal crypt, would provide a greater insight into the earliest cellular
events in the progression from normal to neoplastic behaviour. The development
of a large intestinal stem cell specific inducible Cre mouse strain, coupled with
the production of a double floxed or floxed/null Ape mouse strain would allow
this level of control. As mentioned in section 3.1, the ability to generate the Ape
null genotype in the stem cell would also aid in the determination of whether Ape
mutation alone is sufficient to provoke polyp (and eventually tumour) formation
in the intestine. A project has been undertaken in Edinburgh to generate a
transgenic mouse line bearing APC alleles whose entire lengths were flanked by
loxP sites. This transgenic CC mouse line was generated through the work of a
previous PhD student, Cindy Cooper; the analysis of the transgenic animals is
presented in this chapter.
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5.2 Derivation of floxed APC line
The transgene used by Ms. Cooper in the generation of the CC mouse line was
assembled around a human cDNA clone supplied by Dr. Joanna Groden,
University of Cincinnati, OH (Groden et al., 1995). The APC cDNA was excised
from its original plasmid backbone and through a number of cloning steps
introduced into a new construct between two directly oriented loxP sites. The
APC cDNA transgene expression construct was completed with the addition of
the 3-phosphoglycerate kinase-1 (PGK) promoter and the SV40 polyadenylation
sequences; the final transgene construct was termed pAPC 2M35 (see figure 5.1)
(Adra et al., 1987; Cooper, 2000). The PGK promoter is known to promote
widespread, though tissue and cell type variable, expression in the mouse
throughout development, as it is a necessary metabolic enzyme in the ubiquitous
glycolytic pathway (McBurney et al., 1994). Prior to use in pronuclear injections,
Ms. Cooper successfully tested the transgene construct for its ability to undergo
Cre mediated recombination reactions in a prokaryotic system, the constitutive
Cre expression E. Coli strain BNN132 (Mo Bi Tech, GmbH). Introduction of the
pAPC 2M35 plasmid into the BNN132 cells resulted in the appearance of DNA
molecules consistent with the expected APC excision event (Cooper, 2000).
The pAPC 2M35 transgene was linearised with the restriction enzyme Ahd-1
(see figure 5.1) and injected into eggs derived from F1 (C57BL/6 x CBA) x F1
(C57BL/6 x CBA) matings. One successful founder mouse was generated,
proving positive for the presence of the pAPC 2M35 transgene by PCR reaction
(see figure 5.3 for an example of the transgene detection PCR product). The
founder mouse was immediately bred onto a C57BL/6 mouse line bearing the
Min mutation in an effort to generate partial or complete rescue of Min
homozygous mice which are normally embryonic lethal (Moser et al., 1995).
Detection of the transgenic sequence in early mice (transgene heterozygotes) by
southern blot was not successful (Cooper, 2000). CC mice have also been
screened for transgene expression using reverse transcriptase (RT) PCR and
transgene expression was detected in several tissues (kidney, spleen, pancreas,
muscle, large and small intestine, lung, heart, testis, liver, brain, thymus,
mammary and salivary glands), however no information regarding the level of
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expression could be inferred from the RT-PCR results (Cooper, 2000).
Additionally, no information regarding expression from the pAPC 2M35
transgene could be determined by immunoblotting as the mouse and human
proteins are similar enough to cause cross reactivity with any of the currently
available antibodies directed against APC.
To determine if the pAPC 2M35 transgene was capable of undergoing Cre
mediated recombination following its introduction into the mouse genome, Ms.
Cooper derived embryonic fibroblasts from transgene positive embryos and
infected them with an altered adenovirus coding for the Cre recombinase.
Following infection with the adenovirus vector, DNA was extracted from the
cells and screened by PCR for the presence of recombination products. The PCR
used primers outside the floxed region of the pAPC 2M35 linearised transgene;
recombination events would result in the primers spanning a region of 190bp
while lack of recombination would leave the primer binding sites over 13kb
apart, making PCR amplification unlikely. The detection of a 190bp band in
infected transgene fibroblast populations indicated that Cre mediated
recombination was successful (Cooper, 2000).
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Figure 5.1: A) The floxed APC expression transgene vector constructed by Cindy
Cooper. Expression of the human APC cDNA is driven by the mouse 3-
phosphoglycerate kinase-1 (PGK-1) promoter. B) The pAPC 2M35 vector was
linearised by digestion with the restriction enzyme Ahdl prior to pronuclear
injection.
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5.2.1 in vitro analysis of transgene expression
In collaboration with Ms. Cooper, the Ahd-1 linearised construct was also
introduced by calcium phosphate transfection into a number of human colorectal
adenoma derived cell lines including DLD-1, HCT 116, HT 29 and SW 480. A
linearised Neo resistance plasmid was co-transfected with the APC expression
transgene and the cell lines were placed under G418 selection to isolate resistant
cells. No stable clones were recovered from the cell lines DLD-1 or HT 29,
which express a truncated version of the APC protein while one slow growing,
morphologically altered clone (see figure 5.2) derived from SW 480, which also
only expresses a truncated APC protein, survived for a brief period. Similar
results were seen in another study involving the introduction of APC expression
vectors into human colorectal cell lines (Groden et al., 1995). Several HCT 116
clones survived G418 selection and were shown by PCR (pAPC 2M35 transgene
PCR, see section 2.2.2) to contain the APC transgene. The HCT 116 cell line
normally expresses a full-length APC protein; a (3-catenin mutation in this cell
line hinders its phosphorylation, making it resistant to ubiquitination and
subsequent degradation (Ilyas et al., 1997). The transfections involving the
pAPC 2M35 transgene suggested that this floxed human APC expression
transgene was actively transcribed in these cell lines and that the translation
product was capable of stopping (or greatly slowing) growth in those cells in
which full length APC was normally absent.
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Figure 5.2: Effect of introduction ofAPC transgene into SW 480 colorectal
cell line
Figure 5.2: A) SW 480 cells which have been transfected with the Neo/Tk
resistance vector alone showing normal morphology. B) Cells co-transfected with
the Neo/Tk resistance vector and the pAPC 2M35 transgene vector showing an
altered morphology. Magnification is indicated in the centre column.
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5.3 Analysis of the CC transgenic mouse line
To date 207 informative progeny mice have been generated from the original
founder mouse. CC mice derived from the original founder were screened for
their Min status by PCR (see section 2.2.2) in addition to being screened for the
presence of the pAPC 2M35 transgene (see section 2.2.2, figure 5.3); the pAPC
2M35 PCR does not distinguish between heterozygosity and homozygosity for
the transgene. Three litters were excluded from the analysis of the CC mouse
line. These litters were the product of matings between pAPC 2M35
heterozygous, Apc+/+ animals and pAPC 2M35 negative, ApcM"^+ animals. The
litters containing 11,6, and 9 mice (CC 26-51) were all weened in the same week
and all animals proved to be transgene negative, Apc+/+ on PCR analysis. The
chance of generating this genotype from the described matings, assuming one
site of transgene integration, is 0.25 for each offspring. Even for the smallest
litter, the chance of the observed genotypes occurring by chance is 0.00024
(0.256). Because the weenings all occurred in the same week it is assumed that
these weening were mislabelled and they were excluded from all further analysis.
The genotypes of mice generated to date from the various matings are
summarised in the following table. Expected numbers were calculated assuming
no embryonic lethality and a single transgene integration site.
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Figure 5.3: PCR detection of the integrated pAPC 2M35 transgene
A > PGK promoter APC coding sequence




PCR primer 1 (11799) PCR primer 2 (12035)
Figure 5.3: A) Vector diagram showing the expected state of the integrated pAPC
2M35 transgene; the PCR primers used to detect the sequence spanning the SV40
poly adenylation signal are indicated. B) Gel electrophoresis of the transgene
sequence amplified from CC mice. Lane 1: Marker VI (Roche). Lane 2: PCR
product amplified from genomic DNA from CC 240. Lane 3: The same
amplification reaction preformed using genomic DNA from CC 246.
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Table 5.1: CC mouse line genotypes:










pAPC 2M35+/" Apc+/+ pAPC 2M35+l'Apc+/+ 16.5 15
X pAPC 2M35+/~ ApcMM+ 16.5 15
pAPC 2M357" ApcMin/+ pAPC 2M35+/" Apcmnjmn 0 0
Total pAPC 2M35 + 33 30
pAPC 2M357" Apc+/+ 16.5 21
pAPC 2M35-'-ApcMin/+ 16.5 15
pAPC 2M357" ApcMinJMin 0 0
Total pAPC 2M35 - 33 36
Total offspring 66 66
pAPC 2M35+/" Apcm"/+ pAPC 2M35+/" Apc+/+ 4.125 9
X pAPC 2M35+/" ApcMinJ+ 8.25 11
pAPC 2M357" ApcMin/+ pAPC 2M35+/" ApcMinJMi" 4.125 0
Total pAPC 2M35 + 16.5 20
pAPC 2M357" Apc+/+ 4.125 7
pAPC 2M357" ApcMin/+ 8.25 6
pAPC 2M357" ApcMin/Min 4.125 0
Total pAPC 2M35 - 16.5 13
Total offspring 33 33
pAPC 2M35+/" Apcmn/+ pAPC 2M35+nApc+/+ 20.25 21
X pAPC 2M35+// ApcMin/+ 40.5 57
pAPC 2M35+/" ApcMm/+ pAPC 2M35+/? ApcMin/Min 20.25 0
Total pAPC 2M35 + 81 78
pAPC 2M357" Apc+/+ 6.75 15
pAPC 2M357" ApcMiny+ 13.5 15
pAPC 2M357" ApcMin/Mi" 6.75 0
Total pAPC 2M35 - 27 30
Total offspring 108 108
Total number of mice = 207
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Southern hybridisation analysis of DNA derived from later generations of CC
transgenic mice (possible transgene homozygotes), digested with Nhel, an
enzyme which cuts once within the transgene sequence, has shown a band of the
size expected from digestion of a tandem array of transgenes (see figure 5.4). To
date no hybridisation bands corresponding to digestion of sequence flanking
tandem array integration sites have been detected, preventing direct
determination of the number of integration sites or approximate number of copies
of the transgene present within the CC mouse genome by densitometry
comparisons between the tandem array band and integration site bands.
However, the number of integration sites for the pAPC 2M35 transgene can be
estimated from the proportion of transgene positive mice generated from the
mating data. The expected numbers of transgene positive offspring listed
previously were generated assuming a single integration site of one transgene
tandem array. With this assumption 130.5 transgene positive mice could be
expected to be generated in the various matings. The actual number of transgene
positive mice generated is 128; this ratio is statistically consistent with a single
site of integration (%2[ = 0.041, P = 0.839).
Using the mating data it is also possible to determine that homozygosity for the
pAPC 2M35 transgene is not embryonic lethal; matings between two transgene
heterozygote parents produced 108 offspring. With a single site of tandem array
integration 81 of these mice would be expected to be transgene positive, of which
33%, or 27 mice would be expected to be homozygous for the transgene tandem
array. The observed number of transgene positive mice (heterozygotes and
homozygotes) from these matings is 78. The observed number of transgene
positive mice and the expected number of transgene positive mice are not
significantly different = 0.214, P = 0.643), suggesting that all transgene
positive mice, regardless of transgene dosage, are surviving. Further, if transgene
array homozygosity were lethal, then only 54 transgene positive mice would be
expected to be generated out of 108 mice total. This is significantly different
from the observed 78 transgene positive mice (X x = 11.221, P = 0.001),
suggesting again that transgene array homozygosity is not lethal.
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Figure 5.4: Southern detection of pAPC 2M35 in transgenic mice Genomic
DNA was prepared from liver samples obtained during dissections. The genomic
DNA was digested overnight with a 10 fold excess ofNhel which cuts once in the
transgene sequence. The DNA blot was probed with a 236bp probe amplified by
PCR from the SV40 poly adenylation sequence present in the transgene construct.
Lane 1: Kilobase ladder (NEB). Lane 2: DNA from mouse CC 268, transgene
negative by PCR screening. Lane 3: DNA from mouse 271, transgene positive
by PCR. Not visible in the autoradiograph is Lane 4: Marker II (Roche) The
expected 13.25kb transgene copy number band is clearly visible in the lane
corresponding to the transgene positive DNA sample.
5.3.1 Min rescue
To date no Min homozygous mice have been generated; if transgene positivity
(heterozygous or homozygous) were capable of rescuing the embryonic lethality
of the Min homozygous phenotype the number of rescued mice would be
expected to be approximately 25 (see table 5.1), significantly more than the
number observed (%2i = 27.432, P < 0.001). Additionally, approximately 7 (6.75)
Min homozygotes could be expected out of the anticipated 27 transgene
homozygous mice generated from the matings between transgene heterozygotes.
The lack ofMin rescue in the expected transgene homozygote population is also
statistically significant (%21 = 8.043, P = 0.005), indicating that inheritance of two
transgene tandem arrays is not sufficient to overcome Min homozygous
embryonic lethality.
Despite the lack of rescue, the APC expression transgene may have more subtle
effects on the phenotype of the Min mice. One possibility is that the pAPC 2M35
transgene has some effect on the severity of the Min phenotype and as such
affects survival times.
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5.3.2 Comparison of survival times
The direct comparison of survival times within the CC colony is somewhat
complicated by variation in the genetic background of the different generations
of mice, as the background of a mouse bearing a Min mutation greatly affects the
overall disease phenotype (Bilger et al., 1996). The initial founder mouse
possessed a 50% C57BL/6 / 50% CBA strain background; later generations are
progressively more completely C57BL/6 (75% and 87.5%). In order to be able to
compare survival times across generations, some means of correcting for the
gradual change in background had to be found. While multiple genetic factors
affect the Min phenotype, one particular gene polymorphism is known to
contribute approximately 50% of the variation in tumour burden observed across
different backgrounds (Dietrich et al., 1993). The Mom-1 locus (modifier ofMin-
1) has been identified as the secretory phospholipase-a2 (Pla2g2, see section
1.4.1); the C57BL/6 mouse strain bears a polymorphism of the Mom-1 gene
which results in high susceptibility to the Min phenotype (Gould et al., 1996a;
Gould et al., 1996b). A number of polymorphisms of the Mom-1 locus can be
distinguished by PCR amplifications followed by digestion with BamHI (see
section 2.2.2). The C57BL/6 inbred mouse strain gives a 138bp Mom-1
genotyping PCR product which does not contain a BamHI site (Santos et al.,
1998). No published data regarding the size of the CBA Mom-1 PCR/BamHI
genotyping reaction could be found, although the Mom-1 genotyping PCR
products from a number of other inbred strains digest with BamHI to give shorter
DNA molecules. It was determined that the Mom-1 PCR product of the CBA
strain is approximately 138bp in length and digests with BamHI to give a DNA
molecule of approximately 118 bp (see figure 5.5). Mom-1 PCR reactions and
digests using both CBA and C57BL/6 genomic DNA as template showed that the
polymorphisms could be successfully distinguished following electrophoresis on
4% agarose TBE gels (see chapter 2).
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Figure 5.5: A) Mom-1 PCR genotype PCR product generated from a CBA strain
genomic DNA sample. Lane 1: Marker VI (Roche), Lane 2: Undigested CBA
1 PCR product, 132bp. Lane 3: CBA Mom-1 PCR product digested with BamHI,
resulting in cleavage to a —118bp product. B) Comparison of the CBA and
C57BL/6 Mom-1 PCR products. Lane 1: Marker VI (Roche). Lane 2: Undigested
PCR product from mixed CBA / C57BL/6 genomic DNA. Lane 3: The mixed CBA
/ C57BL/6 PCR product digested with BamHI, showing the 132bp C57BL/6 and
the ~118bp CBA bands. Lane 4: Undigested C57BL/6 I Mom-1 PCR product. Lane
5: C57BL/6 Mom-1 PCR product digested with BamHI.
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Genotyping genomic DNA samples from early CC mice determined that the
founder mouse was homozygous for the C57BL/6 Mom-1 polymorphism. As the
Min mutant strain involved in subsequent matings is of a 100% C57BL/6
background, all CC mice are homozygous for this permissive C57BL/6 Mom-1
polymorphism. While some variation may still result from the small inter-
generation differences in strain background in the CC mice, the homogeneity of
the Mom-1 locus within the colony makes the direct comparison of survival times
considerably more statistically valid.
Comparison of survival times involved 15 pAPC 2M35_/~, ApcM,n/+ mice, 13
pAPC 2M35+/\ ApcMin/+ mice and 15 pAPC 2M35+/?, ApcMin/+ mice, a proportion
of which are expected to be transgene array homozygous. Survival of the
transgene positive mice was analysed in groups based on the transgene status of
their parents to determine if the mice which may have inherited transgene arrays
from both parents had any difference in survival phenotype when compared to
mice inheriting a single array of the pAPC 2M35 transgene. Statistical
comparison of survival times was performed using the K-test (Lee, 1992).
Survival times of mice which died of causes unrelated to tumour development
(injuries or infections) or of unknown causes such as death during unmonitored
periods when decay may obscure the precise cause of death were treated as
censored data (see appendix 3 for raw data). Kaplan-Meier survival plots were
also calculated and plotted (see figure 5.6) (Kaplan and Meier, 1958). The
ranking of survival time used in the K-test indicate that no significant difference
in the overall survival times exists between any of the groups of mice tested (X {
= 2.96, P > 0.05).
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Figure 5.6: The corrected survival curves for each mouse cohort. The dark blue
curve represents the survival of transgene negative, Apc'v/",/+ mice. The mauve
curve is represents the data from the transgene positive, ApcMm/+ mice with one
transgene positive parent. The yellow curve is representative of the transgene




















5.3.3 Comparison of tumour burden
The consistent Mom-1 background in the CC colony also allows for the
comparison of tumour burden between transgene positive and transgene negative
ApcM",/+ mice. Haematoxylin and eosin stained sections of rolled gut
preparations from 8 transgene positive and 8 transgene negative ApcM',,/+ mice
were visually inspected for the presence of lesions (see figure 5.7). The intestinal
sections were screened and the total number of lesions (small intestine and large
intestine/colon) in each sample counted. The scoring was done without
knowledge of the transgene status of the sample. While the number of tumours
varied considerably from one individual animal to another, the median number of
tumours per animal in each group (transgene positive and transgene negative)
were very similar and a non-parametric test (Wilcoxon rank test) showed no
significant difference between the two groups (P = 0.645); the raw data are
presented in the following table.
Table 5.2 Tumour burden data
Transgene positive mice Transgene negative mice
Tumour number Tumour number
Small Large Total Small Large Total
intestine intestine Intestine intestine
22 0 22 6 3 9
25 0 25 7 0 7
4 0 4 7 0 7
3 0 3 9 0 9
6 0 6 23 0 23
20 2 22 4 0 4
10 5 15 23 1 24
6 2 8 23 0 23
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Figure 5.7: A) A large lesion of the small intestine in mouse CC 240, a transgene
positive / ApcM"l/+ animal. B) A similar lesion in the small intestine of mouse CC
246, a transgene negative / ApcM,n/+ animal. Images are magnified ~200x.
Figure 5.7: Small intestinal tumours in pAPC 2M35 transgene, Ape Min/+ and
Apcv,/"/+ littermates
5.3.4 Comparison of histological sections
In addition to intestinal samples, a number of other tissue samples were taken
during dissection of harvested CC mice. No consistent morphological
abnormalities were observed in these tissues during dissection and this was
confirmed by histological examination. Sectioned and haematoxylin/eosin
stained samples of liver, pancreas, kidney and spleen from transgene positive and
negative ApcM"i/" mice were examined for any histological differences (see figure
5.8). No detectable transgene associated changes could be discerned in the
samples examined.
5.3.5 Transgenic embryos
As previously mentioned correct regulation of the Wnt-1 signalling pathway is
essential during embryogenesis in a wide variety of species. The introduction of
the pAPC 2M35 transgene may interfere with the developmentally regulated
Wnt-1 pathway by provoking the expression of APC independent of
developmental signals. A previous embryo screen involving transgene positive
ApcM,n/+ mice had found 2 embryos (day 9 and 10), which exhibited exencephaly
(Cooper, 2000). In order to determine if the pAPC 2M35 transgene has an effect
on the process of embryogenesis in the absence of the Min mutation, matings
were set up between a transgene positive, Apc+I+ male and two transgene
negative, Apc++ females. Pregnant females were harvested at day 8 to 10 of
gestation and the embryos PCR screened for the presence of the pAPC 2M35
transgene (see section 2.2.2) and visually inspected under a dissection
microscope for any developmental abnormalities (see figure 5.9). This set of
timed matings generated a total of 15 embryos, 14 of which proved to be
transgene positive. No developmental abnormalities were noted in any of the
embryos, in particular there was no suggestion of failure of neural tube closure or
malformation of the head.
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Figure 5.8: Haematoxylin and eosin stained sections from four representative
tissues. Images in the column "A" are from the transgene positive mouse CC 10.
Images in the column "B" are from the transgene negative mouse CC 63. Al/Bl)
Kidney samples. A2/B2) Liver samples. A3/B3) Pancreas samples. A4/B4) Spleen
samples. The transgene positive / ApcMin/+ mice showed no obvious histological
alterations when compared with transgene negative / ApcMin/+ mice. All images are
at ~200x magnification.
Figure 5.8: Histology of pAPC 2M35 transgene /Ape Min/+ and Apcv/"'A mice
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Figure 5.9: pAPC 2M35 transgenic embryo
Figure 5.9: Example of a pAPC 2M35 transgene positive, Apc+/+ embryo. The
gross morphologies of the 14 transgene positive embryos were indistinguishable
from similarly aged transgene negative embryos. 25x magnification.
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5.4 Discussion
While the breeding and analysis of the CC line was underway, at least one other
mouse strain bearing floxed Ape alleles has been developed (Shibata et al.,
1997). The homozygous Apc580S line appears phenotypically normal, displaying
none of the phenotype associated with the Min mouse, despite the fact that the
14th exon of both Ape alleles has been flanked by loxP sites and the expression
level of Ape from the altered loci appears to be only 30% that found in normal
mice. On introduction of Cre-encoding adenovirus, via enema, these mice rapidly
develop intestinal polyps, some of which progress to adenomas. The adenomas
seen in these mice appear to be lacking the floxed exon 14, indicating that
adenoma formation is correlated to successful recombination events. As
previously mentioned, however, the adenovirus mediated excision in the Apc580S
line fails to answer the question of whether loss of function of Ape alone is
sufficient to provoke tumour formation. The development of further floxed Ape
lines and the advent of an intestinal stem cell specific Cre line will better enable
the investigation of the early event of colorectal carcinogenesis. The evidence
collected to date, however, suggests that the presence of the pAPC 2M35
transgene has no statistically significant effect on the Min phenotype. In
particular, no survival benefit (embryonic or adult) appears to be conferred on
transgene positive animals, nor is there a significant reduction in the disease
phenotype as evidenced by the tumour burden data.
There are a number of possible reasons for the lack of altered Min phenotype
exhibited by pAPC 2M35 transgene CC mice. Although the original founder
mouse was determined to harbour the transgene by PCR, this provides no
information regarding the number of copies of the transgene present within the
genome. Attempts to detect the transgene by Southern hybridisation in early mice
failed, although faint signal was detected in genomic digestions spiked with 10
copies per mouse genome of the pAPC 2M35 transgene vector (Cindy Cooper,
personal communication). While not strictly statistically valid, this suggested that
the transgene was present in low numbers (<10) within the early CC mice. The
detection of a transgene tandem array band by southern hybridisation indicates
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that there exist at least 2 head-to-tail copies of the transgene inserted into at least
one site.
While the PGK-1 promoter used in the pAPC 2M35 transgene is known to give
global expression, the levels of expression can vary significantly from tissue to
tissue (McBurney et al., 1994). It is possible that the PGK-1 promoter does not
promote sufficient expression in cells critical to embryonic survival to allow the
PGK-1 driven expression of APC to compensate for lack of full length Ape
protein in AycMui/Mm embryos, although PGK-1 expression appears to be
upregulated during gastrulation, the stage of lethality for Min homozygotic
embryos (Sturm et al., 1999). PGK-1 activity also appears to be heavily
influenced by methylation during development; it is possible that the PGK-1
promoter is downregulated in the same manner (Pravtcheva et al., 1991).
Another possible influence on expression from the pAPC 2M35 transgene is the
location of integration into the mouse genome. It is known that the integration of
transgenic material into certain chromosomal regions can result in suppression of
transgene expression, even in transgenes using very strong promoters. This may
be due to transgenes integrating near endogenous silencer element or into
methylation or architecturally silenced regions of chromosomes. The patterns of
inheritance of the transgene in early CC mice suggests that the transgene had
initially integrated into only one location; this leaves open the possibility that the
transgene has simply been incorporated into the genome in such a way that it can
drive only limited expression. Southern detection of the transgene was possible
in later CC mice which may harbour copies of the transgene array inherited from
both parents, however no information regarding the number of integration sites
could be determined from the autoradiograph.
To date it has not been possible to quantify expression from the pAPC 2M35
transgene beyond determining by RT-PCR that transgene mRNA is being
produced in a global manner. Immunoblot analysis would be inconclusive as the
homology between the mouse and human protein is such that currently available
antibodies would cross react between the endogenous mouse Ape and the human
APC. Additionally, the similarity in the DNA sequence between the mouse and
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human APC gene would make it very difficult to distinguish between mRNA
transcribed from the endogenous mouse Ape locus and mRNAs transcribed from
the transgene array using a northern blot technique.
While the pAPC 2M35 transgene is certainly present within the genome of the
CC mouse strain and some expression can be detected, the lack of modulation of
the Min phenotype makes the CC mouse line of limited use in the study of Ape





of the Wnt-1 pathway
221
Chapter 6- Methylation and manipulation of the Wnt-1 pathway
6.1 Background
Any cell which comes into contact with the outside environment or with the
metabolic products of normal physiology will eventually encounter potentially
genotoxic DNA damaging agents. These agents include reactive oxygen species
generated during aerobic metabolism, radiation in the form of UV light and a
host of chemical agents found in air, food and water. One of the most common
types of genotoxic chemical agents encountered are alkylating agents. These
reactive molecules are capable of bonding hydrocarbon groups to many types of
normal cellular molecules including proteins and DNA. While the addition of
these adducts to peptide macromolecules essential for cellular functioning can
hinder or alter their normal spectrum of activity and may lead to cell death or
apoptosis, the addition of these chemical groups to DNA can result in the
generation of mutations if the adducts are present during DNA synthesis. In
response to their constant exposure to alkylating agents all cells have evolved
mechanisms to recognise and remove or replace nucleotides which have been
altered by alkylation, or, if the damage is too great, to provoke apoptosis. These
mechanisms appear to be important in the suppression of tumour formation;
germline mutations in the MSH2 gene, involved in the cellular recognition and
response to a particular class of nucleotide methyl-group alterations, appear to
cause some cases of the human HNPCC phenotype (see section 1.1.2.1) while
many different types of cancers have been found to bear mutations in the p53
tumour suppressor, another protein involved in cellular responses to various
forms of DNA damage.
There appears to be a complex relationship between the MSH2 mismatch repair
(MMR) mechanisms of mammalian cells and the tumour suppressor protein p53.
Mutations in either system appear to decrease the incidence of apoptosis,
although the mechanisms by which each of these proteins influence apoptotic
potential appear to be at least partially distinct (Clarke et al., 1994; Dou et al.,
1995). While the two systems are able to initiate apoptosis in response to DNA
damage it now appears that the apoptotic response to DNA alkylation is
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primarily under the control of the MMR mechanisms alone (Toft et al., 1999;
Dou et al., 1995). Despite this apparent independence it has been shown that the
p53 pathway requires the presence of functional MMR mechanisms in order to
respond to certain specific classes of DNA methylation damage; the MutSa
pathway of MMR, involving heterodimers of MSH2 and the related protein
MSH6, is responsible for the stabilisation and subsequent accumulation of p53 in
response to the presence of 06-methylguanine (06MeG) DNA adducts (Hickman
and Samson, 1999). The 06MeG DNA adduct is one of several genotoxic insults
resulting from exposure to the powerful methylating agent A-methyl-A'-nitro-A-
nitrosoguanidine (MNNG). As mentioned previously (see section 1.3.3) the
levels of both the APC protein and its precursor mRNA are upregulated in a
human colorectal cell line and in MEFs in response to MNNG exposure;
additionally this upregulation has been shown to be dependant on the presence of
functional p53 within the treated cell (Jaiswal and Narayan, 1998; Narayan and
Jaiswal, 1997). The p53 dependant correlation between methylation damage and
cellular levels of the APC tumour suppressor protein may have physiological
significance; the levels of 06MeG damage on normal DNA in cancer prone
regions of the human large intestine have been found to be elevated (Povey et al.,
2000). The ability for this type of adduct, frequently encountered in the relatively
highly genotoxic environment of the large intestine, to upregulate cellular levels
of the tumour suppressor most often mutated in colorectal tumours may represent
an important protective mechanism. p53 dependant upregulation of APC in
response to this type of methylation may help prevent neoplastic behaviour in
06MeG damaged cells by indirectly inducing downregulation of Wnt-1
responsive genes, many of which have been shown to have oncogenic potential
(see section 1.3.1.6.2).
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6.2 in vivo MNNG treatment
Initial experiments were carried out to determine whether this p53 dependant
Ape upregulation in response to MNNG treatment could be observed in vivo.
Immunodetection to compare cellular levels of the Ape target protein P-catenin
in the various fibroblast populations would also allow observation of the
immediate downstream Wnt-1 pathway effects of the expected Ape upregulation.
Levels of P-catenin in protein extracts derived from murine intestine were
compared between wild type mice treated with 50pg/kg MNNG and untreated
controls, to determine if the expected reduction of P-catenin levels due to Ape
upregulation could be detected. Unfortunately, the levels of P-catenin appeared
to vary considerably along the length of the small intestine and there also proved
to be considerable variation between protein samples prepared from individual
mice (see figure 6.1). As this inter-sample variation would make subtle changes
in P-catenin levels difficult to detect, further experiments were carried out using
murine embryonic fibroblasts (MEFs). In an effort to determine whether the
accumulation of Ape protein following MNNG exposure was also dependant on
the presence of functional Msh2 protein, MEFs bearing the relevant p53 and/or
Msh2 homozygous null mutations were isolated and exposed to significant doses
ofMNNG.
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Figure 6.1: Western blot analysis of P-catenin levels in various sections of the
murine intestine showing high variability. A) Diagram showing the dissection of
the intestine for protein extraction. 1) proximal small intestine 2) mid-small
intestine 3) distal small intestine 4) large intestine/colon B) 90kDa signal
corresponding to P-catenin. and a 25 kDa signal corresponding to IgG light chain.
P-catenin was detected with an antibody directed against an epitope coded for in
exon 14. C) The same samples probed with an antibody directed against an epitope
coded for in exon 2 of P-catenin.
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6.3 Embryonic fibroblasts
6.3.1 Preparation and genotyping
Embryonic fibroblasts were generated using the protocol outlined in section
2.3.1. The embryos used in the generation of MEFs were derived from matings
between pairs of animals heterozygous and/or homozygous for the null alleles of
one or both of p53 and Msh2. In all cases a small tissue sample was taken at the
time of embryo harvesting in order to PCR genotype the individual embryos for
the relevant mutations (see section 2.2.2 for PCR conditions, see figure 6.2a and
6.2b). The cells were cultured, treated with MNNG and harvested for protein as
outlined in section 2.3.
6.3.2 MNNG induced alteration of (3-catenin levels
The upregulation of APC levels in MEFs observed by Jaiswal et al. appeared to
be optimal after 15 hours of exposure to 50pM concentrations of MNNG in 0.5%
serum. Accordingly, the various fibroblast populations in the present study were
each split into 2 flasks, one being treated with a 50p,M concentration of the
methylating agent for 15 hours prior to protein harvesting and the other being an
untreated control. The protein concentrations in the extracts were compared (see
section 2.4.2) and the samples adjusted in order to ensure equal loading prior to
gel electrophoresis; immunoblots were prepared as previously outlined and
probed with monoclonal antibodies directed against epitopes coded for in either
exon 14 or exon 2 of (3-catenin (exon 14, C-terminal antibody: Clone 14,
Transduction Laboratories; exon 2, N-terminal antibody: Clone 7D11, Upstate
Biotechnology).
6.3.2.1 (3-catenin levels in wild type fibroblasts
Untreated wild type fibroblasts displayed a strong signal band at the expected
size of ~90kDa after culture in 0.5% serum for 15 hours. On administration of
MNNG the relative level of (3-catenin signal observed appeared to drop
significantly (see figure 6.2). Densitometry analysis of the bands on a sub-
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saturation film exposure confirmed the initial observations of reduced P-catenin
signal. Densitometry analysis was further corrected for gel loading by
comparison of P-catenin signal with densitometry of an unrelated high molecular
weight band in the Coomasie stained post-transfer gel (see figure 6.2b and 6.2c).
Corrected densitometry data confirmed the reduction of P-catenin signal
following MNNG treatment.
6.3.2.2 P-catenin levels in p53_/" fibroblasts
An identical comparison of the p-catenin levels in treated and untreated p53 null
fibroblasts revealed a small reduction in p-catenin signal strength, which was
related to MNNG dose (see figure 6.3). The reduction was far less distinct than
that observed in the wild type fibroblast preparations; further loading correction
performed as outlined above proved the slight observed reduction to be even
smaller than initially measured.
6.3.2.3 P-catenin levels in Msh2~'' fibroblasts
Msh2 null fibroblasts, which retained wild type alleles of p53, showed a
significant drop in P-catenin levels following MNNG exposure (see figure 6.4).
Loading correction performed as above confirmed this observed P-catenin
reduction and showed that the level of reduction was comparable to that observed
in the wild type fibroblast experiments.
6.3.2.4 P-catenin levels in p53-/7Msh2~'~ fibroblasts
Double null fibroblasts, bearing homozygous mutations in both p53 and Msh2
alleles were also subjected to MNNG treatment. Analysis of P-catenin levels
before and after treatment showed a small level of P-catenin reduction,
comparable to that observed in the p53 single null cells (see figure 6.5).
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Figure 6.2: (3-catenin levels in wild type fibroblasts
A) 0 |iM MNNG 50 |xM MNNG
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Figure 6.2: Western blot analysis of p-catenin levels in wild type murine
embryonic fibroblasts following exposure to MNNG. A) 90kDa signal
corresponding to P-catenin. Lanes 1-3 are protein extracts from untreated
fibroblasts, lanes 4-6 correspond to protein extracts from the same fibroblast
preparations treated with 50 pM MNNG for 15 hours prior to harvesting. B) An
example of a coomasie stained acrylamide gel showing the high molecular weight
proteins retained in the gel following protein transfer to nitrocellulose membrane;
the stained gels were used to correct for small variations in protein loading
levels.C) Loading corrected densitometry values for the P-catenin signal.
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Figure 6.3: P-catenin levels in p53 null fibroblasts
A) 0 nM MNNG 50 |aM MNNG




Figure 6.3: Western blot analysis of P-catenin levels in MSH2 null murine
embryonic fibroblast following exposure to MNNG. A) 90kDa signal corresponding
to p-catenin. Lanes 1-3 are protein extracts from untreated fibroblasts, lanes 4-6
correspond to protein extracts from the same fibroblast preparations treated with 50
pM MNNG for 15 hours prior to harvesting. B) Loading corrected densitometry
values for the P-catenin signal. 1-3 are untreated fibroblast values, 4-6 are MNNG
treated. C) Averaged corrected values showing a relatively small reduction in the
relative p-catenin levels occurring on exposure to MNNG.
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Figure 6.4: P-catenin levels in MSH2 null fibroblasts
A) 0 [0.M MNNG 50 pM MNNG
I 1 2 3 | | 1 2 3 |
untreated 50pM MNNG
Figure 6.4: Western blot analysis of p-catenin levels in MSH2 null murine
embryonic fibroblast following exposure to MNNG. A) 90kDa signal corresponding
to P-catenin. Lanes 1-3 are protein extracts from untreated fibroblasts, lanes 4-6
correspond to protein extracts from the same fibroblast preparations treated with 50
pM MNNG for 15 hours prior to harvesting. B) Loading corrected densitometry
values for the P-catenin signal. 1-3 are untreated fibroblast values, 4-6 are MNNG
treated. C) Averaged corrected values showing a large reduction in the relative P-
catenin levels occurring on exposure to MNNG.
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Figure 6.5: Western blot analysis of p-catenin levels in p53/MSH2 null murine
embryonic fibroblast following exposure to MNNG. A) 90kDa signal corresponding
to P-catenin. Lanes 1-3 are protein extracts from untreated fibroblasts, lanes 4-6
correspond to protein extracts from the same fibroblast preparations treated with 50
pM MNNG for 15 hours prior to harvesting. B) Loading corrected densitometry
values for the P-catenin signal. 1-3 are untreated fibroblast values, 4-6 are MNNG
treated. C) Averaged corrected values showing a relatively small reduction in the
relative P-catenin levels occurring on exposure to MNNG.
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6.4 Discussion
The upregulation of APC levels in human cell lines and MEFs in response to
MNNG exposure has previously been shown to depend on an increase in cellular
levels of functional p53 tumour suppressor protein (Jaiswal and Narayan, 1998;
Narayan and Jaiswal, 1997). It has also previously been shown that a functional
MutSa pathway, which includes the Msh2 protein, is a requirement for the
stabilisation and subsequent accumulation of p53 in MEFs in response to
(96MeGs formation following MNNG exposure (Hickman and Samson, 1999).
Based on these observations it would then be expected that APC accumulation
and the subsequent increased rate of degradation of (3-catenin would depend on
the presence of functional Msh2.
The data presented here clearly show a reduction in the levels of (3-catenin in
MNNG treated Msh2 null fibroblasts, while the levels of this protein remain
relatively constant in p53 null or p53/Msh2 null cells regardless of treatment. It
would appear that (3-catenin levels are suppressed in a manner at least partially
dependent on p53 but independent of Msh2 status. This suppression may occur
either at the level of transcription or post-translationally through some APC-
independent breakdown of (3-catenin. While some evidence points to a
dependence on the presence of a functional MutSa pathway to upregulate and/or
phosphorylate p53 in various cell lines, there is strong evidence for some
functional independence between Msh2 and p53 DNA damage responses in
murine systems. The administration of 50mg/kg MNNG to wild type mice results
in elevated levels of apoptosis in the small intestine. This increase in apoptosis
does not appear to occur in p53 null mouse lines, indicating that the apoptotic
response to MNNG is p53 dependant. The same chemical treatment of Msh2 null
mouse lines resulted in a reduced but still significant wave of apoptosis some 6
hours following treatment with MNNG (Toft et al., 1999). While p53
stabilisation following MNNG treatment may be strictly dependent on a
functional MutSa pathway in some cell lines, there is clearly some evidence for
downstream p53 effects following MNNG treatment in MutSa deficient in vivo
systems.
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It is possible that MNNG induced lesions other than 06MeGs, or indeed
alkylation of molecules other than DNA, are capable of initiating p53 dependant
pathways which ultimately cause the observed effects on (3-catenin levels.
Double strand breaks in DNA are known to induce cellular responses, including
apoptosis, in a p53 dependant manner; these breaks may arise in actively
dividing cells which have failed to remove DNA adducts prior to DNA
replication (Karran and Bignami, 1994). The MEF populations in the set of
experiments presented in this chapter were cultured in 0.5% FCS starvation
medium prior to and during MNNG treatment in an effort to slow or stop cell
division. The Msh2 null cells, both with and without p53 deficiency, appeared to
be able to grow and divide despite the low level of serum supplement in the
culture medium. An attempt was made to quantify this phenomenon using
clonogenic survival studies (data not presented), however the ability of the Msh2
null cells to replicate in starvation medium seemed to be highly confluence
dependent. When either Msh2~'~ or Msh2~'~/p53_/" null cell at 75% confluence were
switched to starvation medium 18 hours prior to MNNG treatment they often
reached nearly 100% confluence prior to MNNG addition, while the sparse
seeding in the clonogenic survival study produced very little growth, making the
determination of number of clones very difficult. The apparent ability of Msh2
null cells to grow through starvation regimes may allow for the formation of
DNA strand breaks and the associated p53 stabilisation. This would in turn lead
to Ape upregulation and finally (3-catenin degradation. The ability of MMR
deficient cells to grow through normal cell cycle checkpoints has been observed
previously; both MLH1 null human cell lines and murine fibroblasts have been
shown to have a reduced G2/M cell checkpoint arrest following ionising
radiation (Davis et al., 1998).
While p53 upregulation of Ape levels is perhaps the most likely cause of the
observed (3-catenin downregulation there are other ways in which the levels of P-
catenin present within a cell may be altered without a significant increase in Ape
protein levels. P-Transducin repeat containing protein (P-Trcp) has recently been
shown to interact with phosphorylated P-catenin and can influence its
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degradation by the ubiquitin-proteosome pathway (Hart et al., 1999; Liu et al.,
1999; Easwaran et al., 1999b). Another protein, casein kinase Ie (CKIe), has also
been shown to influence (3-catenin degradation. This protein binds the Wnt-1
pathway component Axin; overexpression of CKIe mimics the effects of Wnt
signalling, resulting in the accumulation of P-catenin and the activation of
transcription from Wnt target genes (Sakanaka et al., 1999). Upregulation of P-
Trcp levels or downregulation of CKIe could both result in the increased rates of
P-catenin degradation observed in the Msh2 null fibroblasts. It is possible that





Chapter 7 - Conclusions
The investigations undertaken in this thesis focussed on three main areas; the
first being the characterisation of novel promoter sequence of the intestinal
epithelial-specific Cdx-1 homeobox gene and work towards engineering this
sequence into a conditional transgenic construct, secondly, the thorough
phenotypic characterisation of a floxed APC transgenic mouse line and finally
the investigation of downstream effects of methylating agent exposure on the
Wnt-1 pathway.
Numerous attempts to generate a BAC based Cdx-1 promoter driven Cre
expression transgene through the use of an in vivo recombination system failed to
produce the desired transgene construct. The failure to generate a recombination
modified BAC, despite efforts to optimise the system, could have a number of
possible causes, as discussed in section 3.4. The conclusions drawn here are that,
while the potential for the rapid generation of transgene or targeting constructs
using this in vivo system is great, the efficiency of the system may be hampered
by a number of factors. Careful consideration of the nature of the selection
systems employed, as well as an awareness of potential problems posed by
special features of the sequences composing the arms of homology are key to
successful application of this in vivo recombination system. It may be that certain
BAC manipulations will prove inefficient or impossible within the limitations of
the Reda-(3-y based protocol. At least one other BAC alteration system based on
recombination has been developed; this sytem uses a single arm of homology and
a highly efficient Cre mediated recombination event to introduce planned
changes into the BAC sequence (Dr. Chris Boyd, personal communication). This
alternative system may overcome some of the problems posed by the Reda-(3-y
recombination protocol.
A fragment of one of the Cdx-1 positive BAC clones (BAC 219) containing
novel Cdx-1 promoter sequence was successfully subcloned by Dr. Sula Corbet
and Dr. Jane Armstrong. As part of this thesis, this fragment was mapped and its
full length sequenced; the derived sequence data revealed a number of putative
transcription factor binding sites in addition to confirming the presence of a
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number of previously partially characterised motifs. Four EGFP reporter
plasmids, driven by varying lengths of the isolated Cdx-1 promoter sequence,
each containing a different complement of transcription factor binding sites, were
assembled and introduced into a number of cell types. Expression levels
measured varied considerably between the cell types and also between reporter
constructs, providing information about transcription motifs responsible for
expression levels and possibly tissue specificity.
Had time allowed, an investigation of the role played by the putative
transcription factor binding sites in the control of Cdx-1 transcription would have
proved interesting. Preliminary investigations into the extent of transcriptional
control of the Cdx-1 locus contributed by c-myb would consist of DNA
footprinting or electrophoretic mobility shift assays (EMSAs) to determine if the
sequence motif in question does indeed interact physically with c-myb in vitro.
Effects of the presence of c-myb on the expression of Cdx-1 in vivo could be
conducted by co-transfection of ES cells (or another appropriate cell type) with
Gix-EGFP reporters containing the putative c-myb binding site and c-myb
overexpression vectors. Alternatively some information regarding the function of
the potential c-myb binding site may be obtained through transfection of cell
lines known to overexpress c-myb in parallel with the transfection of related lines
which do not overexpress this oncogene. Should the results of these experiments
suggest a role for c-myb in Cdx-1 expression, site directed mutagenesis of the c-
myb binding site could be performed to determine if sequence alterations
abrogate the previously observed c-myb effects. Similar experiments could be
performed to determine if the putative CREB binding sites identified are
physiologically important transcription factor motifs. The investigation of the
properties of the isolated Cdx-1 promoter sequence using Cdx-1 based reporter
constructs would be of interest in the study of developmental control of the Cdx-
1 homeobox gene and will be of importance if characterisation of the Cdx-1-
CreERtm transgenic mouse line generated by Drs. Jane Armstrong and Sula
Corbet reveals any unexpected pattern of expression or recombination.
Phenotypic characterisation of the CC floxed APC mouse line revealed that,
while some expression from the introduced transgenic construct could be
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detected by the very sensitive RT-PCR method, presence of the transgene was
insufficient to significantly alter the Min phenotype when the transgenic line was
crossed onto the Ape mutant strain. Histological appearances, embryogenesis,
gross anatomy, survival times and tumour burden were not significantly altered
by the presence of the pAPC 2M35 transgene. The lack of phenotype alteration
seen in the CC line could have a number of causes. Perhaps the most plausible
explanation for the lack of effect is absence of sufficient expression. Low levels
of expression from the pAPC 2M35 transgene could have a number of causes,
including poor expression from the PGK promoter used in the transgene
construct or the integration of a small number of copies of the transgene into a
silenced area of the mouse genome. While it was possible to establish through
Southern hybridisation that the transgene was in fact present in the genome in a
detectable quantity, no information regarding the number of integration sites has
been gleaned from this hybridisation. Additionally, Southern detection was only
accomplished using genomic DNA from later generations of CC mice which may
have inherited copies of the transgene array from both transgene positive parents,
effectively doubling the transgene copy number. Inheritance of the transgene in
early breeding from the founder mouse, and the generation immediately
following, suggested that the transgene had integrated in only one location within
the single founder animal's genome. The difficulty in detecting the transgene in
early mice, coupled with the breeding information regarding transgene
inheritance, suggests that the transgene was present in a relatively small number
of copies in only one genomic location. This increases the likelihood of low
expression levels, caused by integration into a silenced location, being the cause
for the lack of rescue of the Min phenotype.
While the transgene has thus far failed to modify the Min phenotype, the
transfection of the transgene into human colorectal derived cell lines appears to
show that the transgene is transcribed in vitro. Further pronuclear injections may
generate a founder mouse with multiple sites of transgene array integration,
possibly generating sufficient expression to affect the Min phenotype.
Additionally, it may be possible to re-engineer the pAPC 2M35 transgene
construct to increase transcription levels; a different promoter may give higher or
more consistent expression across different cell types and replacing the SV40
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polyA signal with the bovine growth hormone polyA signal may result in
significantly higher translation levels (Pfarr et al., 1986).
The final area of investigation presented in this thesis involves the Wnt-1
pathway responses to the alkylating agent MNNG in MEFs derived from mice
engineered to be deficient for the tumour suppressor genes p53 and/or Msh2. The
upregulation of Ape in response to exposure to MNNG has been observed in a
human derived colorectal cell line and in MEFs and is dependent on the presence
of functional p53 protein. There is evidence to suggest that the stabilisation of
p53 in human lymphoblastoma cell lines exposed to MNNG is dependent on a
functional MutSa pathway and as such is Msh2 dependent. The data presented
here shows a clear downregulation of the Ape target P-catenin in MEFs deficient
in Msh2 following 15 hours of exposure to 50pm MNNG, while MEFs derived
from p53 null animals showed a much smaller reduction in P-catenin following
the same treatment. This suggests that the downregulation of p-catenin in
response to MNNG is p53 dependent but at least partially independent of the
MutSa pathway.
Evidence for Msh2 independent p53 effects following MNNG treatment has been
seen previously in vivo. In wildtype mice treated with 50mg/kg MNNG there is a
wave of p53 dependent apoptosis seen in the small intestine occurring 6 hours
following treatment. In Msh2 deficient mice this response is reduced by
approximately 50-60% but still significant, indicating that there exists some
MutSa independent means of activating p53 following MNNG treatment (Toft et
al., 1999). The p53 dependent / Msh2 independent reduction in P-catenin levels
in MNNG treated fibroblasts may be triggered in a manner similar to that
occurring in the mouse small intestine.
Time permitting, further investigations of the observed reduction in P-catenin
levels following MNNG treatment would have been carried out. It would be of
interest to determine if p53 accumulation could be detected by immunoblot in the
Msh2 null MNNG treated MEFs. Failure to detect increased amounts of p53 by
western blot may indicate that the p53 dependent MNNG response displayed by
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the MEFs is transduced through some means other than a simple increase in the
amount of the p53 protein present in the cell, while increased levels of p53 would
point to an Msh2 independent stabilisation of p53 in these cells. Also of interest
would be an investigation of the kinetics of (3-catenin loss following MNNG
exposure, coupled with a measure of cell proliferation or cycling. A time course
experiment may show a delay in the (3-catenin reduction in the Msh2 null cells
when compared with the wild type MEFs which, if coupled with a detection of
persistent proliferation of Msh2 null fibroblasts in starvation medium, would
begin to suggest that failure to remove methyl adducts prior to DNA synthesis is
involved in the observed downstream p53 effects.
The upregulation of APC levels in response to MNNG was initially observed in a
human colorectal cell line containing wild type APC alleles but a degradation
resistant (3-catenin mutation. The measurement of (3-catenin levels in APC
deficient cell lines (such as SW 480) following MNNG exposure would help to
determine if the observed reduction of (3-catenin in vitro on MNNG exposure is
solely (or largely) dependent on an increase in APC.
The development of improved and refined conditional transgenic and gene
targeting techniques will undoubtedly contribute much to our understanding of
biological processes, including the early stages of colorectal carcinogenesis.
Ligand activation of inducible promoters or fusion proteins will continue to
improve, offering tighter control over the timing of gene expression. At the same
time, the number of known promoter sequences, including novel tissue-specific
promoters, will only grow as more genomes are sequenced and analysed. Both
of these developments will enable the dissection of molecular events in normal
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380g Acrylamide (Kodak 5521)
20g N,N-Methylene-bisacrylamide (Kodak 8383)
Dissolve in approx. 800ml of deionised water and adjust to a final volume of 1L
with deionised water (store at 4°C).
lOx Agarose gel loading dye
1.5g Ficoll (Sigma F-2637)
0.02g Bromophenol blue (Sigma B-0126)
0.02g xylene cyanole FF (Kodak T-1579)
dH20 to 10ml (store at -20°C).
Alkaline lysis solution (NaOH/SDS)
20ml 1 N NaOH
10ml 10% SDS
dH20 to 100ml (make fresh)






15% Ammonium persulfate (APS)
1.5g APS
dH20 to 10ml (store at 4°C).
Ampicillin (Amp)
0.5g Ampicillin (Sigma A-9518)








4% sodium sulphate solution
lmg/ml BSA (bovine serum albumin)
5mg BSA (Sigma A-9647)
dH20 to 5ml (aliquot and store at -20°C)
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100 mM calcium chloride (CaCl2)
1.48g CaCl2-2H20
dH20 to 100ml
autoclave to sterilize (store at 4°C)
50 mM calcium chloride
0.74g CaCl2-2H20
dH20 to 100ml
autoclave to sterilize (store at 4°C)
Cre reaction buffer





2ml 1 M Tris-HCl, pH 9.5
20pl 0.5 M EDTA, pH 8.0
lml 100 mM spermidine




2g Bovine serum albumin (Fraction V)
make up to 100ml with dH20
1 M DTT (Dithiothreitol, Cleland's reagent)
1.54g DTT (Calbiochem 233155)
dH20 to 10ml (aliquot and store at -20°C).
DNase-free RNase A
200mg RNase A (Sigma R-5500)
3.3pl 3 M NaOAc, pH 4.5
dH20 to 10ml
boil for 10 minutes (aliquot and store at -20°C).
0.5 M EDTA, pH 8.0 (disodium ethylenediamine tetraacetate)
186.lg Na2EDTA
Dissolve in approx. 400ml dH20, adjust pH to 8.0 with 10 N NaOH, and adjust
to 1 litre final volume with distilled water.
100 mM EDTA
20ml 0.5 M EDTA
80ml dH20
5mg/ml ethidium bromide (EtBr)







1 M HEPES, pH 7.5
23.83g HEPES (Sigma H-3375)
dH20 to 100ml
adjust pH to 7.5 with potassium hydroxide (KOH) (store at 4°C).
IPTG (isopropyl (3-D-thiogalactopyranoside)
250mg IPTG (Sigma 1-5502)
dH20 to 10ml (aliquot and store at -20°C)
Kanamycin sulfate (Kan)
0.5g Kanamycin Monosulfate (Sigma K 4000)
dH20 to 100ml (Add to media for final cone. 20 pg/ml)




7.5pM each of dGTP, dCTP, dTTP
LB Medium
lOg Bacto-Tryptone (Difco 0123-01-1)
5g Bacto-yeast extract (Difco 0127-05-3)
lOg NaCl
dH20 to 1 L
adjust the pH to 7.0 and then autoclave to sterilize
LB plates
lOg Bacto-Tryptone (Difco 0123-01-1)
5g Bacto-yeast extract (Difco 0127-05-3)
lOg NaCl
15g Bacto-agar (Difco 0140-01)
dH20 to 1 L
autoclave to sterilize, cool to 55°C, add antibiotic if desired, and pour into sterile
petri dishes (approx. 20ml/plate).
lOx Ligation buffer
5ml 1 M Tris-HCl, pH 7.6
lml 1 M MgCl2
lml 1 M DTT
lml 100 mM ATP
2.5mg BSA





Stored at room temperature
1 M MgCh (magnesium chloride)
20.33g MgCl2-6H20
dH20 to 100ml
1 M MgS04 (magnesium sulfate)
12.04g MgS04









adjust pH to 7.2 with citric acid
1 M MOPS
20.93g MOPS (Sigma M-1254)
Dissolve in 80ml dH20, adjust pH to 7.5 with 1 N NaOH, and bring volume to
100ml.
10X MOPS buffer
400ml 1 M MOPS, pH 7.5
170ml 3 M NaCl
100ml 1 M MgC12
330ml dH20
20 mM dNTP stocks:
80|ol 100 mM dNTP
40pl 50:1 TE buffer
280pl dH20
Neutralisation/Solution P3
3.0M potassium acetate, pH 5.5




lOmM phosphate buffer salts
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5x plasmid reaction buffer








5ml 1 M KC1
lml 1 M Tris-HCl, pH 8.5
150pl 1 M MgCl2
dH20 to 10ml
PCR Deoxynucleotide Preparation
250pl 100 mM dATP
250pl 100 mM dCTP
250pl 100 mM dGTP
250pl lOOmMdTTP
II.5ml dH20
Aliquot this into 25 tubes with 500|al in each tube.
Phenol, TE-saturated
Add an equal volume of 10 mM Tris-HCl, pH 7.5-8.0, 1 mM Na2EDTA to
ultrapure phenol, mix well, allow phases to separate, remove and discard upper
(aqueous) phase. Repeat until the pH of the aqueous phase is between 7.5-8.0





Buffer QBT (Equilibration buffer)
750mM NaCl
50mM MOPS, pH 7.0
15% isopropanol
0.15% Triton® X-100
Buffer QC (wash buffer)
1.0M NaCl
50mM MOPS, pH 7.0
15% isopropanol
Buffer QF (Elution buffer)
1.25M NaCl




50mM Tris-HCl, pH 8.0
lOmM EDTA
100|ig/ml RNase A












Sequenase® enzyme dilution buffer






75ml 19:1, 40% acrylamide solution
50ml lOxTBE
175ml dH20
For each gel 60ml of the above solution was mixed with 60pl of TEMED and





0.5g/l xylene cyanol FF
Sequencing Termination Mixes
one of each of:
80pM dATP + 8pM ddATP
80pM dCTP + 8pM ddCTP
80pM dGTP + 8pM ddGTP
80pM dTTP + 8pM ddTTP
SOC Media
2% w/v Tryptone
0.5% w/v Yeast Extract
0.05% NaCl
Autoclave and add the following filter sterilised reagents. 1% (v/v) 1M MgCl2,
1% (v/v) 1M MgS04 and 0.1% (v/v) 2M glucose solution.
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2M NaOAc (sodium acetate)
21 .Tig Na0Ac-3H20
dH20 to 100ml
3M NaOAc, pH 4.5
408.24g Na0Ac-3H20
Dissolve in approx. 800ml dH20, adjust pH to 4.5 with glacial acetic acid and
bring to a final volume of 1 L with dH20.
3M NaCl (sodium chloride)
17.53g NaCl
dH20 to 100ml






10% SDS (sodium dodecyl sulfate)
lOg SDS (Fisher S529-3)
dH?0 to 100ml
20X SSC (standard saline-citrate:
17.53g NaCl
8.82g sodium citrate
Dissolve in approx. 80ml dH20, adjust pH to 7.0 with HC1 and bring final
volume to 100ml.
IX SSC (standard saline-citrate)
5ml 20X SSC
95ml dH20










Dissolve in approx. 700ml of deionised water, adjust the pH to 8.3 with glacial











make up to 4L with dH20, pH to 7.4 with HC1








make up to 4L with dH20, pH to 7.4 with HC1
add 12.5ml Tween-20
make up to 5L
TEMED (N,N,N' ,N' -tetramethylethylenediamine)
Severn 20-3000-01, store protected from light at 15°C.
TE (10:1) buffer
10ml 1 M Tris-HCl, pH 7.6
2ml 0.5 M EDTA
dH20 to 1 L
Tetracycline stock (Tet)
lg Tetracycline (Sigma T-3383)
50ml 100% ethanol
dH20 to 100ml (store at 4°C in the dark)
Add to media for final conc. 20pg/ml.
1M Tris-HCl, pH 7.6, 8.0, 8.5, 9.0, 9.5
121.lg Tris base
dH20 to 800ml
Adjust pH with concentrated HC1 and then add dH20 to 1 L.
X-gal (5-bromo-4-chloro-3-indolyI b-D-galactopyranoside):
200mg X-gal (Sigma B-4252)
dimethylformamide (DMF) to 10ml






Positions are listed relative to the transcription start site
-6456 CTCGAGAGAT TGGGGGGGGG GGCTGCCATT TCCGGCCAGC CCAGCCATCC
GAGCTCTCTA ACCCCCCCCC CCGACGGTAA AGGCCGGTCG GGTCGGTAGG
-6406 GCTGGCCCAT CTGGAAGCAC TTAGTTCTAC CACCATTAAC CCTTGGTGGG
CGACCGGGTA GACCTTCGTG AATCAAGATG GTGGTAATTG GGAACCACCC
-6356 CACAGGAGCT GTTTCTCCTC CCTGTGATGG GATGCAAGCG ATACAAAACT
GTGTCCTCGA CAAAGAGGAG GGACACTACC CTACGTTCGC TATGTTTTGA
-6306 ACACAGAGTG CCACAGGGCA CTCTCGAAGG CCTGGACCCA GAGACTAAAG
TGTGTCTCAC GGTGTCCCGT GAGAGCTTCC GGACCTGGGT CTCTGATTTC
-6256 TTGAGTTCTG ACTCCAGCCT CTCTGTTTGA AGCTGGAAGA CCTTGTTGAA
AACTCAAGAC TGAGGTCGGA GAGACAAACT TCGACCTTCT GGAACAACTT
-6206 TGTCCCTGAG CTGCCCAGCC TGCTTTCTGC TCTAGACAGC AGGTAAGTCA
ACAGGGACTC GACGGGTCGG ACGAAAGACG AGATCTGTCG TCCATTCAGT
-6156 GGGCCGGGTC TGCACCCGCA GCTTCTTCAG CAGTCTGTGG GTGAACGAGT
CCCGGCCCAG ACGTGGGCGT CGAAGAAGTC GTCAGACACC CACTTGCTCA
-6106 ATGTAGCATC ACGCTAGGGT GGCCAGCATG GTCCCAGCCC CACTGTGGAC
TACATCGTAG TGCGATCCCA CCGGTCGTAC CAGGGTCGGG GTGACACCTG
-6056 AGAACGAATC AAGCACACTC ATTCCACGCC CAGATCCTGG GAGCCGGTTT
TCTTGCTTAG TTCGTGTGAG TAAGGTGCGG GTCTAGGACC CTCGGCCAAA
-6006 ACCTATGGTC AAACACTGAG GGAAAAGCTG CTGAGAACGG GTGGTGGGTA
TGGATACCAG TTTGTGACTC CCTTTTCGAC GACTCTTGCC CACCACCCAT
-5956 GAGTTCAAAA GGGGCTCCAG CCTTGGGGCG TCACGCTTTT TTCTACCTAC
CTCAAGTTTT CCCCGAGGTC GGAACCCCGC AGTGCGAAAA AAGATGGATG
-5906 CCAGAATGGC GGTCTACTTC ATGCATGAGA ATCTGAGCGC TAAGCCTGAG
GGTCTTACCG CCAGATGAAG TACGTACTCT TAGACTCGCG ATTCGGACTC
-5856 GCTCCGAACT CAGTTGCGTC TTAGCTGTGT GACTCTCAAA ATGCCCAGAG
CGAGGCTTGA GTCAACGCAG AATCGACACA CTGAGAGTTT TACGGGTCTC
-5806 CCTTGGGGTT TTTAAAATAA AGGCTTGTGT GCCCACCTCA CATGCTGTGA
GGAACCCCAA AAATTTTATT TCCGAACACA CGGGTGGAGT GTACGACACT
-5756 GGGACATGAG TACAAGATTC ATACAGGTTT GGGGCGAGCC TAGAGGCAGA
CCCTGTACTC ATGTTCTAAG TATGTCCAAA CCCCGCTCGG ATCTCCGTCT
-5706 AGGAGAGGAG AACTACAAAG GATAACCAGT CCTCCCTGGG GCTGCTGTCA
TCCTCTCCTC TTGATGTTTC CTATTGGTCA GGAGGGACCC CGACGACAGT
-5656 CAGGAGTCCA TAATCAGGGC CGGAAGGACC CCCCTCCACC CACTCTCTTT


















ATAGCCAACG TAAGGGGTCT TGACAGAGTG GCTCATGTGA GGCTGTATGA
TATCGGTTGC ATTCCCCAGA ACTGTCTCAC CGAGTACACT CCGACATACT
TCCTGCAGTG TGAGCACAGA TACCATGGCA ACAAAGGCTT GGCCCCAAGT
AGGACGTCAC ACTCGTGTCT ATGGTACCGT TGTTTCCGAA CCGGGGTTCA
TTTATACCCA CGTTCTGCCC TAGAGGAGGG GTCCAGGTTG CGCATAATCC
AAATATGGGT GCAAGACGGG ATCTCCTCCC CAGGTCCAAC GCGTATTAGG
CTGATACCTC CCTCACTGTC AGAGCAGGAA GCAGGGCTCT GTGGAGTGTG
GACTATGGAG GGAGTGACAG TCTCGTCCTT CGTCCCGAGA CACCTCACAC
GGCTGAGGGG CCCGGAAGGG GATCCCCATG GGAGATGTCC CTGTGGATCA
CCGACTCCCC GGGCCTTCCC CTAGGGGTAC CCTCTACAGG GACACCTAGT
GCTCAGCACC AGCAGCTACC ACAGCTGGCT CTCCCACGCT CCTGAAGCTG
CGAGTCGTGG TCGTCGATGG TGTCGACCGA GAGGGTGCGA GGACTTCGAC
CCCTGGAGGC TCGCAGAGCA GGCATGGGGT GTGAGGAAGC AGCTCACGTT
GGGACCTCCG AGCGTCTCGT CCGTACCCCA CACTCCTTCG TCGAGTGCAA
CCAAACTTAC ACAATCAGNT CGGTGTCCNG AAGGACGTCC TNTAGGTCTC
GGTTTGAATG TGTTAGTCNA GCCACAGGNC TTCCTGCAGG ANATCCAGAG
TACTGACAAC TTAGGAAATG GAAGGCTTGC AGGAGGTCCT GACGGTAAGA
ATGACTGTTG AATCCTTTAC CTTCCGAACG TCCTCCAGGA CTGCCATTCT
TATTAAGCCA GATCTTCCCT ATTACTCACT GTGAGAGATA GNTAGNCCTN
ATAATTCGGT CTAGAAGGGA TAATGAGTGA CACTCTCTAT CNATCNGGAN
CTANAGCTGT CTACNGTAGC TGGAAAGTCA AGTCTTAGGG TAGGAGTCAC
GATNTCGACA GATGNCATCG ACCTTTCAGT TCAGAATCCC ATCCTCAGTG
AGCACCGTTG ACACTTGGAG CAGGTGTCCG AGGAGGCAGC AGGGACATGA
TCGTGGCAAC TGTGAACCTC GTCCACAGGC TCCTCCGTCG TCCCTGTACT
Smal
GTCATCTTCA ACAGAGATTC TTGGAAACCC TCTTCCCGGG CCAGGCTCCA
CAGTAGAAGT TGTCTCTAAG AACCTTTGGG AGAAGGGCCC GGTCCGAGGT
CTAAAGCAGG ACATTTGAAG TTCAAGACAT GTCCATTCAT ACTTACCCCA
GATTTCGTCC TGTAAACTTC AAGTTCTGTA CAGGTAAGTA TGAATGGGGT
GCCTCCCAAC CACCCTATCC TATGCTACCT CAGTGCCCCC GGAACACAGG
CGGAGGGTTG GTGGGATAGG ATACGATGGA GTCACGGGGG CCTTGTGTCC
GCACTGTGGC ACATCCTCCT ACCATATACA GAAGTCTCAA AGAAATACAG
CGTGACACCG TGTAGGAGGA TGGTATATGT CTTCAGAGTT TCTTTATGTC
278
4806 CAGTAGCACC CTTGAAGACG ATATTGTTTC TCCCTCACGA GAACACTGGC
GTCATCGTGG GAACTTCTGC TATAACAAAG AGGGAGTGCT CTTGTGACCG
4756 TCTTAAGACC CAGAAGTGGG TACAGAACCT GACTGAAGGC ACATAATATG
AGAATTCTGG GTCTTCACCC ATGTCTTGGA CTGACTTCCG TGTATTATAC
4706 TCTTCCGTGG GGCCTCTCAC CCCTAATTTC AGGCTGTCCT GTTTCTCCCA
AGAAGGCACC CCGGAGAGTG GGGATTAAAG TCCGACAGGA CAAAGAGGGT
4656 TTGTGCATCT GCATGAAGGG AGTTAGTTCG CTGAACACCT ACTATGTGAC
AACACGTAGA CGTACTTCCC TCAATCAAGC GACTTGTGGA TGATACACTG
4606 CTGCCTCCCC ACGCCCCTTC CCAGAGCTCA CAAGCAAACA TCAAGGAAGC
GACGGAGGGG TGCGGGGAAG GGTCTCGAGT GTTCGTTTGT AGTTCCTTCG
4556 AACGGATGAA TAACACCAAT CTGTGGTTGG TACAATGAAA GATACAGAAA
TTGCCTACTT ATTGTGGTTA GACACCAACC ATGTTACTTT CTATGTCTTT
4506 TCACAGAGTT GGGCAGATGG GGGTGGGGGG TCATGCTCAG GCCTGTAGAA
AGTGTCTCAA CCCGTCTACC CCCACCCCCC AGTACGAGTC CGGACATCTT
4456 GCTCCAAGGG NATAACGCTC TTTGGGGAAG ACGTATCTCC GCTCAGACCT
CGAGGTTCCC NTATTGCGAG AAACCCCTTC TGCATAGAGG CGAGTCTGGA
4406 GAGGTTGAAA GGCCATCCAT GAAACAAGAA TGGGAACAGT GTTGAAAGCA
CTCCAACTTT CCGGTAGGTA CTTTGTTCTT ACCCTTGTCA CAACTTTCGT
4356 AAGGGATCAG CCCCTGCAAA TTCTTTGAGG TTCACAAGAC CTTGAAGTGG
TTCCCTAGTC GGGGACGTTT AAGAAACTCC AAGTGTTCTG GAACTTCACC
4306 TAGATCAGAA GAGAGGAGAG GGATTGCCAG GATGGGGAAG GCAGCTGGGG
ATCTAGTCTT CTCTCCTCTC CCTAACGGTC CTACCCCTTC CGTCGACCCC
4256 GCCAGCGCAA AGACTTGAGG GCTCTTGGGA GCCCAGCTTT TATTCTGAGG
CGGTCGCGTT TCTGAACTCC CGAGAACCCT CGGGTCGAAA ATAAGACTCC
SphI
4206 TCAGCAAGCC GCTGCAGCTC AGCATGCATG AGACCAGGTA GCTGAGGTAT
AGTCGTTCGG CGACGTCGAG TCGTACGTAC TCTGGTCCAT CGACTCCATA
4156 AGTGTGGGGG TGTAAGGCTG GGCTGGAGTC TTGGGGAGCT TGTGGGCAAC
TCACACCCCC ACATTCCGAC CCGACCTCAG AACCCCTCGA ACACCCGTTG
4106 TGTGAATCAG AGTTGGAACC TCTAGGCTCT CTCTGAGCTT TGACCCCTGA
ACACTTAGTC TCAACCTTGG AGATCCGAGA GAGACTCGAA ACTGGGGACT
4056 GTCTCCGTGC CTCCTTTCCT CCCCTGGCCT GTCTGTTTGC ACATTGTTGG
CAGAGGCACG GAGGAAAGGA GGGGACCGGA CAGACAAACG TGTAACAACC
279
4006 GCACAAGGAC ATTCTGTGCT TGTTCTGAGC CCTGATTCTG GTGTCTTCTT
CGTGTTCCTG TAAGACACGA ACAAGACTCG GGACTAAGAC CACAGAAGAA
TCF/LEF binding motif
3956 TGATCTCTGG TGTCTGGATA AGGAGGTTGT CTCAATTCCC CAATACCTCC
ACTAGAGACC ACAGACCTAT TCCTCCAACA GAGTTAAGGG GTTATGGAGG
3906 TGTTATCTGA GACTAGGCAA TAAGGGACTA ATTTCTCCTG TCATGCTCTA
ACAATAGACT CTGATCCGTT ATTCCCTGAT TAAAGAGGAC AGTACGAGAT
3856 AAGGCCAGCA GGTGGCGACA TCCCTCTAAA GGGCTGGAGA ATGACAGCCT
TTCCGGTCGT CCACCGCTGT AGGGAGATTT CCCGACCTCT TACTGTCGGA
Smal
3806 GTCTATAAAC CAAAATTTTC CCGGGACCCT ACTGTCGATA CNNGCGATNG
CAGATATTTG GTTTTAAAAG GGCCCTGGGA TGACAGCTAT GNNCGCTANC
3756 CGNGGCTCAT NTTTGCCTCT GNGANGCTGA CAGCCNTNCN TGTTTTNNGA
GCNCCGAGTA NAAACGGAGA CNCTNCGACT GTCGGNANGN ACAAAANNCT
3706 GGAGAACCGG TGACCCCNAG AAGGGAACTA NCCTNCCNAG GGNCAGANAG
CCTCTTGGCC ACTGGGGNTC TTCCCTTGAT NGGANGGNTC CCNGTCTNTC
3656 CTTGGAAGAA NCTNGTNTGA CCCTTGGTAA NATNTCNGNA NAGGGACTCN
GAACCTTCTT NGANCANACT GGGAACCATT NTANAGNCNT NTCCCTGAGN
3606 ANTATGNTAG NNGNGGGGGC ATGGTGGGTN TGACACTANT CCCTGGTGTN
TNATACNATC NNCNCCCCCG TACCACCCAN ACTGTGATNA GGGACCACAN
3556 NANTGGCTTT CNTGAAGCAA ACCTAATNTN AGCAGGAACT GANCCCCAGA
NTNACCGAAA GNACTTCGTT TGGATTANAN TCGTCCTTGA CTNGGGGTCT
3506 CCTTNCNCTT NCAGGGCCAT AAACCAAGTT ATCANNACNA TCTTTATANG
GGAANGNGAA NGTCCCGGTA TTTGGTTCAA TAGTNNTGNT AGAAATATNC
3456 GCCTNNATNT GGGTACCCCA CCCCAGGAGG CCCCGGAGTG AGAGCCTCCA
CGGANNTANA CCCATGGGGT GGGGTCCTCC GGGGCCTCAC TCTCGGAGGT
3406 GGGGGAAGAG GGAAGAAGGA GGGGTCCAAT AAACAGCCAC CCCCACAGAT
CCCCCTTCTC CCTTCTTCCT CCCCAGGTTA TTTGTCGGTG GGGGTGTCTA
3356 AACGGGATTG CCTGTAAACA GCCACGCCCA GAGATAAGGG GATTGCCTGA
TTGCCCTAAC GGACATTTGT CGGTGCGGGT CTCTATTCCC CTAACGGACT
3306 AAGGAAGAGG CTGCTTCAGG ATAGGCGGGG CCGGCACAGT GGTACAGTTA
TTCCTTCTCC GACGAAGTCC TATCCGCCCC GGCCGTGTCA CCATGTCAAT
3256 ACAGTCCCGG AGGGCACATG TGAAACTGGT GTCCAGGGGC TCAAGATCGG





















GTCGCAGGTC AGAGGTGGGG GTGTACGGCA CTACAATCTC AGACTTAAAT
CAGCGTCCAG TCTCCACCCC CACATGCCGT GATGTTAGAG TCTGAATTTA
AAGGTTATAA TTCCTTTCTT TAAGGAACTG ATGCTAAAGC CTCTAACCAG
TTCCAATATT AAGGAAAGAA ATTCCTTGAC TACGATTTCG GAGATTGGTC
GGGGTCCACC TAGGTGTGAG GGTGGCTGGA GCCTTGAGGC TGAGGAGGAA
CCCCAGGTGG ATCCACACTC CCACCGACCT CGGAACTCCG ACTCCTCCTT
GAGGAACCAG CAATTTGTTA AGCAAAATCC AGCTAACAAG TTGTCAGGTG
CTCCTTGGTC GTTAAACAAT TCGTTTTAGG TCGATTGTTC AACAGTCCAC
GGGGTGTCAG TGTCAGGATC ACTCTCTGTG CTCAGTGGGT CAACCATCTC
CCCCACAGTC ACAGTCCTAG TGAGAGACAC GAGTCACCCA GTTGGTAGAG
TAGAGGGAAG AAAAACTGCC AGCTAGGTGG GTTTTCTGTG TGACTCTAGG
ATCTCCCTTC TTTTTGACGG TCGATCCACC CAAAAGACAC ACTGAGATCC
AAGGTGACTT TACCTCTCTG AACACATTTG TTAATCTGGG GAAAAAAATG
TTCCACTGAA ATGGAGAGAC TTGTGTAAAC AATTAGACCC CTTTTTTTAC
GGGGTAGCAA TCGCTTTTTT TCCCTTGATG GTGGTCANGA TGAACCGAGG
CCCCATCGTT AGCGAAAAAA AGGGAACTAC CACCAGTNCT ACTTGGCTCC
ACACACGCTG GCCGTGAGAT GTCACTCTCA GCACCTGCTC AGTGTGTGGA
TGTGTGCGAC CGGCACTCTA CAGTGAGAGT CGTGGACGAG TCACACACCT
AGTGCCATTG TCACAAACCA GTGTGCCATC TCAGAGAGAG ACAGCGGATA
TCACGGTAAC AGTGTTTGGT CACACGGTAG AGTCTCTCTC TGTCGCCTAT
CTCAGAAAGG GTGGTGCAGC CCAGGAGCAC CTGTAGATGG GGGGTGGGGG
GAGTCTTTCC CACCACGTCG GGTCCTCGTG GACATCTACC CCCCACCCCC
GCGGTATGTC CACCCTTTGA GGGTACAGCA TTGAGAAACG TCTCTGCAGC
CGCCATACAG GTGGGAAACT CCCATGTCGT AACTCTTTGC AGAGACGTCG
AGGCTTCTGA ATTTCCTATA AGGTCCCCTG CCACCCTGAC CCATCCATCT
TCCGAAGACT TAAAGGATAT TCCAGGGGAC GGTGGGACTG GGTAGGTAGA
CTAAGCCACT ACCAAATCCT GGCTATGTCT CAGTCACTTA GGATCCCTGC
GATTCGGTGA TGGTTTAGGA CCGATACAGA GTCAGTGAAT CCTAGGGACG
CCAGCTTCCC TCTCCTGGTG CAGGGGTTAG GAGGGGTGGG TGTGTTCTCA
GGTCGAAGGG AGAGGACCAC GTCCCCAATC CTCCCCACCC ACACAAGAGT
GATCAGCTTC CTGCTTCTCC CTCAGGGCTG GGTTATCAGT TCTAGGGGAA
CTAGTCGAAG GACGAAGAGG GAGTCCCGAC CCAATAGTCA AGATCCCCTT
CACACATTCC TCGCCCCCTA AGGCCTTGGC GCACACTGAC CACTGGACTA
GTGTGTAAGG AGCGGGGGAT TCCGGAACCG CGTGTGACTG GTGACCTGAT
CACTGCCCTT GTCTACTCGC CCCGACTGAT GTGTCACCTC CTTCCCAAAA
GTGACGGGAA CAGATGAGCG GGGCTGACTA CACAGTGGAG GAAGGGTTTT
EcoRI
GAATTCTCTA GCTTGGCTCC CAACTAGATC CAAGATGTGA TATTCCCTTC




















ACTGAACATT TAATTCACGC CTTGCCCCCC AGGACTGAAG GCACCTTAAG
TGACTTGTAA ATTAAGTGCG GAACGGGGGG TCCTGACTTC CGTGGAATTC
TTAGAAGGGG CTTCATTCCA TATTGAACAT GGCGCCAGCA CGGTTGTGTG
AATCTTCCCC GAAGTAAGGT ATAACTTGTA CCGCGGTCGT GCCAACACAC
GGTCAGTCTG TCCGTGTCAA AGGGATGAAT ATGTGAGCAA ATAAATTTCT
CCAGTCAGAC AGGCACAGTT TCCCTACTTA TACACTCGTT TATTTAAAGA
AATCCCAAAT GGCAAGCCTC TTGACTAGGC AAGAACTGGC ATAGAGAGGA
TTAGGGTTTA CCGTTCGGAG AACTGATCCG TTCTTGACCG TATCTCTCCT
TTAGAGGCCA CCAATTTCCT GCTTTCCCCA GAAAAAGTGT GACCCCTCAC
AATCTCCGGT GGTTAAAGGA CGAAAGGGGT CTTTTTCACA CTGGGGAGTG
TGGAGATACC CAGCCATCCC TTGCACACCT CCCTTGACGA TAAACTCACT
ACCTCTATGG GTCGGTAGGG AACGTGTGGA GGGAACTGCT ATTTGAGTGA
TCF/LEF binding motif
CACTACAGGA CCATCCGTCT GCTTTGTACT GGATGGTCCT ACAGTGAGCA
GTGATGTCCT GGTAGGCAGA CGAAACATGA CCTACCAGGA TGTCACTCGT
TTCATTCTAG ACAGGTAGGT TAGACTCCAT GCCTGCAGCT CTCTCTCTCA
AAGTAAGATC TGTCCATCCA ATCTGAGGTA CGGACGTCGA GAGAGAGAGT
GGTCCCTGCC CTCCATGCTA GGCCTTCACT TCCCACAGTG AGGAGCAGGC
CCAGGGACGG GAGGTACGAT CCGGAAGTGA AGGGTGTCAC TCCTCGTCCG
EcoRI
CTGGTTACCC CAGGTGAGAG CAGAATTGAA TTCTGCCCTC TTGGGGTATC
GACCAATGGG GTCCACTCTC GTCTTAACTT AAGACGGGAG AACCCCATAG
TCTTGGTTGT GCTCTCACTG GAACCCAGAA CTCTAGGTGT CTTCTGACCT
AGAACCAACA CGAGAGTGAC CTTGGGTCTT GAGATCCACA GAAGACTGGA
GAGAATGTGG CGCCCCTCCC CCATGCTGTG ACACCCATGT GCTCATACCG
CTCTTACACC GCGGGGAGGG GGTACGACAC TGTGGGTACA CGAGTATGGC
TCATCTGTGT TGGCGACAAG TAGCTACCTT CCCCTCTCTT GTAAGCAGCC
AGTAGACACA ACCGCTGTTC ATCGATGGAA GGGGAGAGAA CATTCGTCGG
ATCATTATAA AGCATGAACT GGAGTTCTGC CCTTTCCTCT CTGGGCCTCC
TAGTAATATT TCGTACTTGA CCTCAAGACG GGAAAGGAGA GACCCGGAGG
CTGCTTCCAT CCATTGAGCA GGAAGGGGAC CATTAGGCTT ACTGCTATGT
GACGAAGGTA GGTAACTCGT CCTTCCCCTG GTAATCCGAA TGACGATACA
GTAAGTGTCA CTGATTGAGG ACACCTTCAC GGGCAGGTCA TCTGTGCACT
CATTCACAGT GACTAACTCC TGTGGAAGTG CCCGTCCAGT AGACACGTGA
CGCACAGGGC TCAGCTGAAT CCTGCCACTA TGAAATTCTA GGTCATTTTG
GCGTGTCCCG AGTCGACTTA GGACGGTGAT ACTTTAAGAT CCAGTAAAAC
GAACAACCTG GCATTTGCAT TTTGCACTGC ATCTGCCGGC AGGGTACAGC
CTTGTTGGAC CGTAAACGTA AAACGTGACG TAGACGGCCG TCCCATGTCG
282
1356 ATGGCCTCGA CTCCCCTGCT TGCCCCTGTA AAGAGAAAGA AAGTCTAATA
TACCGGAGCT GAGGGGACGA ACGGGGACAT TTCTCTTTCT TTCAGATTAT
1306 GCCAAGACCT GTGTCTTGCT TTGAGGCATC GGAAATTCTG CATGGCCCTA
CGGTTCTGGA CACAGAACGA AACTCCGTAG CCTTTAAGAC GTACCGGGAT
1256 GAGCACCAGA AATCCATCTC AGAGGACTCC TCTGCACACT TTCCTCCTGG
CTCGTGGTCT TTAGGTAGAG TCTCCTGAGG AGACGTGTGA AAGGAGGACC
1206 CCCATAGTCT TCCTTCTGAA TCCGTCCTCA GCAATGCCTT CTCTTCCCAG
GGGTATCAGA AGGAAGACTT AGGCAGGAGT CGTTACGGAA GAGAAGGGTC
1156 TCTCAGCTAT GCCTTTCCCT GCTCAGGTAG CTGTGGAATG CCTGCCTGCC
AGAGTCGATA CGGAAAGGGA CGAGTCCATC GACACCTTAC GGACGGACGG
1106 TGTCTTCAAC GGTGCAGGAA AGACCCACAT GGACATTTAA AATACCAGCG
ACAGAAGTTG CCACGTCCTT TCTGGGTGTA CCTGTAAATT TTATGGTCGC
1056 GGATCCGTTT TCCATTTCCA TTACCAACGA GGATCATCAA GCCAACTGCA
CCTAGGCAAA AGGTAAAGGT AATGGTTGCT CCTAGTAGTT CGGTTGACGT
1006 AAATCGCGTT GTTTCTTTTT TTTCCCCCCA ATCAGTCAGA GTACACAGAA
TTTAGCGCAA CAAAGAAAAA AAAGGGGGGT TAGTCAGTCT CATGTGTCTT
TCF/LEF binding motif
956 TATAAACTTT GTTCGATAAT AAATACTCAG GAATTTGTCC CTGTATTTTA
ATATTTGAAA CAAGCTATTA TTTATGAGTC CTTAAACAGG GACATAAAAT
906 AAGACTCGGG CTGATGTGTG TAGGGGTAAA ACGACATGAA GCCTGGAATT
TTCTGAGCCC GACTACACAC ATCCCCATTT TGCTGTACTT CGGACCTTAA
856 TGTTTTTAAA TTGTTCCGAA AATGCTTTAG GAAAAAAAAC AAAAGGCAGT
ACAAAAATTT AACAAGGCTT TTACGAAATC CTTTTTTTTG TTTTCCGTCA
806 AGATTTAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAGGTG ACAGAAACCC
TCTAAATTTT TTTTTTTTTT TTTTTTTTTT TTTTCTCCAC TGTCTTTGGG
756 GATAAGTAAT GGAAGCTGCA AGGTAGGTAC ACAATGCAAC TCGGTGTATA
CTATTCATTA CCTTCGACGT TCCATCCATG TGTTACGTTG AGCCACATAT
706 TGTATGTTTG AAACATTTCA GCAATGATAA TGTCAAGGTA ATACGCATCA
ACATACAAAC TTTGTAAAGT CGTTACTATT ACAGTTCCAT TATGCGTAGT
656 AAAGTTTGTG AAGTTTCCCA AGGTGTCCCC AGAAACCCCC CTGGTCCACA
TTTCAAACAC TTCAAAGGGT TCCACAGGGG TCTTTGGGGG GACCAGGTGT
606 CCTTTGAGAA TTTCTCTGGG GAGCCAATAA GAGAAACAGT AGCTTGCAGA
GGAAACTCTT AAAGAGACCC CTCGGTTATT CTCTTTGTCA TCGAACGTCT
Retinoic Acid Response Element
556 CTGGCTATCT GCATATGCAC ATCACCATAG CTTTCATCTG GGACCCGAAG
GACCGATAGA CGTATACGTG TAGTGGTATC GAAAGTAGAC CCTGGGCTTC
283
-506 GGTCGTGACC CCTAACCCCA CCACCACCCC TCCCAGAGAC GCCCGCTACC
CCAGCACTGG GGATTGGGGT GGTGGTGGGG AGGGTCTCTG CGGGCGATGG
-456 TTACAGACGG AACCCCCGTT TGAAGTCAGC CTTGCTCTCC GCCTCACCTC
AATGTCTGCC TTGGGGGCAA ACTTCAGTCG GAACGAGAGG CGGAGTGGAG
-406 AAGCTGGTGG TCACTGCTGA CAGTGTCCCC ATGCTCTGTG GCGGGTGTGA
TTCGACCACC AGTGACGACT GTCACAGGGG TACGAGACAC CGCCCACACT
-356 GGCTCGCCTA GGGTCATGCC ACCACTCCAC CCCGCTCCTC GGAGCCAGTT
CCGAGCGGAT CCCAGTACGG TGGTGAGGTG GGGCGAGGAG CCTCGGTCAA
-306 TCTCCACCTG TAACCCAGGG GTGGGTGGTG GGGAGGTCCC TGCGACCCCC
AGAGGTGGAC ATTGGGTCCC CACCCACCAC CCCTCCAGGG ACGCTGGGGG
-256 GAAGGAGGAG TCGGAACCCC AAGCTGGGAC CGGACCGTCA TCCAGGCCGC
CTTCCTCCTC AGCCTTGGGG TTCGACCCTG GCCTGGCAGT AGGTCCGGCG
-206 GCCCTCCGGG TCCCCAGCCC GCTGGCCCAT CCACCTCCCG CTTAGGGCGG
CGGGAGGCCC AGGGGTCGGG CGACCGGGTA GGTGGAGGGC GAATCCCGCC
TCF/LEF binding motif
-156 CAATTTGTCT CCTTTTGAAC CCCCTCGCCC GACGGGCTTC CCCCTTTGAT
GTTAAACAGA GGAAAACTTG GGGGAGCGGG CTGCCCGAAG GGGGAAACTA
TCF/LEF binding motif
-106 TCGCGGCCCC GAGGCTTCCC CCCGCTTTGA AATGCAAAGC CGCCCGGCTG







-6 CGGCGGCCGC GGGGCCAGGT GAGCAGTCGC TGGTCGTCGG GGCGGCCGGC
GCCGCCGGCG CCCCGGTCCA CTCGTCAGCG ACCAGCAGCC CCGCCGGCCG
SphI(+7 3)
+44 CGGGCGCGGC GGCTCCAGGG CCCAGCATGC GCGGGGGACC CTGCGGTCAC
GCCCGCGCCG CCGAGGTCCC GGGTCGTACG CGCCCCCTGG GACGCCAGTG
Translation start site (+95)
I
+94 CATGTACGTG GGCTATGTGC TGGACAAGGA CTCCTAGCC..













CC F WT POS (HET) Micro-injection Breed 30/11/99
CC1 M WT NEG CC x F1 WT 10/03/98 Cull
CC2 M WT POS (HET) CC x F1 WT 10/03/98 Breed
3 M WT NEG CC x Min 30/03/98 Cull
4 M WT POS (HET) CC x Min 30/03/98 Breed
5 F WT NEG CC x Min 30/03/98 Cull
6 M WT POS (HET) CC x Min 30/03/98 Breed
7 F WT NEG CC x Min 30/03/98 Cull
8 M WT NEG CC x Min 30/03/98 Cull
9 M WT NEG CC x Min 30/03/98 Cull
10 F HET POS (HET) CC x Min 30/03/98 Gut tumours 26/02/99 326
11 M WT POS (HET) CC x Min 30/03/98 Breed
12 M WT NEG CC x Min 30/03/98 Cull
13 F WT NEG CC2 x Min 14/05/98 Found dead 16/06/98 32
14 M WT NEG CC2 x Min 14/05/98 Cull
15 F WT NEG CC2 x Min 14/05/98 Cull
16 M WT POS (HET) CC2 x Min 19/05/98 Cull
17 M HET NEG CC2 x Min 19/05/98 Cull
18 M HET POS (HET) CC2 x Min 19/05/98 Gut tumours 26/02/99 277
19 M HET POS (HET) CC2 x Min 19/05/98 Breed
20 F WT POS (HET) CC2 x Min 01/06/98
Cull for MEFs
(x Min)
21 M WT NEG CC2 x Min 01/06/98 Gut tumours 05/02/99 244
22 M HET NEG CC2 x Min 01/06/98 Gut tumours 14/06/99 373
23 F WT NEG CC2 x Min 01/06/98
Cull for MEFs
(x Min)
24 F HET POS (HET) CC2 x Min 01/06/98 Breed
25 F WT NEG CC2 x Min 01/06/98 Found dead 06/07/98 35
26 M NT NEG CC x Min 05/06/98 Cull
27 M WT NEG CC x Min 05/06/98 Cull
28 F WT NEG CC x Min 05/06/98 Found dead 06/07/98 31
29 F WT NEG CC x Min 05/06/98 Found dead 30/06/98 25
30 F WT NEG CC x Min 05/06/98 Cull
31 F WT NEG CC x Min 05/06/98 Cull
32 M WT NEG CC x Min 05/06/98 Cull
33 M WT NEG CC x Min 05/06/98 Cull
34 F WT NEG CC x Min 05/06/98 Cull
35 M WT NEG CC x Min 05/06/98 Cull
36 F WT NEG CC x Min 05/06/98 Found dead 06/07/98 31
37 F WT NEG CC11 x Min 06/06/98 Cull
38 M WT NEG CC11 x Min 06/06/98 Cull
39 F WT NEG CC11 x Min 06/06/98 Cull












































WT NEG CC11 x Min 06/06/98 Cull
WT NEG CC11 x Min 06/06/98 Cull
M WT NEG CC4 x Min 08/06/98 Cull
M WT NEG CC4 x Min 08/06/98 Cull
M WT NEG CC4 x Min 08/06/98 Cull
M WT NEG CC4 x Min 08/06/98 Cull
WT NEG CC4 x Min 08/06/98 Cull
WT NEG CC4 x Min 08/06/98 Cull
M WT NEG CC4 x Min 08/06/98 Cull
M WT NEG CC4 x Min 08/06/98 Cull
WT NEG CC4 x Min 08/06/98 Cull
M WT POS (HET) CC4 x Min 15/06/98 Cull 16/03/00
M WT NEG CC4 x Min 15/06/98 Gut tumours 05/02/99
M HET POS (HET) CC11 x Min 12/06/98 Breed
M HET POS (HET) OC11 x Min 12/06/98 Gut tumours 02/02/99
M HET NEG 0011 x Min 12/06/98 Gut tumours 19/01/99
WT NEG 0011 x Min 12/06/98
Cull for MEFs
(x Min)
HET NEG 0011 x Min 12/06/98 Found dead 09/08/99
M HET POS (HET) 0011 x Min 12/06/98 Breed
HET POS (HET) 0011 x Min 12/06/98 Breed
WT NEG 0011 x Min 12/06/98
Cull for MEFs
(x CC2)
HET POS (HET) 0011 x Min 12/06/98 Breed
HET NEG 002 x Min 10/06/98 Gut tumours 10/08/99
M WT NEG 002 x Min 10/06/98 Cull 10/09/98
M HET NEG 002 x Min 10/06/98 Cull
WT POS (HET) CC2 x Min 10/06/98 Cull
HET POS (HET) 002 x Min 10/06/98 Gut tumours 02/02/99
WT POS (HET) CC2 x Min 10/06/98 Cull
WT POS (HET) CC2 x Min 10/06/98 Cull
WT POS (HET) OC2 x Min 10/06/98 Cull
WT POS (HET) 002 x Min 10/06/98 Cull
WT NEG 0C2 x Min 10/06/98 Cull 10/09/98
M WT NEG 002 x Min 10/06/98 Cull 10/09/98
M WT NEG CC10 x Min 29/06/98 Cull 13/03/00
HET NEG CC10 x Min 29/06/98 Found dead 03/09/99
WT NEG CC10 x Min 29/06/98 Cull
M HET NEG 0010 x Min 29/06/98 Found dead 03/01/00
HET POS (HET) CC10 x Min 29/06/98 Gut tumours 02/02/99
M HET NEG 0011 x Min 03/07/98 Missing
M WT NEG 0011 x Min 03/07/98 Gut tumours 05/02/99
HET NEG C011 x Min 03/07/98 Gut tumours 26/02/99
M HET POS (HET) 0011 x Min 03/07/98 Breed
287
83 F HET POS (HET) CC11 x Min 03/07/98 Breed
84 F HET NEG CC4 x Min 09/07/98 Gut tumours 16/11/99 487
85 F WT NEG CC4 x Min 09/07/98 Cull
86 F HET NEG CC4 x Min 09/07/98 Gut tumours 21/06/99 342
87 M HET POS (HET) CC4 x Min 09/07/98 Breed
88 M HET NEG CC4 x Min 09/07/98 Cull
89 M WT NEG CC4 x Min 09/07/98 Cull
90 M WT POS (HET) CC4 x Min 09/07/98 Cull
91 F WT POS (HET) CC4 x Min 09/07/98 Breed
92 M WT POS (HET) CC11 x Min 14/07/98 Cull
93 F WT NEG CC11 x Min 14/07/98 Cull
94 M HET NEG CC11 x Min 14/07/98 Cull
95 M HET NEG CC11 x Min 14/07/98 Cull
96 F WT NEG CC11 x Min 14/07/98 Cull
97 F WT POS (HET) CC11 x Min 14/07/98 Cull 16/03/00 602
98 M HET POS (HET) CC11 x Min 14/07/98
99 M WT NEG CC11 x Min 14/07/98 Cull 13/03/00
100 M HET NEG CC11 x Min 14.07.98
101 M WT NEG CC10 x CC18 19/08/98 Cull 13/03/00
102 F HET POS (HOM) CC10 x CC18 19/08/98
Cull for
embryos
103 M WT NEG CC10 x CC18 19/08/98 Cull 13/03/00
104 F HET NEG CC10 x CC18 19/08/98
105 F HET POS (HOM) CC10 x CC18 19/08/98
Cull for
embryos
106 F HET POS (HOM) CC10 x CC18 19/08/98 Cull embryos
107 M HET NEG CC55 x CC62 26/08/98 Gut tumours 04/02/99 158
108 M HET POS (HOM) CC55 x CC62 26/08/98 Gut tumours 21/01/99 145
109 M HET NEG CC55 x CC62 26/08/98 Gut tumours 21/01/99 145
110 F WT POS (HOM) CC55 x CC62 26/08/98 Cull
111 F HET POS (HOM) CC55 x CC62 26/08/98
Cull for
embryos
112 M WT NEG CC59 x CC67 02/09/98 Cull 05/02/99 153
113 M WT NEG CC59 x CC67 02/09/98 Cull 05/02/99 153
114 M HET POS (HOM) CC59 x CC67 02/09/98 Cull 16/03/00
115 M WT POS (HOM) CC59 x CC67 02/09/98 Found dead 05/02/99 153
116 M HET POS (HOM) CC59 x CC67 02/09/98 Gut tumours 07/02/00 515
117 M HET POS (HOM) CC59 x CC67 02/09/98 Gut tumours 14/06/99 282
118 F HET POS (HOM) CC59 x CC67 02/09/98 Gut tumours 22/06/99 290
119 F HET POS (HOM) CC54 x CC60 07/09/98
Cull for
embryos
120 M HET POS (HOM) CC54 x CC60 07/09/98 Cull
121 M HET POS (HOM) CC54 x CC60 07/09/98 Found dead 30/08/99 353
122 F HET POS (HOM) CC54 x CC60 07/09/98 Cull
123 F HET NEG CC54 x CC60 07/09/98 Cull
124 F HET POS (HOM) CC19 x CC24 07/09/98
Cull for
embryos
125 F WT POS (HOM) CC19 x CC24 07/09/98 Cull 05/02/99 148
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126 F WT POS (HOM) CC19 x CC24 07/09/98 Cull 05/02/99 148
127 F WT NEG CC19 x CC24 07/09/98 Cull
128 F WT POS (HOM) CC10 x CC18 11/09/98 Cull
129 M WT POS (HOM) CC10 x CC18 11/09/98 Cull
130 F HET NEG CC10 x CC18 11/09/98 Cull
131 M WT POS (HOM) CC10 x CC18 11/09/98 Found dead 05/02/99 144
132 M WT POS (HOM) CC10 x CC18 11/09/98 Found dead 05/02/99 144
133 F HET POS (HOM) CC10 x CC18 11/09/98
Cull for
embryos
134 M WT POS (HOM) CC10 x CC18 11/09/98 Found dead 05/02/99 144
135 F HET POS (HOM) CC55 x CC62 20/09/98
Cull for
embryos
136 F HET POS (HOM) CC55 x CC62 20/09/98 Cull
137 M WT POS (HOM) CC55 x CC62 20/09/98 Found dead 16/03/99 176
138 F HET POS (HOM) CC55 x CC62 20/09/98
139 F HET POS (HOM) CC55 x CC62 20/09/98 Cull
140 M HET POS (HOM) CC55 x CC62 20/09/98 Gut tumours 01/09/99 341
141 F HET POS (HOM) CC55 x CC62 20/09/98 Found dead 20/10/98 30
142 F WT POS (HOM) CC55 x CC62 20/09/98 Cull
143 M HET POS (HET) CC91 x Min 23/09/98 Breed, Cull 18/12/98 85
144 M WT POS (HET) CC91 x Min 23/09/98 Found dead 20/10/98 27
145 F WT POS (HET) CC91 x Min 23/09/98 Found dead 20/10/98 27
146 F WT POS (HET) CC91 x Min 23/09/98 Found dead 20/10/98 27
147 F WT POS (HET) CC91 x Min 23/09/98
148 M WT NEG CC91 x Min 23/09/98 Cull 05/02/99 132
149 M HET POS (HET) CC91 x Min 23/09/98 Gut tumours 02/09/99 339
150 M HET POS (HOM) CC54 x CC60 01/10/98 Cull
151 M WT POS (HOM) CC54 x CC60 01/10/98 Cull
152 M HET POS (HOM) CC54 x CC60 01/10/98 Cull
153 M HET POS (HOM) CC54 x CC60 01/10/98 Cull
154 M HET POS (HOM) CC59 x CC67 02/10/98 Cull
155 F HET POS (HOM) CC59 x CC67 02/10/98 Gut tumours 18/06/99 256
156 No animal
157 M WT POS (HOM) CC59 x CC67 02/10/98 Cull
158 F HET NEG CC59 x CC67 02/10/98 Cull
159 M WT POS (HOM) CC59 x CC67 02/10/98 Cull
160 M HET POS (HOM) CC59 x CC67 02/10/98 Cull
161 M HET NEG CC19 x CC24 04/10/98 Cull
162 F HET POS (HOM) CC19 x CC24 04/10/98 Cull
163 M WT POS (HOM) CC19 x CC24 04/10/98 Cull
164 M WT POS (HOM) CC10 x CC18 05/10/98 Found dead 09/11/98 34
165 F HET POS (HOM) CC10 x CC18 05/10/98 Cull
166 M WT POS (HOM) CC10 x CC18 05/10/98 Cull
167 M HET POS (HOM) CC10 x CC18 05/10/98 Cull
168 F HET POS (HOM) CC10 x CC18 05/10/98 Cull
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169 F HET POS (HOM) CC10 x CC18 05/10/98 Cull
170 F WT NEG CC10 x CC18 05/10/98 Cull
171 M HET POS (HOM) CC54 x CC60 25/10/98 Cull
172 F
sample
missing CC54 x CC60 25/10/98 Cull
173 F
sample
missing CC54 x CC60 25/10/98 Cull
174 F
sample
missing CC54 x CC60 25/10/98 Cull
175 F HET POS (HOM) CC54 x CC60 25/10/98 Cull
176 M
sample
missing CC54 x CC60 25/10/98 Cull
177 F
sample
missing CC54 x CC60 25/10/98 Cull
178 F HET POS (HOM) CC10 x CC18 01/11/98 Cull
179 M HET NEG CC10 x CC18 01/11/98 Cull 12/02/99 101
180 F HET POS (HOM) CC10 x CC18 01/11/98 Cull
181 F HET POS (HOM) CC59 x CC67 04/11/98 Cull
182 M HET POS (HOM) CC59 x CC67 04/11/98 Cull
183 F WT POS (HOM) CC59 x CC67 04/11/98 Cull
184 F HET NEG CC59 x CC67 04/11/98 Cull 12/02/99 98
185 M HET POS (HOM) CC59 x CC67 04/11/98 Cull
186 F HET NEG CC59 x CC67 04/11/98 Cull 12/02/99 98
187 M HET NEG CC55 x CC62 07/10/98 Cull 12/02/99 125
188 F HET POS (HOM) CC55 x CC62 07/10/98 Cull
189 F HET NEG CC55 x CC62 07/10/98 Cull 12/02/99 125
190 F HET POS (HOM) CC55 x CC62 07/10/98 Cull
191 M HET POS (HOM) CC55 x CC62 07/10/98 Cull
192 M HET NEG CC55 x CC62 07/10/98 Cull 12/02/99 125
193 M WT NEG CC54 x CC60 23/11/98 Cull 12/02/99 79
194 M WT NEG CC54 x CC60 23/11/98 Cull 12/02/99 79
195 F WT NEG CC54 x CC60 23/11/98 Cull 12/02/99 79
196 M WT NEG CC54 x CC60 23/11/98 Cull 12/02/99 79
197 M WT NEG CC54 x CC60 23/11/98 Cull 12/02/99 79
198 M WT NEG CC55 x CC62 02/12/98 Cull 12/02/99 70
199 M HET NEG CC55 x CC62 02/12/98 Cull 12/02/99 70
200 M WT POS (HOM) CC55 x CC62 02/12/98 Cull
201 F WT NEG CC55 x CC62 02/12/98 Cull 12/02/99 70
202 F HET POS (HOM) CC55 x CC62 02/12/98 Gut tumours 02/08/99 240
203 F HET POS (HOM) CC55 x CC62 02/12/98 Gut tumours 14/06/99 192
204 M WT POS (HOM) CC55 x CC62 02/12/98 Cull
205 M HET POS (HOM) CC55 x CC62 02/12/98
206 F HET POS (HOM) CC55 x CC62 02/12/98 Gut tumours 30/04/99 148
207 M
sample
missing CC10 x CC18 26/11/98 Cull
208 F HET POS (HOM) CC54 x CC60 19/12/98 Gut tumours 13/12/99 354
209 F HET POS (HOM) CC54 x CC60 19/12/98 Gut tumours 13/09/99 264
290
210 M HET POS (HOM) CC54 x CC60 19/12/98 Gut tumours 22/02/00 423
211 F HET NEG CC54 x CC60 19/12/98 Cull
212 F WT NEG CC54 x CC60 19/12/98
213 F WT NEG CC54 x CC60 19/12/98
214 M HET POS (HOM) CC10 x CC18 17/12/98 Cull
215 F WT POS (HOM) CC10 x CC18 17/12/98 1/02/99 01/02/99 44
216 M HET POS (HOM) CC10 x CC18 17/12/98 Cull
217 M HET POS (HOM) CC10 x CC18 17/12/98 Cull
218 M HET POS (HOM) CC55 x CC62 26/12/98 Cull
219 F HET POS (HOM) CC55 x CC62 26/12/98 Cull
220 F WT POS (HOM) CC55 x CC62 26/12/98 Gut tumours 14/06/99 168
221 F HET POS (HOM) CC55 x CC62 26/12/98 Cull
222 F HET POS (HOM) CC55 x CC62 26/12/98 Gut tumours 18/06/99 172
223 M HET POS (HOM) CC55 x CC62 26/12/98 Cull
224 M WT NEG CC143 x Min 10/01/99 Cull
225 M HET POS (HOM) CC143 x Min 10/01/99 Cull
226 M WT POS (HOM) CC143 x Min 10/01/99 Cull
227 M HET POS (HOM) CC143 x Min 10/01/99 Breed
228 M HET NEG CC143 x Min 10/01/99 Cull
229 F HET NEG CC143 x Min 10/01/99
230 M WT NEG CC143 x Min 10/01/99
231 F HET POS (HOM) CC143 x Min 10/01/99
232 M WT POS (HOM) CC143 x Min 04/02/99 Found dead 24/04/00 440
233 M HET NEG CC143 x Min 04/02/99 Gut tumours 25/04/00 165
234 M WT NEG CC143 x Min 04/02/99
235 F HET POS (HOM) CC143 x Min 04/02/99 Gut tumours 11/05/99 97
236 F HET NEG CC143 x Min 04/02/99 Gut tumours 12/06/00 488
237 F WT NEG CC143 x Min 04/02/99
238 M WT POS (HOM) CC143 x Min 04/02/99 Gut tumours 27/01/00 353
239 M HET POS (HOM) CC143 x Min 04/02/99 Found dead 24/04/00 440
240 M HET POS (HOM) CC143 x Min 04/02/99
241 F HET POS (HOM) CC143 x Min 20/04/99 Gut tumours 16/11/99 206
242 F WT POS (HOM) CC143 x Min 20/04/99
243 F HET POS (HOM) CC143 x Min 20/04/99 Gut tumours 28/01/00 278
244 M HET NEG CC143 x Min 20/04/99 Cull
245 M HET POS (HOM) CC143 x Min 20/04/99
246 F HET NEG CC143 x Min 20/04/99 Gut tumours 19/10/99 179
247 M HET POS (HOM) CC227 x 231,241 07/06/99 Gut tumours 30/11/99 173
248 M HET NEG CC227 x 231,241 07/06/99 Found dead 17/01/00 220
249 F WT POS (HOM) CC227 x 231,241 07/06/99
250 M WT POS (HOM) CC227 x 231,241 07/06/99
251 F
sample
missing CC227 x 231,241 12/06/99
252 F WT NEG CC227x 231,241 12/06/99
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253 M HET POS (HOM) 00227x231,241 12/06/99
254 M HET NEG CC227x231,241 27/07/99
255 F HET NEG 00227x231,241 27/07/99 Cull
256 F WT POS (HOM) 00227x231,241 27/07/99 Cull
257 F HET POS (HOM) 00227x231,241 27/07/99
258 M HET NEG 00227x231,241 27/07/99
259 F WT POS (HOM) 00227x231,241 07/08/99 Found dead 24/04/00 267
260 F HET POS (HOM) 00227x231,241 07/08/99 Gut tumours 12/06/00 315
261 F HET POS (HOM) 00227x231,241 07/08/99 Cull
262 F HET POS (HOM) 00227x231,241 07/08/99 Gut tumours 12/06/00 305
263 M HET POS (HOM) 00227x231,241 07/08/99
264 M WT POS (HOM) 00227x231,241 07/08/99
265 M HET NEG CC227 x CC231 22/09/99
266 F HET POS (HOM) CC227 x CC231 22/09/99
267 F HET NEG CC227 x CC231 22/09/99
268 F HET NEG CC227 x CC231 22/09/99
269 F HET NEG CC227 x CC231 22/09/99
270 M WT NEG CC227 x CC231 22/09/99
271 F HET POS (HET) Min x CC91,0061 22/09/99
272 M WT POS (HET) Min x CC91,0061 16/10/99
273 M WT NEG Min x CC91,0061 16/10/99
274 M WT NEG Min x CC91,0061 16/10/99
275 M HET POS (HOM) CC227 x CC231 06/11/99
276 M WT POS (HOM) CC227 x CC231 06/11/99
277 F HET POS (HOM) CC227 x CC231 06/11/99 Gut tumours 27/11/00 381
278 F HET POS (HOM) CC227 x CC231 06/11/99 Gut tumours 17/05/00 191
279 F HET POS (HOM) CC227 x CC231 06/11/99
280 F HET NEG CC227 x CC231 01/12/99 Found dead 10/07/00 219
281 M WT POS (HOM) CC227 x CC231 01/12/99
282 F HET NEG CC227 x CC231 01/12/99
283 M WT NEG CC250 x CC256 18/03/00
284 M WT NEG CC250 x CC256 18/03/00
285 F WT NEG CC250 x CC256 18/03/00
286 F WT NEG CC250 x CC256 18/03/00
CC mouse database legend
Ape status Transgene status
HET = ApcM,nJ+ NEG = Transgene negative by PCR
WT = Apc+/+
POS (HET) = Transgene positive by
PCR, one transgene
positive parent
POS (HOM) = Transgene positive by
PCR, two transgene
positive parents
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